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Summary 
Breast cancer is the most common cancer, and second most common cause of cancer-related 
death, in Australian women. In 2011, 14,465 women were diagnosed with breast cancer, and 
in 2012 there were 2,795 deaths from this disease.  
A national screening program introduced in Australia in 1991—BreastScreen Australia—
aims to reduce illness and death resulting from breast cancer. This is achieved through 
organised screening to detect cases of unsuspected breast cancer in women, thus enabling 
early intervention.  
Critical to the success of BreastScreen Australia is the ability to measure quality, performance 
and outcomes to inform a continuous quality improvement approach to breast cancer 
screening in Australia. This relies on the collection of accurate and consistently defined data 
for every episode of care for every woman screened. 
Services accredited under BreastScreen Australia are expected to operate according to 
National Accreditation Standards (NAS) covering access and participation, cancer detection, 
assessment, timeliness, data management and information systems, client focus, and 
governance and management.  
Standardised and comparable data are also provided annually to the Australian Institute of 
Health and Welfare (AIHW) for monitoring and evaluation of BreastScreen Australia 
performance against agreed performance indicators in the AIHW’s BreastScreen Australia 
monitoring report series. 
The BreastScreen Australia data dictionary is intended to be the authoritative source of data 
definitions used by BreastScreen Australia to meet the need for national consistency in data 
collected for program monitoring and evaluation, and for accreditation of BreastScreen 
Australia services. To fulfil this role, it includes metadata standards to support data collected 
at every episode of care for every woman screened, and data specifications for NAS 
Measures required for accreditation of BreastScreen Australia services, as well as data 
specifications for performance indicators used to monitor BreastScreen Australia.
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1 Introduction 
1.1 What is the BreastScreen Australia data 
dictionary? 
BreastScreen Australia is Australia’s national breast cancer screening program. It aims to 
reduce illness and death resulting from breast cancer through organised screening to detect 
cases of unsuspected breast cancer in women, thus enabling early intervention.  
Critical to the success of BreastScreen Australia is the ability to measure quality, performance 
and outcomes to inform a continuous quality improvement approach to breast cancer 
screening in Australia. This relies on the collection of accurate and consistently defined data 
for every episode of care for every woman screened.  
The BreastScreen Australia data dictionary is intended to be the authoritative source of data 
definitions that underpins the accreditation process of BreastScreen sevices, and supports the 
monitoring and evaluation of BreastScreen Australia.  
Development of the first iteration of a national dataset for Australia’s breast cancer screening 
program began in 1991 alongside the introduction of the then National Program for the Early 
Detection of Breast Cancer (now called BreastScreen Australia) and its first National 
Accreditation Requirements. This document was known simply as the ‘Minimum Data Set’, 
and was an unpublished paper circulated in 1994 (see ‘National Program for the Early 
Detection of Breast Cancer 1994’ in the References section). This ‘Minimum Data Set’ formed 
the backbone for all later iterations of the data dictionary. 
Development of the Data Set into a data dictionary—the BreastScreen Australia data dictionary: 
version 1—occurred alongside the development of the National Accreditation Standards 
(NAS) in 2001 by the National Quality Management Committee (NQMC) under the auspices 
of the Australian Screening Advisory Committee, with further revisions and amendments 
over subsequent years. The BreastScreen Australia data dictionary: version 1 was endorsed by 
the NQMC in 2004, and published in 2005 (BreastScreen Australia 2005). 
Another review of the NAS occurred from 2011–2014 when, in 2011, the BreastScreen 
Australia Accreditation Review Committee (ARC) was established to oversee and guide a 
comprehensive review of the governance arrangements and accreditation system of 
BreastScreen Australia, including the National Accreditation Standards (NAS) following 
recommendations made as a result of the BreastScreen Australia Evaluation (BreastScreen 
Australia 2009). The Committee recognised that the BreastScreen Australia data dictionary, as 
an integral document supporting the accreditation process of BreastScreen Australia, would 
therefore review and revision alongside the overarching review.  
Under the direction of the ARC, and guided by expert BreastScreen database managers, 
epidemiologists and clinicians, the AIHW updated the BreastScreen Australia data dictionary in 
line with the changes made to the NAS, as well as other additions and improvements. 
This process of review and revision resulted in the BreastScreen Australia data dictionary: 
version 1.1, which was endorsed by the Australian Health Ministers’ Advisory Council’s 
Community Care and Population Health Principal Committee, Standing Committee on 
Screening on 18 November 2014. 
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Terminology changes have accompanied the iterations of the data dictionary. National 
Accreditation Requirements as they were known when the program was first established 
were replaced with National Accreditation Standards (NAS) in the BreastScreen Australia data 
dictionary: version 1, which were then replaced with NAS Measures in the BreastScreen 
Australia data dictionary: version 1.1. 
A change in the target age group for BreastScreen Australia from women aged 50–69 to 
women aged 50–74 also coincided with the review of the NAS in 2011–2014. This has 
necessitated that the NAS Measures that appear in the BreastScreen Australia data dictionary: 
version 1.1 include both historic Measures for women aged 50–69 alongside the new NAS 
Measures that are specific to women aged 50–74. 
Note that there are more NAS Measures that appear in the BreastScreen Australia data 
dictionary: version 1.1; NAS Measures for accredication are comprised of quantitative and 
non-quantitative NAS Measures. The data dictionary only provides data specifications for 
quantitative NAS Measures. 
1.2 Objectives of the BreastScreen Australia data 
dictionary 
The BreastScreen Australia data dictionary has been developed as the authoritative source of 
data definitions used by BreastScreen Australia to meet the need for national consistency in 
the data collected for program monitoring and evaluation. It was developed to ensure 
standardisation and comparability of data across the program. It was also designed to make 
data collection activities more efficient, by reducing duplication of effort in the field, and 
more effective, by ensuring that the information collected is fit for purpose. 
The objectives of the BreastScreen Australia data dictionary are to: 
• establish a core set of uniform definitions relating to the full range of BreastScreen 
Australia screening and assessment services, and an agreed  range of population 
parameters. 
• promote uniformity, availability, reliability, validity, consistency and completeness in the 
data. 
• accord with nationally- and internationally-agreed protocols and standards, wherever 
possible.  
• promote the national standard definitions through being readily available to all 
individuals and organisations involved in the generation, use and/or development of 
breast cancer screening services information.  
The BreastScreen Australia data dictionary outlines data items to be collected at the Service 
and/or State Coordination Unit (SCU) level for monitoring and evaluation purposes and for 
the purposes of client care. The use of standard definitions and agreed methods for 
calculating screening performance measures facilitates comparisons among services, states 
and territories, and international breast cancer screening programs. 
Each state and territory is required to provide data to the AIHW annually to prepare 
BreastScreen Australia monitoring reports. These reports are publicly available and used to 
measure the performance of the  program through a set of key performance indicators. It is 
therefore critically important that such comparative data are accurate and consistent.  
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There is a requirement for the Service and/or SCU to conform with the BreastScreen Australia 
data dictionary, with regard to the collection of all required data items and the definitions and 
methods used by the Service and/or SCU in the calculation of performance measures.  
Note, however, that the BreastScreen Australia data dictionary will not cover all data elements 
collected by all states and territories. There may be historic, legislative or operational reasons 
why some jurisdictions may collect additional data elements of their own, or may derive 
data dictionary data elements from other data elements that they collect. Nevertheless, the 
BreastScreen Australia data dictionary fulfils its role of supporting the BreastScreen Australia 
accreditation process and achieving national consistency in data collected for program 
monitoring and evaluation. 
Please note that, at the time of publication, the contents of this data dictionary have not yet 
been assessed for inclusion in the National Health Data Dictionary and thus may not align with 
some related standards currently specified in the National Health Data Dictionary, although 
complete alignment is intended. 
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2 Summary of updates to the 
BreastScreen Australia data dictionary 
This chapter summarises updates made to the BreastScreen Australia data dictionary: version 1 
(BreastScreen Australia 2005). These updates reflect changes made to the BreastScreen 
Australia accreditation system following a review in 2011–2014, directed by the BreastScreen 
Australia Accreditation Review Committee and endorsed by the Australian Health 
Ministers’ Advisory Council’s Community Care and Population Health Principal 
Committee, Standing Committee on Screening. The chapter is provided to help determine 
any changes required to State and Territory BreastScreen Registers in order to conform to the 
new BreastScreen Australia data dictionary: version 1.1, as well as informing all users more 
generally of the changes made since Version 1. 
The most significant area of change has been to the accreditation measures, which appear in 
Section 5 of the data dictionary. Previously called National Accreditation Standards (NAS), 
these are now called NAS Measures. Briefly, seven high level Standards (previously termed 
‘clusters’) have been introduced. Each standard is made up of Criteria (previously termed 
‘performance objectives’), which include a number of individual NAS Measures (Table S1). 
The NAS Measures describe the specific requirements for accreditation. 
Table S1: Summary of differences between Version 1 and Version 1.1 of the BreastScreen 
Australia data dictionary 
Version 1 Version 1.1 
4 Outcomes  
6 Aims  
12 Objectives 6 Objectives 
10 Clusters 7 Standards 
38 Performance objectives 29 Criteria 
55 NAS 42 NAS Measures 
99 Data elements 104 Data elements 
These changes have been endorsed by the BreastScreen Australia Accreditation Review 
Committee (ARC) and its two subcommittees—the NAS and Data Subcommittee, and the 
Performance Improvement and Governance Subcommittee. 
Some NAS Measures are updates of the previous NAS, while others are new. Some of the 
‘old’ NAS have been retired. To support these changes, many data elements have been 
updated and new ones introduced to Section 3 of the data dictionary, while other data 
elements have been retired. Changes to NAS Measures/NAS and data elements are outlined 
in Tables S2–S7. 
As with previous versions of the BreastScreen Australia data dictionary, there is the potential 
for further review that may require future additional changes. The Australian Health 
Ministers’ Advisory Council’s Community Care and Population Health Principal 
Committee, Standing Committee on Screening has given the NQMC authority to undertake 
future reviews of the accreditation system and provide suggested revisions to the Standing 
Committee for endorsement. 
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Data elements 
Table S2: Revised data elements 
Name Definition Description of 
change Version 1.1 Version 1 
B.3.1 Area of usual 
residence (SA2) 
B.3.1 Area of usual 
residence 
A designated region describing location 
and contact details that represents a 
medium-sized area built from a number of 
Statistical Area 1, as represented by a 
code. The aim is to represent a community 
that interacts together socially and 
economically. 
Slight name change. 
B.6.2 Family history of 
breast cancer–relationship 
B.6.2 Family history—
relationship 
 Slight name change. 
B.6.3 Family history of 
breast cancer—age 
B.6.3 Family history—age  Slight name change. 
B.6.4 Family history of 
breast cancer—laterality 
B.6.4 Family history—
laterality 
 Slight name change. 
B.7.2 Previous history of 
breast cancer—year 
B.7.2 Previous history—
year 
 Slight name change. 
B.7.3 Previous history of 
breast cancer—laterality 
B.7.3 Previous history—
laterality 
 Slight name change. 
C.3.1 Total number of 
images used 
C.3.1 Total number of 
films used 
The number of images used to screen a 
woman during her screening visit(s). 
Slight name change. 
D.7.1 Result of ultrasound D.7 Result of ultrasound The result of the Ultrasound done after the 
recommendation ‘to assessment centre’ 
was made at the screening visit (see 
‘Recommendation—screening’, C.5). 
Renumbering of data 
element. 
D.7.2 Description of 
ultrasound lesion 
D.8 Description of 
ultrasound lesion 
The description of the lesion based on 
ultrasound findings. 
Renumbering of data 
element. 
D.9 Other procedures 
performed 
D.11 Other assessment 
procedures performed 
Whether other procedures were used to 
assess the mammographic lesion(s). 
Slight name change 
and numbering 
change. 
D.10 Final result of 
assessment visit 
D.12 Final result of 
assessment visit 
The combined result of all procedures 
carried out during the assessment of a 
woman. 
Renumbering of data 
element. 
D.11.1 
Recommendation—
assessment 
D.13.1 
Recommendation—
assessment 
The recommended action following the 
assessment workup for this screening 
episode. 
Renumbering of data 
element. 
D.11.2 
Recommendation—
number of months 
D.13.2 
Recommendation—
number of months 
The number of months to the time when 
the Early review is recommended to take 
place. 
Renumbering of data 
element. 
D.11.3 Date 
recommendation made 
D.13.3 Date 
recommendation made 
The date the recommendation after the 
assessment workup for this screening 
episode was made. 
Renumbering of data 
element. 
D.11.4 Assessment visit—
date 
D.13.4 Assessment visit—
date 
The date the woman attended for a visit 
during this assessment episode. 
Renumbering of data 
element. 
D.12 Discharge from 
BreastScreen Australia 
following assessment 
D.14 Discharge from 
Program following 
assessment 
Whether or not a woman was discharged 
from BreastScreen Australia  following the 
outcome of assessment. 
Slight name change 
and renumbering of 
data element. 
D.13.1 Date woman 
notified in writing of 
assessment results 
D.15 Date woman notified 
of assessment results 
The date the woman was first notified in 
writing of the outcome of her assessment 
visit(s). 
Slight name change 
and renumbering of 
data element. 
D.14.1 Letter to general 
practitioner about 
assessment results 
D.16.1 Letter to general 
practitioner about 
assessment results 
Whether or not a letter about the outcome 
of the woman’s attendance for assessment 
was sent to her general practitioner. 
Renumbering of data 
element. 
D.14.2 Letter to general 
practitioner about 
assessment results—date 
D.16.2 Letter to general 
practitioner about 
assessment results—date 
The date the letter about the outcome of 
the woman’s attendance for assessment 
was sent to her general practitioner. 
Renumbering of data 
element. 
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E.2 Date excision 
performed 
E.2 Date local excision 
performed 
The date on which the local excision was 
performed. 
Slight name change. 
E.4.1 Marking method E.4 Marking method The marking method used to localise the 
lesion during surgical excision. 
Renumbering of data 
element. 
E.4.2 Localisation 
technique 
E.5 Localisation technique The technique used to localise the lesion 
during surgical excision. 
Renumbering of data 
element. 
E.8.1 Lesion removal E.8.1 Lesion identified in 
specimen 
Whether the screen detected lesion has 
been removed through needle biopsy or 
surgery. 
Data element name 
and definition 
changed to detail 
whether or not the 
lesion has been 
removed. 
E.13 Discharge from 
BreastScreen Australia 
following local excision 
E.13 Discharge from 
Program following local 
excision 
 Slight name change. 
F.1.3 Cancer diagnosed in 
BreastScreen Australia 
F.1.3 Cancer diagnosed in 
Program 
 Slight name change. 
G.1 Nature of primary 
treatment 
G.1 Primary treatment 
form 
The nature of primary treatment. Slight name change. 
G.5.1 Radiotherapy G.5 Adjuvant radiotherapy Whether or not radiotherapy was given as 
a part of the treatment regime. 
Name change and 
numbering change. 
 
Table S3: New data elements 
Name Definition 
C.8 Annual screening flag Identifies whether the woman is recommended for annual routine screening. 
D.2.3 Date first offered 
appointment for assessment 
The date the woman is offered an appointment for assessment, for this episode.  
D.8.1 Percutaneous needle 
biopsy performed 
Whether or not a percutaneous needle biopsy was performed, including details of the type 
of needle biopsy performed or the reason why a needle biopsy was not performed. 
D.8.2 Percutaneous needle 
biopsy guidance method 
The method used to direct needle position for percutaneous needle biopsy. 
D.8.3 Percutaneous needle 
biopsy result 
The result of the percutaneous needle biopsy.  
D.11.5 Results visit—date The date the woman attended for a results visit during this assessment episode. 
D.13.2  Date woman notified 
verbally of biopsy results 
The date the woman was verbally notified of the outcome of her cytology or pathology 
assessment result(s). 
E.5 Palpability of lesion Whether or not lesion was palpable or impalpable. 
G.5.2 Chemotherapy Whether or not chemotherapy was given as a part of the treatment regime. 
 
Table S4: Retired data elements 
Name Definition 
D.9.1 Fine needle cytology 
method 
The method used to direct needle position for the fine needle cytology. 
D.9.2 Fine needle cytology result The result of the fine needle cytology. 
D.10.1 Core biopsy method The method used to direct needle position for the core biopsy. 
D.10.2 Core biopsy result The result of the core biopsy. 
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NAS Measures 
Table S5: NAS Measures revised from previous NAS 
Name Definition Description of change 
Version 1.1 Version 1 
  
1.1.1 (a) 1.1.1 The Service and/or SCU monitors and reports the participation 
rate of women aged 50–74 years who participate in screening in 
the most recent 24-month period. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.1.1 (b)  1.1.1 ≥70% of women aged 50–69 years participate in screening in the 
most recent 24-month period. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.1.2 (a) 1.2.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening 
episode within the Program who are rescreened within 27 
months. 
Split into parts (a) and (b) 
to include the new target age 
group. 
1.1.2 (b) 1.2.1 ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 
months. 
Split into parts (a) and (b) to 
include the new target age 
group. 
1.1.3 (a) 1.2.2 The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and 
subsequent screen within the Program, who are rescreened 
within 27 months of their previous screening episode. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.1.3 (b) 1.2.2 ≥90% of women aged 50–67 years who attend for their second 
and subsequent screens within the Program are rescreened 
within 27 months of their previous screening episode. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.2.1 (a)(i) 1.3.5 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(i) Indigenous women. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.2.1 (b)(i) 1.3.5 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(i) Indigenous women. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.2.1 (a)(ii) 1.3.5 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(ii) women from culturally and linguistically diverse backgrounds. 
Split into parts (a) and (b) to 
include the new target age 
group.  
1.2.1 (b)(ii) 1.3.5 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
Split into parts (a) and (b) to 
include the new target age 
group.  
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linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(ii) women from culturally and linguistically diverse backgrounds. 
1.2.1 (a)(iii) 1.3.5 (c) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(iii) women residing across different remoteness areas. 
Split into parts (a) and (b) to 
include the new target age 
group. Updated to reflect new 
ABS geography methodology. 
1.2.1 (b)(iii) 1.3.5 (c) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(iii) women residing across different remoteness areas. 
Split into parts (a) and (b) to 
include the new target age 
group. Updated to reflect new 
ABS geography methodology. 
1.2.1 (a)(iv) 1.3.5 (d) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(iv) women residing across different socioeconomic locations. 
Split into parts (a) and (b) to 
include the new target age 
group. Updated to reflect new 
ABS geography methodology. 
1.2.1 (b)(iv) 1.3.5 (d) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates 
are below that of the overall population, implements specific 
strategies to encourage their participation in screening. 
Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
(iv) women residing across different socioeconomic locations. 
Split into parts (a) and (b) to 
include the new target age 
group. Updated to reflect new 
ABS geography methodology. 
1.2.2 (a) 1.1.2 The Service and/or SCU monitors the proportion of all women in 
the Service who are screened and recalled for assessment, 
aged 40–49 years and 75 years and over. 
(a) women who are screened. 
Numbering change, slight 
change in wording and age 
group. 
1.2.2 (b) 2.6.3 The Service and/or SCU monitors the proportion of all women in 
the Service who are screened and recalled for assessment, 
aged 40–49 years and 75 years and over. 
(b) women who are recalled for assessment. 
Numbering change, slight 
change in wording and age 
group. 
2.1.1 (a) 2.1.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening 
episode who are diagnosed with invasive breast cancer. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.1.1 (b) 2.1.1 ≥50 per 10,000 women aged 50–69 years who attend for their 
first screening episode are diagnosed with invasive breast 
cancer. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.1.2 (a) 2.1.2 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or 
subsequent screening episode who are diagnosed with invasive 
breast cancer. 
Split into parts (a) and (b) to 
include the new target age 
group.  
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2.1.2 (b) 2.1.2 ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with 
invasive breast cancer. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.1.3 (a) 2.2.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening 
episode who are diagnosed with small (≤15 mm) invasive breast 
cancer. 
Split to expand on former NAS 
which was for all screening 
rounds. 
2.1.3 (b) 2.2.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or 
subsequent screening episode who are diagnosed with small 
(≤15 mm) invasive breast cancer. 
Split to expand on former NAS 
which was for all screening 
rounds. 
2.1.3 (c) 2.2.1 ≥25 per 10,000 women aged 50–69 years who attend for 
screening are diagnosed with small (≤15 mm) invasive breast 
cancer. 
Split to expand on former NAS 
which was for all screening 
rounds. 
2.2.1 (a) 2.3.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening 
episode who are diagnosed with DCIS. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.2.1 (b) 2.3.1 ≥12 per 10,000 women aged 50–69 years who attend for their 
first screening episode are diagnosed with DCIS. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.2.2 (a) 2.3.2 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or 
subsequent screening episode who are diagnosed with DCIS. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.2.2 (b) 2.3.2 ≥7 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with 
DCIS. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.3.1 (a) 2.4.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are 
diagnosed with an interval invasive breast cancer 0–12 months 
following a negative screening episode. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.3.1 (b) 2.4.2 (a) <7.5 per 10,000 women aged 50–69 years who attend for 
screening are diagnosed with an interval invasive breast cancer 
0–12 months following a negative screening episode. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.3.2 (a) 2.4.2 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are 
diagnosed with an interval invasive breast cancer 13–24 months 
following a negative screening episode. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.3.2 (b) 2.4.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for 
screening are diagnosed with an interval invasive breast cancer 
13–24 months following a negative screening episode. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.4.1 2.12.3 All screen readers read at least 2,000 mammographic screening 
cases within the Program per year. 
Numbering change and slight 
change in wording. 
2.5.2 2.10.3 The overall repeat rate for the Service and/or SCU is ≤2% of all 
screening images. 
Rule changed from <3% to 
≤2% and numbering change. 
2.6.1 (a) 1.5.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for annual screening. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.6.1 (b) 1.5.1 ≤10% of women aged 50–69 years attend for annual screening. Split into parts (a) and (b) to 
include the new target age 
group.  
2.6.2 1.5.2 The Service and/or SCU monitors and reports the proportion of 
women who attend for annual screening, aged 40–49 years and 
75 years and over. 
Changed from 70 years and 
over to 75 years and over. 
2.6.3 (a) 2.6.1 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening 
episode and are recalled for assessment. 
Split into parts (a) and (b) to 
include the new target age 
group.  
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2.6.3 (b) 2.6.1 <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.6.4 (a) 2.6.2 The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or 
subsequent screening episode and are recalled for assessment. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.6.4 (b) 2.6.2 <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. 
Split into parts (a) and (b) to 
include the new target age 
group.  
2.6.7 2.22.1 <0.2% women who attend for screening are recommended for 
early review for further assessment. 
Numbering change. 
3.1.4 2.8.1 ≤0.35% of women who attend for their first screening episode 
are found not to have invasive breast cancer or DCIS after 
diagnostic open biopsy. 
Numbering change. 
3.1.5 2.8.2 ≤0.16% of women who attend for their second or subsequent 
screening episode are found not to have invasive breast cancer 
or DCIS after diagnostic open biopsy. 
Numbering change. 
3.1.6 2.21.2 All women with impalpable lesions undergoing excision have 
specimen imaging recorded. 
Wording and numbering 
change. 
3.1.7 2.21.3 ≥95% of all lesions are correctly identified at first excision. Wording and numbering 
change. 
3.1.8 (a) 2.7.1 ≥85% of invasive breast cancers or DCIS are diagnosed without 
the need for excision. 
Rule changed from ≥75% to 
≥85%, wording and numbering 
change and split into parts (a) 
and (b). 
4.1.1 (a) 3.7.1 ≥90% of women aged 50–74 years attend for a screening 
appointment within 28 calendar days of their booking date (fixed 
sites only). 
Numbering change and 
restricted to women aged  
50–74 years. 
4.1.2 3.8.1 ≥90% of women have a documented notification of the results of 
screening within 14 calendar days of the date of screening. 
Wording and numbering 
change. 
4.2.1 (a) 3.7.2 ≥90% of women requiring assessment attend an assessment 
visit within 28 calendar days of their screening visit. 
Numbering change. 
4.2.2 2.20.3 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first 
assessment visit. 
Wording and numbering 
change. 
4.2.3 2.20.1 ≥95% of women require no more than two procedural 
assessment visits to receive a definitive recommendation from 
assessment. 
Wording and numbering 
change. 
4.2.4 3.8.3 (a) / 
3.8.3 (b) 
≥85% of women are verbally given the results of percutaneous 
needle biopsy within seven calendar days of the assessment 
procedure. 
New measure created to 
combine two former NAS. 
4.2.5 2.20.2 ≥95% of women complete all assessment within 15 calendar 
days. 
Wording changed from within 
a 2 week period to within 15 
calendar days. 
4.2.6 3.8.6 All women are notified of the results of their assessment in 
writing within 14 calendar days of the date of completion of 
assessment. 
Numbering change. 
5.1.1 2.24.3 ≥95% of data dictionary compliant surgical histopathology 
information is received by the Service and/or SCU. 
Wording and numbering 
change. 
5.1.2 2.24.4 ≥95% of data dictionary compliant primary treatment information 
is received by the Service and/or SCU. 
Changed from ≥80% to ≥95%.  
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Table S6: New NAS Measures 
Name Definition 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of women aged 50–74 years who attend annually 
for screening, who are diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of women aged 50–74 years who attend annually 
for screening, who are diagnosed with small (≤15 mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of women aged 40–49 years who attend annually 
for screening, who are diagnosed with invasive breast cancer. 
2.2.3 The Service and/or SCU monitors and reports the number of women aged 50–74 years who attend annually 
for screening, who are diagnosed with DCIS. 
2.5.1 The Service and/or SCU monitors and reports the percentage of women who have up to 4 images per screen, 
including technical repeats. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive value of a recall to assessment for 
detecting invasive breast cancer or DCIS in women aged 50–74 years who attend for their first screening 
episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive value of a recall to assessment for 
detecting invasive breast cancer or DCIS in women aged 50–74 years who attend for their second or 
subsequent screening episode. 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions are classified as benign or 
inadequate/insufficient. 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a false positive cancer diagnosis, when 
the definitive needle biopsy result is achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core biopsy, prior to recommendation for 
surgery or treatment, is not considered to be a false positive ‘percutaneous needle biopsy’ for the purpose of 
this standard. 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on percutaneous needle biopsy is >90%. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provides the proportion of breast cancers that are 
diagnosed as invasive and DCIS without the need for excision. 
4.1.1 (b) Where part (a) is not met, the Service and/or SCU records and reports the time taken to achieve 90% from 
booking to screening (fixed sites only). 
4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and reports the number of days the Service and/or 
SCU takes to achieve 90%. 
4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and reports the percentage of women who were 
offered assessment within 28 calendar days of their screening visit. 
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Table S7: Retired NAS 
Name Definition 
2.1.3 The Service monitors the rates of invasive breast cancer among women aged 40–49 years and 70 years and over. 
2.2.2 The Service monitors the rates of small (≤15 mm) invasive breast cancer among women aged 40–49 years and 70 
years and over. 
2.3.3 The Service monitors the rates of DCIS among women aged 40–49 years and 70 years and over. 
2.4.3 The Service monitors the number of women aged 40–49 years and 70 years and over diagnosed with an interval 
invasive breast cancer. 
2.8.3 ≤4.0% of women assessed after their first screen are found not to have invasive cancer of DCIS after a diagnostic 
open biopsy. 
2.8.4 ≤3.2% of women assessed after their second or subsequent screen are found not to have invasive cancer of DCIS 
after a diagnostic open biopsy. 
2.18.1  <25% of all lesions assessed by FNA are classified with the result inadequate/insufficient. 
2.18.2 The proportion of core biopsy procedures with a false negative or inadequate result. 
2.19.5 <6% of malignant lesions assessed by FNA have a false negative result. 
2.19.6 (a) <1% of malignant lesions assessed by FNA have a false positive result. 
2.19.6 (b) The proportion of non-malignant lesions assessed by FNA with a false positive result. 
2.19.7 <0.5% of lesions sampled through core biopsy have a false positive result. 
2.19.8   The absolute sensitivity of a diagnosis of breast cancer based on FNA cytology is >60%. 
2.19.9 The complete sensitivity of FNA biopsy in the assessment of breast lesions is >80%. 
2.19.10 The absolute sensitivity of core biopsy in the assessment of breast lesions is >70%. 
2.19.11 The complete sensitivity of core biopsy in the assessment of breast lesions is >80%. 
2.19.12 The positive predictive value of a malignant FNA diagnosis is >98%. 
2.19.13 The positive predictive value of a malignant core biopsy diagnosis is >99%. 
3.7.3 ≥70% of open biopsies are performed within 14 calendar days of the recommendation for the procedure. 
3.8.2 All women are notified of the results of their screening in writing, within 28 calendar days of the date of screening. 
3.8.4 All women receive the results of FNA biopsy or core biopsy in writing within 14 calendar days of the assessment 
procedure. 
4.1.3 The Service demonstrates a minimum annual throughput for each independent screening unit of: 4,000 women for 
urban units and 3,000 women for rural/remote units. 
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3 Data elements  
For ease of use, the data element definitions in this data dictionary (excluding those for 
performance indicators) are presented in eight separate segments, A–H, as below.  
A. Identifier segment 
B. Client segment 
C. Screening visit segment 
D. Assessment visit segment 
E. Local excision of lesion segment 
F. Histopathology segment 
G. Primary treatment segment 
H. Death segment. 
Performance indicator data element definitions are presented separately in Chapter 4. 
Please note that the fields that describe the representational form of each data element are 
not meant to prescribe how state and territory database systems should store the 
information.  
Fields such as ‘Datatype’, ‘Field size’, ‘Representational form’ and ‘Representational layout’ 
describe how the data element should be represented for reporting purposes. The 
information can be stored differently in state and territory computer systems as long as the 
information required can be extracted and converted into the format required.  
The ‘Data domain’ field, however, does prescribe the minimum information to be collected. 
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Data elements 
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A—Identifier segment 
Data dictionary Version 1.1 Data dictionary Version 1 
A.1 Client identifier number A.1 Client identifier number 
A.2 Screening unit identifier A.2 Screening unit identifier 
A.3 Assessment unit identifier A.3 Assessment unit identifier 
A.4 Surgical unit identifier A.4 Surgical unit identifier 
A.5 Lesion number A.5 Lesion number 
A.6 Service provider identifier A.6 Service provider identifier 
A.7 Machine identifier A.7 Machine identifier 
A.8 Estimated date flag A.8 Estimated date flag 
A.9 State identifier A.9 State identifier 
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A.1 Client identifier number 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A BreastScreen Australia identifier unique within a State and Territory. 
Context This data element identifies each woman on the BreastScreen database and 
is used for tracking women within a State and Territory. 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain The client identifier number 
Guide for use Only one Client Identifier Number is to be allocated to each woman within 
each jurisdiction. 
This is allocated at the first contact with the service and may include women 
who never attend, e.g. where an appointment is made but not kept. 
Verification rules  
Related data 
elements 
B.1 Name 
Related NAS 
Measures 
Except for NAS Measure 2.5.2, all elements use this data element. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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A.2 Screening unit identifier 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A BreastScreen Australia identifier number for each screening unit unique 
within a State and Territory. 
Context Screening visit. 
This data element identifies the unit in which the mammographic screening 
took place. 
This number also identifies whether the screening unit is a mobile or fixed 
unit. 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain The screening unit identifier number 
Guide for use One Screening Unit Identifier code is to be allocated to each screening unit, 
unique within each Sate and Territory. 
Verification rules  
Related data 
elements 
A.7 Machine identifier 
C.2 Date of first attendance for this episode 
Related NAS 
Measures 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
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and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.2 (a) The Service and/or SCU monitors the proportion of women, aged  
40–49 years and 75 years and over who are screened and recalled for 
assessment. 
(a) screened 
2.1.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast 
cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS. 
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2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second 
or subsequent screening episode are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.5.2 The overall repeat rate for the Service and/or SCU is ≤2% of all 
screening images. 
2.6.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for annual screening. 
2.6.1 (b) ≤10% of women aged 50–69 years attend for annual screening. 
2.6.2 The Service and/or SCU monitors and reports the proportion of women 
who attend for annual screening, aged 40–49 years and 75 years and over. 
2.6.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode and are 
recalled for assessment. 
2.6.3 (b) <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. 
2.6.4 (a) The Service and/or SCU offers, monitors and reports the proportion 
of women aged 50–74 years who attend for their second or subsequent 
screening episode and are recalled for assessment. 
2.6.4 (b) <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
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2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening episode. 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
4.1.1 (a) ≥90% of women aged 50–74 years attend for a screening 
appointment within 28 calendar days of their booking date (fixed sites only). 
4.1.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the time taken to achieve 90% from booking to screening (fixed sites 
only). 
4.1.2 ≥90% of women have documented notification of the results of 
screening within 14 calendar days of the date of screening. 
4.2.1 (a) ≥90% of women requiring assessment attend an assessment visit 
within 28 calendar days of their screening visit. 
4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the number of days the Service and/or SCU takes to achieve 90%. 
4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and 
report the percentage of women who were offered assessment within 28 
calendar days of their screening visit. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments The Screening unit identifier determines the service to which the outcomes of 
screening are attributed. 
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A.3 Assessment unit identifier 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A BreastScreen Australia identifier number for each assessment unit unique 
within a State and Territory. 
Context This data element identifies the assessment centre at which the assessment 
of a client took place. It is also used to indicate whether the assessment 
centre is inside or outside BreastScreen Australia. 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain The assessment unit identifier number 
Guide for use Use an ‘unknown’ identifier code to indicate when the location of the 
assessment centre/service is not known. 
More than one assessment unit identifier can apply to each screening 
episode; e.g., a client may attend for mammographic work-up on a mobile 
unit and further work-up elsewhere or she may attend for her initial work-up in 
one assessment centre and have a core biopsy elsewhere. 
Verification rules  
Related data 
elements 
D.2.1 Attendance for assessment 
Related NAS 
Measures 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
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3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
3.1.7 ≥95% of all lesions are correctly identified at first excision. 
3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provide the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.3 ≥95% of women require no more than two procedural assessment visits 
to receive a definitive recommendation from assessment. 
4.2.4 ≥85% of women are verbally given the results of percutaneous needle 
biopsy within seven calendar days of the assessment procedure. 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
4.2.6 All women are notified of the results of their assessment in writing within 
14 calendar days of the date of completion of assessment. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments The location of the screening visit determines the attribution of the outcome 
of assessment. If a woman is assessed in a Screening and Assessment 
Service (SAS) outside the SAS where screening took place or in an 
assessment centre outside BreastScreen Australia or in another state, then 
the information about assessment is relevant only to the NAS Measures that 
measure the efficiency of the assessment unit undertaking the assessment 
process. The final outcome of assessment is attributed to the SAS where 
screening took place. For example if a cancer is detected then it is attributed 
to the screening SAS and NOT counted in the assessment SAS. This also 
applies to the reporting of NAS Measures such as the proportion returning to 
assessment, etc. The fact that the assessment took place outside the 
screening SAS or that the assessment was carried out in more than one 
assessment centre is captured by the Assessment unit identifier. 
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A.4 Surgical unit identifier 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A BreastScreen Australia identifier for the surgical unit attended by the 
woman for local excision of a lesion, unique within a State and Territory. 
Context Local excision of a lesion for diagnosis or treatment following assessment. 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain The surgical unit identifier number 
Guide for use One Surgical Unit Identifier code is to be allocated to each surgical unit, 
unique within each State and Territory. 
If the woman underwent surgery more than once, this data element is 
repeated. 
Verification rules  
Related data 
elements 
A.6 Service provider identifier 
E.1 Local excision performed 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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A.5 Lesion number 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The number of the suspicious lesion that has been identified during the 
screening visit, during the assessment visit, during local excision or after the 
screening episode (interval cancer or cancer in a non-attender for rescreen). 
Context Lesion number is used to track each lesion for each client. 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min. 2 Max. 2 Representational layout AN 
Data domain The lesion number 
Guide for use Data are collected for up to two lesions for each stage of assessment, 
diagnosis and treatment. These lesions are the most significant lesions within 
each category (mammographic, clinical, etc as listed below) and within each 
stage of reporting. A suggested coding system is set out below. The purpose 
of using a coding system is to be able to track each lesion for each client. 
States and Territories may have their own unique system, providing that it 
allows for the tracking of up to two lesions at the final stage of diagnosis. 
The coding system identifies the type of lesion and the stage of the screening 
episode at which it was first identified. If a lesion at the final stage is found to 
be more significant than that recorded at an earlier stage then the earlier 
lesion should be replaced. 
Services may choose to track more lesions. 
Coding system: 
Mammographic lesions detected at screening (two lesions): 
M1 = the first mammographic lesion to be worked up. 
M2 = the second mammographic lesion to be worked up. 
Clinical symptoms/signs reported prior to assessment (by self-report from 
woman or sign noted at screening) which on mammographic workup does not 
correspond to a mammographic lesion (up to one lesion): 
S1 = a clinical symptom/sign to be worked up. 
Mammographic lesion found during assessment (up to one lesion): 
M3 = a mammographic lesion found during assessment. 
Lesion found at clinical examination during assessment that does not 
correspond to a mammographic lesion (up to one lesion): 
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C1 = a clinical lesion found at clinical examination during assessment. 
Lesion identified at Ultrasound during assessment that does not correspond 
to a mammographic lesion (up to one lesion): 
U1 = a lesion identified at Ultrasound during assessment. 
Lesion identified at local excision (i.e. not identified at assessment) (up to one 
lesion): 
E1 = a lesion identified at local excision. 
Lesion detected after completion of the last screening episode (i.e. interval 
cancer or cancer in a non-attender for rescreen) (up to one lesion): 
I1 = a lesion detected after completion of the last screening episode. 
The meaning of the codes is: 
M = Mammographic 
S = Symptom/sign 
C = Clinical 
U = Ultrasound 
E = Local excision 
I = Interval cancer/cancer in a non-attender for rescreen. 
Sometimes a third or fourth mammographic lesion may turn out to be more 
significant than M1 or M2. In this case one of the lesions collected and 
recorded as M1 and M2 will need to be replaced by this more significant 
lesion. The same applies to other lesion types. 
Verification rules  
Related data 
elements 
D.3.1 Nature of mammographic lesion(s) to be assessed 
D.3.2 Nature of mammographic lesion(s) to be assessed—side 
D.5 Result of mammography 
D.6.1 Result of clinical examination 
D.6.2 Correspondence of clinical examination to mammographic 
 abnormality 
D.7.1 Result of ultrasound 
D.7.2 Description of ultrasound lesion 
D.8.1 Percutaneous needle biopsy performed 
D.8.2 Percutaneous needle biopsy guidance method 
D.8.3 Percutaneous needle biopsy result 
D.9 Other procedures performed 
E.4.1 Marking method 
E.4.2 Localisation technique 
E.5 Palpability of lesion 
E.6 Frozen section 
E.7 Specimen imaging 
E.8.1 Lesion removal 
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E.9 Local excision result 
F.2.1 Axillary dissection 
F.2.2 Sentinel node biopsy performed 
F.2.3 Axillary dissection—total number of nodes 
F.2.4 Axillary dissection—number of nodes positive 
F.3 Histopathology of non-malignant lesions 
F.4 Histopathology of malignant lesions 
F.5 Size of tumour 
F.6 Histological grade 
F.7 Dominant lesion identification number 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
3.1.7 ≥95% of all lesions are correctly identified at first excision. 
3.3.2 ≥ 95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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A.6 Service provider identifier 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Identifying code of the service provider. 
Context This data element is used to identify each service provider involved with the 
mammographic screening, assessment and/or treatment of a client. 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain The service provider identifier  
Guide for use This data element is used to identify the following service providers, using a 
unique code for each service provider, to be allocated by the State and 
Territory Coordination Unit: 
Radiographer: the person who operated the mammography machine. Coded 
for radiographer of initial screening images (C.3.1) and radiographer of 
technical repeat images (C.3.3), if different. 
Reader (usually radiologist): the person who read the mammographic 
screening images (C.4) and mammographic assessment images (D.5). 
Clinical examiner: the person who carried out the clinical exam during 
assessment of the client (D.6.1). 
Ultrasound interpreter: the person (usually radiologist) who interpreted the 
ultrasound images during assessment of the client (D.7.1). 
Percutaneous needle biopsy operator: the person who performed the 
percutaneous needle biopsy during assessment of the client (D.8.2). 
Percutaneous needle biopsy interpreter: the cytologist/pathologist who 
interpreted the cytology/pathology of the percutaneous needle biopsy 
specimen (D.8.3). 
Assessment coordinator: the person who coordinated the assessment team 
(D.12). 
Surgeon: the doctor who performed the local excision of lesion (E.1). 
Local excision interpreter: the pathologist (F.3 to F.6). 
Treating doctor: the doctor responsible for the primary treatment for clients 
diagnosed with breast cancer (G.1). 
Verification rules  
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Related data 
elements 
A.4 Surgical unit identifier 
A.7 Machine identifier 
C.3.1 Total number of images used 
C.3.2 Technical repeat status 
C.3.3 Number of technical repeats 
C.4 Screening mammogram reading results 
D.5 Result of mammography 
D.6.1 Result of clinical examination 
D.7.1 Result of ultrasound 
D.8.2 Percutaneous needle biopsy guidance method 
D.8.3 Percutaneous needle biopsy result 
D.10 Final result of assessment visit 
E.1 Local excision performed 
E.8.2 Further surgery recommended 
F.3 Histopathology of non-malignant lesions 
F.4 Histopathology of malignant lesions 
F.5 Size of tumour 
F.6 Histological grade 
Related NAS 
Measures 
2.4.1 All screen readers read at least 2,000 mammographic screening cases 
within the Program per year. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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A.7 Machine identifier  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Identifying code of the mammography machine used to screen the client. 
Context This data element is used to identify the mammography machine and 
modality (analogue or digital) used to screen the client 
Relational and representational attributes 
Datatype Alpha 
numeric 
 Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain Number of machine used for initial screening images 
Number of machine used for technical repeat images 
Guide for use The machine number changes when a machine is replaced. If only the tube is 
replaced, the machine number should be retained with a letter added to 
denote the new tube. For example, original machine number = 2; modified 
machine number = 2A. 
Mammography machine is identified by the screening unit where the 
screening mammogram was performed. 
Verification rules  
Related data 
elements 
A.2 Screening unit identifier 
A.6 Service provider identifier 
C.3.1 Total number of images used 
C.3.2 Technical repeat status 
C.3.3 Number of technical repeats 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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A.8 Estimated date flag 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition An indication of whether any component of a reported date was estimated. 
Context Provision of a date is often a mandatory requirement in data collections. 
However, at times, the actual date or part thereof is not known (e.g. date of 
birth). 
This data element is designed to flag the part or parts of a date that have 
been estimated when a date provided is based on an approximation of the 
date in question rather than reporting of the actual date. This data element 
may assist with record linkage processes (for example when the date of birth 
is a component of the linkage key). 
Relational and representational attributes 
Datatype Alphabetic  Representational form CODE 
Field size Min. 0 Max. 3 Representational layout AAA 
Data domain Null date not estimated 
A date estimated from reported age  
D day value in date was estimated  
DM day and month values in date were estimated  
DMY all values (day, month, year) in date were estimated 
M month value (only) in date was estimated 
MY month and year values in date were estimated 
Y year value (only) in date was estimated 
DY day and year values in date were estimated 
Guide for use May be used to record an estimated date for date of birth or data elements for 
other dates such as date of death. 
This data element should be reported in conjunction with a reported date 
when any part of the date represents an estimate rather than the actual or 
known date. 
Verification rules  
Related data 
elements 
B.2 Date of birth—date of birth, date DDMMYYYY 
C.1 Booking date 
C.2 Date of first attendance for this episode 
C.6 Date woman notified of screening results 
C.7.2 Letter to general practitioner about screening results—date 
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D.2.2 Date of first attendance for assessment 
D.2.3 Date first offered appointment for assessment 
D.11.3 Date recommendation made 
D.13.1 Date woman notified in writing of assessment results 
D.13.2 Date woman notified verbally of biopsy results 
D.14.2 Letter to general practitioner about assessment results - date 
E.2 Date excision performed 
E.11 Date of definitive diagnosis 
F.1.2 Date of diagnosis 
G.2 Date of commencement of treatment 
H.1 Date of death 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
  
 BreastScreen Australia data dictionary: version 1.1 35 
A.9 State identifier 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition An identifier for State or Territory. 
Context Health services 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1 New South Wales 
2 Victoria 
3 Queensland 
4 South Australia 
5 Western Australia 
6 Tasmania 
7 Northern Territory 
8 Australian Capital Territory 
9 Other territories (Cocos (Keeling) Islands, Christmas Island and 
 Jervis Bay Territory) 
Guide for use This data element is important for national reporting, but does not necessarily 
need to be a separate data element in the State and Territory databases. 
Verification rules  
Related data 
elements 
 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation Australian Institute of Health and Welfare 
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B—Client segment 
Data dictionary version 1.1 Data dictionary version 1 
B.1 Name B.1 Name 
B.2 Date of birth B.2 Date of birth 
B.3.1 Area of usual residence (SA2) B.3.1 Area of usual residence 
B.3.2 Postcode of usual residence  B.3.2 Postcode of usual residence  
B.4 Main language other than English 
spoken at home 
B.4 Main language other than English 
spoken at home 
B.5 Indigenous status  B.5 Indigenous status  
B.6.1 Family history of breast cancer B.6.1 Family history of breast cancer 
B.6.2 Family history of breast cancer—
relationship 
B.6.2 Family history—relationship 
B.6.3 Family history of breast cancer—age B.6.3 Family history—age 
B.6.4 Family history of breast cancer—
laterality 
B.6.4 Family history—laterality 
B.7.1 Previous history of breast cancer B.7.1 Previous history of breast cancer 
B.7.2 Previous history of breast cancer—
year 
B.7.2 Previous history—year 
B.7.3 Previous history of breast cancer—
laterality 
B.7.3 Previous history—laterality 
B.8.1 Mammographic history at first 
screening visit 
B.8.1 Mammographic history at first 
screening visit 
B.8.2 Mammographic history—year B.8.2 Mammographic history—year 
B.9.1 Round number—State/Territory 
program 
B.9.1 Round number—State and Territory 
program 
B.9.2 Round number—national program B.9.2 Round—national program 
B.10 Symptom status B.10 Symptom status 
B.11 General practitioner flag B.11 General practitioner flag 
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B.1 Name 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A set of descriptors identifying each woman allocated a Client identifier 
number, using title, surname and other names of the woman at the time of 
registration, and surname at birth. 
Context Data linkage, administrative purposes and individual identification. 
Relational and representational attributes 
Datatype Character  Representational form TEXT 
Field size Min.  Max.  Representational layout  
Data domain Concatenation of: 
• Title 
• Surname (Family name) 
• First Given Name 
• Second Given Name 
• Surname at Birth 
Guide for use The service should record for each client the woman’s full name on their 
information systems, including as a minimum Surname (Family name), First 
name, Second name (if they have one) and Surname at birth (Maiden name). 
The field length for this data element is at the discretion of information system 
designers. 
Often people use a variety of names, including legal names, married/maiden 
names, nicknames, assumed names, traditional names, etc. Even small 
differences in recording—such as the difference between MacIntosh and 
McIntosh—can make record linkage impossible. To minimise discrepancies in 
the recording and reporting of name information, services should ask the 
person for their full (formal) Given name(s) and Surname. These may be 
different from the name that the person may prefer the staff to use in personal 
dealings. Services may choose to separately record the preferred names that 
the person wishes to be used by the staff. 
In some cultures it is traditional to state the family name first. To overcome 
discrepancies in recording/reporting that may arise as a result of this practice, 
services should always ask the person to specify their first given name and 
their family name or surname separately. These should then be recorded as 
Given name and Family name as appropriate, regardless of the order in 
which they may be traditionally given. 
Verification rules  
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Related data 
elements 
A.1 Client identifier number 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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B.2 Date of birth 
Identifying and definitional attributes 
Data element name Date of birth 
Definition The date of birth of the person. 
Value domain attributes 
Representational 
class 
Date 
Data type Date/Time 
Format DDMMYYYY 
Maximum character 
length 
8 
Data element attributes 
Collection and usage attributes 
Guide for use If date of birth is not known, provision should be made to collect age (in 
years) and a date of birth derived from age. If date of birth is derived from 
age, then date of birth should be entered as 01/01/approximate year. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the date of birth is July 1 1950 the date should be recorded as 
01071950 as specified in the representational layout. 
It is recommended that in cases where all components of Date of birth are not 
known or where an estimate is arrived at from age, a valid date be used 
together with the A.8 Estimated date flag to indicate that it is an estimate. 
If year of birth is derived from age, then date of birth is entered as 
01/01/approximate year. If both date of birth and age are unknown and an 
estimate cannot be obtained, but it has been ascertained that the woman is 
40 years or over, record the date of birth as 99/99/9999. 
Comment Please note that although this data element prescribes the format in which 
estimated date of birth is to be entered, it is acknowledged that not all State 
and Territory Programs are able to comply at this stage. It is recommended 
that State and Territory Programs aim to, in time, adjust their policies in 
relation to this data element. 
Source and reference attributes 
Origin BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Relational attributes 
Verification rules This field must: 
• be ≤C.2 Date of first attendance for this episode 
• not be null 
Related data 
elements 
Date of birth can be used as an aid to uniquely identify a client if other 
identifying information is missing or in question. 
Used with C.2 Date of first attendance for this episode to calculate a woman’s 
age. 
Related NAS 
Measures 
1.1.1 (a) The Service and/or SCU monitors and reports the participation rate 
of women aged 50–74 years who participate in screening in the most recent 
24-month period. 
1.1.1 (b) The Service and/or SCU monitors and reports the participation rate 
of women aged 50–69 years who participate in screening in the most recent 
24-month period. 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–67 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.2 The Service and/or SCU monitors the proportion of women, aged 40–49 
years and 75 years and over who are screened and recalled for assessment. 
(a) screened 
(b) recalled 
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2.1.1 (a) ≥50 per 10,000 women aged 50–74 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–69 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–69 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS. 
2.2.1 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–69 years who attend for their first screening episode who 
are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.2 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–69 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
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screening episode. 
2.3.1 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–69 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an  interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–69 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.6.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for annual screening. 
2.6.1 (b) ≤10% of women aged 50–69 years attend for annual screening. 
2.6.2 The Service and/or SCU monitors and reports the proportion of women 
who attend for annual screening, aged 40–49 years and 75 years and over. 
2.6.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode and are 
recalled for assessment. 
2.6.3 (b) <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. 
2.6.4 (a) The Service and/or SCU offers, monitors and reports the proportion 
of women aged 50–74 years who attend for their second or subsequent 
screening episode and are recalled for assessment. 
2.6.4 (b) <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening episode. 
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B.3.1 Area of usual residence (SA2) 
Admin. status SUPERSEDES  B.3.1 Area of usual residence 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A designated region describing location and contact details that represents a 
medium-sized area built from a number of Statistical Area 1, as represented 
by a code. The aim is to represent a community that interacts together 
socially and economically. 
Context Geographical location is reported using Statistical Area level 2 (SA2) to 
enable accurate aggregation of information to larger areas within the ASGS 
as well as detailed analysis at the SA2 level. 
The ASGS is the ABS’s framework for statistical geography. 
The use of SA2 also allows analysis relating the data to information compiled 
by the ABS on the demographic and other characteristics of the population of 
each SA2.  
In 2011, the ABS replaced the current Australian Standard Geographical 
Classification (ASGC) with the new Australian Statistical Geography Standard 
(ASGS). The ASGS comprises a hierarchy of geographic regions and is the 
future geographical standard on which the ABS will release statistical data. 
Statistical Areas Levels 1–4 (SA1, SA2, SA3 and SA4) are components of the 
new ASGS while Statistical Local Areas (SLA) belonged to the old ASGC 
structure. 
ASGS structures will be updated every Census year. In comparison, SLA 
boundaries were updated annually. 
To assign a single geographic identifier based on the ASGS using Australian 
address components:  
• SA1 classification requires street address, suburb/locality, postcode and 
state 
• SA2 or SA3 classification requires suburb/locality, postcode and state 
• SA4 can be generated from postcode only. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 9 Max. 9 Representational layout NNNNNNNNN 
Data domain The geographical location is reported using a nine digit numerical code to 
indicate the Statistical Area (SA) within the reporting state or territory, as 
defined in the Australian Statistical Geography Standard (ASGS) (ABS 2011). 
SA2 coding structure: An SA2 is identifiable by a 9-digit fully hierarchical 
code. The SA2 identifier is a 4-digit code, assigned in alphabetical order 
within an SA3. An SA2 code is only unique within a state/territory if it is 
preceded by the state/territory identifier. 
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For example: 
State/territory SA4 SA3 SA2 
N NN NNN NNNN 
 
Guide for use The main purpose of the Australian Statistical Geography Standard (ASGS) is 
the dissemination of geographically classified statistics. It provides a common 
framework of statistical geography which enables the publication of statistics 
that are comparable and spatially integrated. 
The ASGS is updated on an annual basis with a date of effect of 1 July each 
year. Therefore, the edition effective for the data collection reference year 
should be used. 
The codes for Statistical Areas are unique within each State and Territory, but 
not within the whole country. Thus, to define a unique location, the code of the 
State or Territory is required in addition to the code for the Statistical Area. 
The information about SA2 is retained for each visit. 
When collecting the geographical location of a person‘s usual place of 
residence, the ABS recommends that ‘usual’ be defined as: the place where 
the person has or intends to live for 6 months or more, or the place that the 
person regards as their main residence, or where the person has no other 
residence, the place they currently reside.‘ Apart from collecting a person‘s 
usual place of residence there is also a need in some collections to collect 
area of residence immediately prior to or after assistance is provided, or at 
some other point in time. 
Verification rules  
Related data 
elements 
B.3.2 Postcode of usual residence 
Related NAS 
Measures 
1.1.1 (a) The Service and/or SCU monitors and reports the participation rate 
of women aged 50–74 years who participate in screening in the most recent 
24-month period. 
1.1.1 (b) ≥70% of women aged 50–69 years participate in screening in the 
most recent 24-month period. 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below that 
of the overall population, implements specific strategies to encourage their 
participation in screening. Consideration of equitable participation rates of at 
least the following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic backgrounds. 
1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below that 
of the overall population, implements specific strategies to encourage their 
participation in screening. Consideration of equitable participation rates of at 
least the following groups is made: women from Indigenous, culturally and 
linguistically diverse, rural/remote and lower socioeconomic backgrounds. 
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Administrative attributes 
Source document ABS 2011. Australian Statistical Geography Standard (ASGS):  
Volume 1—Main Structure and Greater Capital City Statistical Areas.  
Cat no. 1270.0.55.001. Canberra: ABS. 
Source organisation ABS 
Comments There are 2,196 SA2 spatial units. In aggregate, they cover the whole of 
Australia without gaps or overlaps. Jervis Bay Territory, the Territory of the 
Cocos (Keeling) Islands and the Territory of Christmas Island are each 
represented by an SA2. 
Analyses facilitated by the inclusion of SA2 information include: comparison 
of the use of services by persons residing in different geographical areas; 
characterisation of catchment areas and populations for establishments for 
planning purposes; and documentation of the provision of services to 
residents of states or territories other than the state or territory of the 
provider. 
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B.3.2 Postcode of usual residence 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Postcode of usual residence is a four digit numeric code used by Australia 
Post to define a postal delivery area. 
Context This data element may be used for reporting participation in BreastScreen 
Australia by postcode of usual residence. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 4 Max. 4 Representational layout NNNN 
Data domain Valid Australia Post postal code. 
9999 = Unknown 
Guide for use Australian postal addresses should include a valid postcode. 
For a full list of Australian postcodes visit the Australia Post website: 
www.auspost.com.au 
If a woman provides a postal address, the postcode of actual usual residence 
should be collected, if different. 
May be collected as part of the woman’s address or separately. Postal 
addresses may be different from where a person actually resides, or a 
service is actually located. The information about postcode is retained for 
each visit. 
Verification rules  
Related data 
elements 
B.3.1 Area of usual residence (SA2) 
Related NAS 
Measures 
1.1.1 (a) The Service and/or SCU monitors and reports the participation rate 
of women aged 50–74 years who participate in screening in the most recent 
24-month period. 
1.1.1 (b) ≥70% of women aged 50–69 years participate in screening in the 
most recent 24-month period. 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
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1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
Administrative attributes 
Source document Postcode book < http://auspost.com.au/apps/postcode.html> 
Source organisation Australia Post 
Comments Please note that although this data element requires that the information 
about postcode be retained for each visit, it is acknowledged that not all State 
and Territory systems can comply. It is recommended that future upgrades of 
State and Territory systems ensure that prior information on postcode for 
each visit is retained.  
This data element may be used in the analysis of data on a geographical 
basis which involves a conversion from postcodes to the Australian Bureau of 
Statistics (ABS) postal areas. This conversion results in some inaccuracy of 
information as postcodes do not have a geographic definition and boundaries 
are not well defined.  
The AIHW is discouraging use of postcode as a geographic identifier for a 
number of reasons: 
While postcode indexes allow users to allocate data collected with a postcode 
to certain ASGS regions to enable comparison to ABS data, they are limited 
to the larger geographic boundaries. Coding data using postcode to smaller 
geographic boundaries does not provide consistently accurate results. 
Postcodes are, in Australia Post's words, ‘maintained solely for mail 
processing purposes’. They do not follow the ABS's boundaries in many 
cases. Therefore where a postcode crosses one of ABS’s region boundaries 
a decision must be made as to where to assign the postcode. This may 
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include assigning proportions to different boundaries. 
Postcodes are sometimes discontiguous which results in discrete parts of 
postcodes physically located a considerable distance away from the ABS 
region to which they are allocated. 
There are a large number of valid postcodes that do not correspond to 
residential areas (such as post boxes, competition mail bags etc) which are 
not appropriate for geographically identifying health information. 
New postcodes are created, and postcode boundaries are updated as 
necessary by Australia Post which makes it difficult to maintain as a 
standardised geographic identifier. 
  
 BreastScreen Australia data dictionary: version 1.1 49 
B.4 Main language other than English spoken at home 
Admin. status SUPERSEDES  B.4 Main language other than English spoken at 
   home 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The language reported by a person as the main language other than English 
spoken by a person in his/her home (or most recent private residential setting 
occupied by the person) on a regular basis, to communicate with other 
residents of the home or setting and regular visitors. 
Context This data element is consistent with that used in the Australian Census of 
Population and Housing and is recommended for use whenever there is a 
requirement for comparison with Census data. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 2 Max. 4 Representational layout NNNN 
Data domain Refer to the ABS Australian Standard Classification of Languages 2005 for 
details. 
Guide for use The Australian Standard Classification of Languages (ASCL) has a three- 
level hierarchical structure. The most detailed level of the classification 
consists of base units (languages) which are represented by four-digit codes. 
The second level of the classification comprises narrow groups of languages 
(the Narrow Group level), identified by the first two digits. The most general 
level of the classification consists of broad groups of languages (the Broad 
Group level) and is identified by the first digit. The classification 
includes Australian Indigenous languages and sign languages. 
For example, the Lithuanian language has a code of 3102. In this case 3 
denote that it is an Eastern European language, while 31 denote that it is a 
Baltic language. The Pintupi Aboriginal language is coded as 8713. In this 
case 8 denote that it is an Australian Indigenous language and 87 denote that 
the language is Western Desert language. 
Language data may be output at the Broad Group level, Narrow Group level 
or base level of the classification. If necessary significant Languages within a 
Narrow Group can be presented separately while the remaining Languages in 
the Narrow Group are aggregated. The same principle can be adopted to 
highlight significant Narrow Groups within a Broad Group. 
Recommended question: 
Do you/Does the person/Does (name) speak a language other than English 
at home? (If more than one language, indicate the one that is spoken most 
often.)  
No (English only) ____  
 50 BreastScreen Australia data dictionary: version 1.1 
Yes, Italian ____  
Yes, Greek ____  
Yes, Cantonese ____  
Yes, Arabic ____  
Yes, Mandarin ____  
Yes, Vietnamese ____  
Yes, Spanish ____  
Yes, German ____  
Yes, Hindi ____  
Yes, Other (please specify) ______________________________  
This list reflects the nine most common languages other than English spoken 
in Australia. 
Languages may be added or deleted from the above short list to reflect 
characteristics of the population of interest. 
Alternatively a tick box for 'English' and an 'Other - please specify' response 
category could be used. 
Related data 
elements B.5 Indigenous status 
Related NAS 
Measures 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
Administrative attributes 
Source document Australian Bureau of Statistics 2014. Standard Australian Classification of 
Countries (SACC). 2nd edition. ABS cat. no. 1269.0. Canberra: ABS. 
Source organisation Australian Bureau of Statistics 
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Comments This data element is important in identifying those people most likely to suffer 
disadvantage in terms of their ability to access services due to language 
and/or cultural difficulties. In conjunction with Indigenous status, Proficiency 
in spoken English and Country of birth this data element forms the minimum 
core set of cultural and language indicators recommended by the Australian 
Bureau of Statistics (ABS). 
Data on main language other than English spoken at home are regarded as 
an indicator of 'active' ethnicity and also as useful for the study of inter-
generational language retention. The availability of such data may help 
providers of health and community services to effectively target the 
geographic areas or population groups that need those services. It may be 
used for the investigation and development of language services such as 
interpreter/ translation services. 
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B.5 Indigenous status 
Admin. status SUPERSEDES  B.5 Indigenous status 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether a woman identifies as being of Aboriginal or Torres Strait Islander 
descent. This is in accord with the first two of three components of the 
Commonwealth definition. 
Context Australia's Aboriginal and Torres Strait Islander peoples occupy a unique 
place in Australian society and culture. In the current climate of reconciliation, 
accurate and consistent statistics about Aboriginal and Torres Strait Islander 
peoples are needed in order to plan, promote and deliver essential services, 
to monitor changes in wellbeing and to account for government expenditure 
in this area. The purpose of this data element is to provide information about 
people who identify as being of Aboriginal or Torres Strait Islander origin. 
Agencies or establishments wishing to determine the eligibility of individuals 
for particular benefits, services or rights will need to make their own 
judgments about the suitability of the standard measure for these purposes, 
having regard to the specific eligibility criteria for BreastScreen Australia 
concerned. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Aboriginal but not Torres Strait Islander origin 
2. Torres Strait Islander but not Aboriginal origin 
3. Aboriginal and Torres Strait Islander origin 
4. Neither Aboriginal nor Torres Strait Islander origin 
9. Not stated 
Guide for use This data element is based on the Australian Institute of Health and Welfare’s 
Metadata Online Registry METeOR standard for Indigenous status. For 
detailed advice on its use and application please refer to the METeOR 
website as indicated in the Reference documents. 
The classification for Indigenous status has a hierarchical structure 
comprising two levels. There are four categories at the detailed level of the 
classification which are grouped into two categories at the broad level. There 
is one supplementary category for 'not stated' responses. The classification is 
as follows: 
• Indigenous: 
 Aboriginal but not Torres Strait Islander origin. –
 Torres Strait Islander but not Aboriginal origin. –
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 Both Aboriginal and Torres Strait Islander origin. –
• Non-indigenous: 
 Neither Aboriginal nor Torres Strait Islander origin. –
• Not stated/ inadequately described: 
This category is not to be available as a valid answer to the questions but is 
intended for use: 
• Primarily when importing data from other data collections that do not 
contain mappable data. 
• Where an answer was refused. 
• Where the question was not able to be asked prior to completion of 
assistance because the client was unable to communicate or a person 
who knows the client was not available. 
Only in the last two situations may the tick boxes on the questionnaire be left 
blank. 
The standard question for Indigenous Status is as follows: 
[Are you] [Is the person] [Is (name)] of Aboriginal or Torres Strait Islander 
origin? 
(For women of both Aboriginal and Torres Strait Islander origin, mark both 
'Yes' boxes.) 
No.................................................... 
Yes, Aboriginal................................ 
Yes, Torres Strait Islander.............. 
This question is recommended for self-enumerated or interview-based 
collections. It can also be used in circumstances where a close relative, 
friend, or another member of the household is answering on behalf of the 
subject. It is strongly recommended that this question be asked directly 
wherever possible. 
When someone is not present, the person answering for them should be in a 
position to do so, i.e. this person must know well the person about whom the 
question is being asked and feel confident to provide accurate information 
about them. 
This question must always be asked regardless of data collectors' 
perceptions based on appearance or other factors. 
The Indigenous status question allows for more than one response. The 
procedure for coding multiple responses is as follows: 
• If the respondent marks 'No' and either 'Aboriginal' or 'Torres Strait 
Islander', then the response should be coded to either Aboriginal or 
Torres Strait Islander as indicated (i.e. disregard the 'No' response). 
• If the respondent marks both the 'Aboriginal' and 'Torres Strait Islander' 
boxes, then their response should be coded to 'Both Aboriginal and 
Torres Strait Islander origin. 
• If the respondent marks all three boxes ('No', 'Aboriginal' and 'Torres 
Strait Islander'), then the response should be coded to 'Both Aboriginal 
and Torres Strait Islander Descent' (i.e. disregard the 'No' response). 
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This approach may be problematic in some data collections, for example 
when data are collected by interview or using screen based data capture 
systems. An additional response category, Yes, both Aboriginal and Torres 
Strait Islander may be included if this better suits the data collection practices 
of the agency or establishment concerned. 
Verification rules  
Related data 
elements 
B.4 Main language other than English spoken at home 
Related NAS 
Measures 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
Administrative attributes 
Source document Australian Institute of Health and Welfare 2014. METeOR: Person—
Indigenous status, code N. Viewed 18 February 2014 
 < http://meteor.aihw.gov.au/content/index.phtml/itemId/291036 >. 
Australian Institute of Health and Welfare 2010. National best practice 
guidelines for collecting Indigenous status in health data sets. Cat. no. IHW 
29. Canberra: AIHW. 
Source organisation Australian Bureau of Statistics 
Comments The following definition, commonly known as 'The Commonwealth Definition', 
was given in a High Court judgement in the case of Commonwealth v 
Tasmania (1983) 46 ALR 625. 
'An Aboriginal or Torres Strait Islander is a person of Aboriginal or Torres 
Strait Islander descent who identifies as an Aboriginal or Torres Strait 
Islander and is accepted as such by the community in which he or she lives'. 
There are three components to the Commonwealth definition: 
• descent 
• self-identification 
• community acceptance. 
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In practice, it is not feasible to collect information on the community 
acceptance part of this definition in general purpose statistical and 
administrative collections and therefore standard questions on Indigenous 
status relate to descent and self-identification only. 
  
 56 BreastScreen Australia data dictionary: version 1.1 
B.6.1 Family history of breast cancer  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether a first degree female relative of the woman has had a diagnosis of 
breast cancer. 
Context This data element is used to determine, in conjunction with B.6.2 relationship, 
B.6.3 age at diagnosis and B.6.4 laterality, whether a woman is at higher than 
average risk of contracting breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use A first degree female relative is a mother, sister or daughter. 
This information is based on the client’s self-report at each visit and is 
retained for each visit. 
Verification rules  
Related data 
elements 
B.6.2 Family history of breast cancer—relationship 
B.6.3 Family history of breast cancer—age at diagnosis 
B.6.4 Family history of breast cancer—laterality 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
Please note that although this data element requires that the information 
about Family history be retained for each visit, it is acknowledged that not all 
State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Family history (B.6.1 to B.6.4), for each visit is retained.  
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B.6.2 Family history of breast cancer—relationship 
Admin. status SUPERSEDES  B.6.2 Family history—relationship 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The relationship of the client’s family member who has had a diagnosis of 
breast cancer to the client.  
Context This data element is used to determine, in conjunction with B.6.3 age at 
diagnosis and B.6.4 laterality, whether a woman is at higher than average risk 
of contracting breast cancer.  
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Mother  
2. Sister  
3. Daughter 
Guide for use This data element is only concerned with first degree female relatives. 
This information is based on the client’s self-report and is retained for each 
visit. 
Verification rules Relationship is to be entered only if entry for B.6.1 Family history of breast 
cancer is ‘yes’. 
Related data 
elements 
B.6.1 Family history of breast cancer 
B.6.3 Family history of breast cancer—age at diagnosis 
B.6.4 Family history of breast cancer—laterality 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
Please note that although this data element requires that the information 
about Family history be retained for each visit, it is acknowledged that not all 
State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Family history (B.6.1 to B.6.4), for each visit is retained. 
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B.6.3 Family history of breast cancer—age at diagnosis 
Admin. status SUPERSEDES  B.6.3 Family history—age 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Age (when diagnosed) of the person in the client’s family who has had a 
diagnosis of breast cancer. 
Context This data element is used to determine, in conjunction with B.6.2 relationship 
and B.6.4 laterality, whether a woman is at higher than average risk of 
contracting breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative 
value 
Field size Min. 1 Max. 3 Representational layout NNN 
Data domain Within valid age range. 
Guide for use Age at diagnosis is the age at which breast cancer was diagnosed.  
This information is based on the client’s self-report and is retained for each 
visit. 
If the woman does not know the exact age, she should be asked to estimate 
the age. If this is not possible, attempts should be made to establish whether 
the relative was under 50 years or not. 
Verification rules Age at diagnosis is to be entered only if entry for B.6.1 Family history of 
breast cancer is ‘yes’. 
Related data 
elements 
B.6.1 Family history of breast cancer 
B.6.2 Family history of breast cancer—relationship 
B.6.4 Family history of breast cancer—laterality 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
Please note that although this data element requires that the information 
about Family history be retained for each visit, it is acknowledged that not all 
State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Family history (B.6.1 to B.6.4), for each visit is retained. 
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B.6.4 Family history of breast cancer—laterality 
Admin. status SUPERSEDES  B.6.4 Family history—laterality 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Laterality of the breast cancer diagnosed in the client’s family member. 
Context This data element is used to determine, in conjunction with B.6.2 relationship 
and B.6.3 age at diagnosis, whether a woman is at higher than average risk 
of contracting breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Unilateral  
2. Bilateral  
3. Unknown 
Guide for use In this context unilateral means one breast affected and bilateral means both 
breasts affected. 
Unknown means unknown laterality.  
This information is based on the client’s self-report and is retained for each 
visit. 
Verification rules Laterality is to be entered only if entry for B.6.1 Family history of breast 
cancer is ‘yes’. 
Related data 
elements 
B.6.1 Family history of breast cancer 
B.6.2 Family history of breast cancer—relationship 
B.6.3 Family history of breast cancer—age.at diagnosis 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
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Please note that although this data element requires that the information 
about Family history be retained for each visit, it is acknowledged that not all 
State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Family history (B.6.1 to B.6.4), for each visit is retained. 
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B.7.1 Previous history of breast cancer  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not the client has had a previous diagnosis of breast cancer, 
including ductal carcinoma in situ. 
Context This data element may be used to report the percentage of women with a 
personal history of breast cancer who participated in BreastScreen Australia . 
It is also used in some State and Territory Programs to determine, in 
conjunction with related data elements, whether a woman is at higher than 
average risk of contracting breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use This information is based on the client’s self-report at each visit and is 
retained for each visit. 
Verification rules  
Related data 
elements 
B.7.2 Previous history of breast cancer—year 
B.7.3 Previous history of breast cancer—laterality 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
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Source organisation BreastScreen Australia 
Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
Please note that although this data element requires that the information 
about Previous history be retained for each visit, it is acknowledged that not 
all State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Previous history (B.7.1 to B.7.3), for each visit is retained. 
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B.7.2 Previous history of breast cancer—year 
Admin. status SUPERSEDES  B.7.2 Previous history—year 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The year in which the client’s previous breast cancer was diagnosed. 
Context This data element provides additional information on the timeframe in relation 
to B.7.1 Previous history of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 4 Max. 4 Representational layout YYYY 
Data domain Valid year 
Guide for use If year is unknown, provision should be made to collect the number of years 
since diagnosis and a year derived from this.  
This information is based on the client’s self-report and is retained for each 
visit. 
Verification rules Year is to be entered only if entry for B.7.1 Previous history of breast cancer 
is ‘Yes’. 
Year >1900 and < current year 
Related data 
elements 
B.7.1 Previous history of breast cancer 
B.7.3 Previous history of breast cancer—laterality 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
Please note that although this data element requires that the information 
about Previous history be retained for each visit, it is acknowledged that not 
all State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Previous history (B.7.1 to B.7.3), for each visit is retained. 
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B.7.3 Previous history of breast cancer—laterality 
Admin. status SUPERSEDES  B.7.3 Previous history—laterality 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Laterality of the client’s previous breast cancer. 
Context This data element provides additional information on the laterality in relation 
to B.7.1 Previous history of breast cancer. 
Relational and representational attributes 
Datatype Character  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout A 
Data domain L Left 
R Right 
B Both 
U Unknown 
Guide for use This information is based on the client’s self-report and is retained for each 
visit. 
Verification rules Laterality is to be entered only if entry for B.7.1 Previous history of breast 
cancer is ‘yes’. 
Related data 
elements 
B.7.1 Previous history of breast cancer 
B.7.2 Previous history of breast cancer—year 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments In conjunction with related data elements, may be used for selecting women 
for annual rescreen. 
Please note that although this data element requires that the information 
about Previous history be retained for each visit, it is acknowledged that not 
all State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
Previous history (B.7.1 to B.7.3), for each visit is retained. 
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B.8.1 Mammographic history at first screening visit 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether the woman has had a mammogram (of both breasts) taken for 
screening or diagnostic purposes, and whether this occurred in the National 
Program or whether she had a screening or diagnostic mammogram outside 
BreastScreen Australia. 
Context This data element is used to determine whether a client is attending for an 
incident or prevalent screen in conjunction with B.8.2 Mammographic 
History—year. 
This data element is also used to code data element number B.9.2 Round  
number—national program. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes, in BreastScreen Australia 
2. Yes, outside BreastScreen Australia 
3. Yes, unknown  
4. No 
Guide for use Code ‘1’ (Yes, in BreastScreen Australia) means that the woman has had a 
screening mammogram within the BreastScreen Program in another State 
and Territory. 
Code ‘2’ (Yes, outside BreastScreen Australia) means that the woman has 
had a screening or diagnostic mammogram outside BreastScreen Australia. 
Code ‘3’ (Yes, unknown) means that the woman has had a previous 
mammogram, but it could not be determined if this occurred in or outside 
BreastScreen Australia. 
Code ‘4’ (No) means that the woman has never had a mammogram. 
This information is based on the client’s self-report at the first visit. 
Verification rules  
Related data 
elements 
B.8.2 Mammographic history—year 
B.9.1 Round number—State/Territory program 
B.9.2 Round number—national program 
Related NAS 
Measures 
 
 BreastScreen Australia data dictionary: version 1.1 67 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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B.8.2 Mammographic history—year 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The year in which the presenting woman has had the most recent 
mammogram (of both breasts) taken for screening or diagnostic purposes, 
either in BreastScreen Australia or elsewhere. 
Context This data element is used to determine whether a client is attending for an 
incident or prevalent screening episode in conjunction with Mammographic 
history at first screening visit. If the last mammogram was more than five 
years ago, the current screening episode is considered a prevalent screen. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 4 Max. 4 Representational layout YYYY 
Data domain Valid year 
Guide for use This information is based on the client’s self-report at the first visit. 
Verification rules Year is to be entered only if entry for B.8.1 Mammographic history at first 
screening visit is ‘yes’. 
Related data 
elements 
B.8.1 Mammographic history at first screening visit 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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B.9.1 Round number—State/Territory program 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The number of the most recent screening round for a particular presenting 
woman, within the State/Territory BreastScreen Program. 
Context This data element records the most recent screening round within the 
State/Territory for each client and is used for service provision, monitoring 
and planning. 
Relational and representational attributes 
Datatype Numeric  Representational form NUMBER 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain 1. First screening episode in the State/Territory Program. 
2. Second screening episode in the State/Territory Program. 
And so on … 
Guide for use This data element is based on records held within each State and Territory 
BreastScreen Program. 
Verification rules  
Related data 
elements 
B.8.1 Mammographic history at first screening visit 
B.9.2 Round number—national program 
Related NAS 
Measures 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
1.2.2 The Service and/or SCU monitors the proportion of women, aged 40–49 
years and 75 years and over who are screened and recalled for assessment. 
(b) recalled 
2.1.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
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are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast 
cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS. 
2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second 
or subsequent screening episode are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
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2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.5.1 The Service and/or SCU monitors and reports the percentage of women 
who have up to 4 images per screen, including technical repeats. 
2.6.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for annual screening. 
2.6.1 (b) ≤10% of women aged 50–69 years attend for annual screening. 
2.6.2 The Service and/or SCU monitors and reports the proportion of women 
who attend for annual screening, aged 40–49 years and 75 years and over. 
2.6.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode and are 
recalled for assessment. 
2.6.3 (b) <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. 
2.6.4 (a) The Service and/or SCU offers, monitors and reports the proportion 
of women aged 50–74 years who attend for their second or subsequent 
screening episode and are recalled for assessment. 
2.6.4 (b) <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening episode  
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
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standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
3.1.7 ≥95% of all lesions are correctly identified at first excision. 
3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provide the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
4.1.1 (a) ≥90% of women aged 50–74 years attend for a screening 
appointment within 28 calendar days of their booking date (fixed sites only). 
4.1.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the time taken to achieve 90% from booking to screening (fixed sites 
only). 
4.1.2 ≥90% of women have documented notification of the results of 
screening within 14 calendar days of the date of screening. 
4.2.1 (a) ≥90% of women requiring assessment attend an assessment visit 
within 28 calendar days of their screening visit. 
4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the number of days the Service and/or SCU takes to achieve 90%. 
4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and 
report the percentage of women who were offered assessment within 28 
calendar days of their screening visit. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.3 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.4 ≥85% of women are verbally given the results of percutaneous needle 
biopsy within seven calendar days of the assessment procedure. 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
4.2.6 All women are notified of the results of their assessment in writing within 
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14 calendar days of the date of completion of assessment. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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B.9.2 Round number—national program 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether the most recent screening for a particular woman is the first or 
subsequent screening round in the National Program. 
Context This data element records the most recent screening round within the 
National Program for each client. 
Relational and representational attributes 
Datatype Numeric  Representational form NUMBER 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain 1. First round in the National Program 
2. Subsequent round in the National Program 
9. Unknown 
Guide for use If a woman has had a previous mammogram in BreastScreen Australia 
(B.8.1) in another State or Territory, round number should reflect round in the 
national Program. 
Use code ‘1’ if B.9.1 =1 and B.8.1 = 2–4 
Use code ‘2’ if B.9.1 =2 or if (B.9.1 =1 and B.8.1 =1) 
Use code ‘9’ if B.9.1=1 and B.8.1=3 
Verification rules  
Related data 
elements 
B.8.1 Mammographic history at first screening visit 
B.9.1 Round number—State/Territory program 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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B.10 Symptom status  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Self-reported breast lump or nipple discharge (clear or blood stained) or other 
breast symptoms (for example dimpling of the skin of the breast) of which the 
woman is aware prior to screening and which she reports at the time of 
screening.  
Context This data element may be used to report the percentage of women 
presenting with symptoms who participated in BreastScreen Australia. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. No symptoms reported 
1. Lump  
2. Nipple discharge—clear 
3. Nipple discharge—blood stained 
4. Other breast symptoms, please specify 
9. Not stated 
Guide for use Symptoms should not be confused with signs, which are recorded after a 
clinical examination.  
The information on symptoms is based on the client’s self-report and is 
retained for each visit. Indicate which symptom(s) she reports. 
Verification rules  
Related data 
elements 
C.5 Recommendation—screening 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
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2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments Please note that although this data element requires that the information 
about symptom status be retained for each visit, it is acknowledged that not 
all State and Territory systems can comply. It is recommended that future 
upgrades of State and Territory systems ensure that prior information on 
symptom status for each visit is retained. 
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B.11 General practitioner flag 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether the woman nominated a general practitioner to receive the results of 
her visit to the screening and assessment service. 
Context This data element is used to identify whether communication of the woman’s 
results to the woman’s general practitioner is required. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use This information is obtained from the client at each screening visit. 
Verification rules  
Related data 
elements 
C.7.1 Letter to general practitioner about screening results 
C.7.2 Letter to general practitioner about screening results—date 
D.14.1 Letter to general practitioner about assessment results 
D.14.2 Letter to general practitioner about assessment results—date 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C—Screening visit segment 
Data dictionary version 1.1 Data dictionary version 1 
C.1 Booking date C.1 Booking date 
C.2 Date of first attendance for this 
episode 
C.2 Date of first attendance for this episode 
C.3.1 Total number of images used C.3.1 Total number of films used 
C.3.2 Technical repeat status C.3.2 Technical repeat status 
C.3.3 Number of technical repeats C.3.3 Number of technical repeats 
C.4 Screening mammogram reading 
results 
C.4 Screening mammogram reading results 
C.5 Recommendation—screening C.5 Recommendation—screening 
C.6 Date woman notified of screening 
results 
C.6 Date woman notified of screening 
results 
C.7.1 Letter to general practitioner about 
screening results 
C.7.1 Letter to general practitioner about 
screening results 
C.7.2 Letter to general practitioner about 
screening results—date 
C.7.2 Letter to general practitioner about 
screening results—date 
C.8 Annual screening flag   
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C.1 Booking date 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date an appointment was made by the woman, or someone on her 
behalf. 
Context Used for monitoring and planning access, participation and outcome of 
screening services. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if a person contacted a service on July 1 2000 the Booking date 
should be recorded as 01072000 as specified in the representational layout. 
The date an appointment was made by the woman, or someone on her 
behalf. 
It is recommended that in cases where all components of Booking date are 
not known, a valid date be used together with A.8 Estimated date flag to 
indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
C.2 Date of first attendance for this episode 
Related NAS 
Measures 
4.1.1 (a) ≥90% of women aged 50–74 years attend for a screening 
appointment within 28 calendar days of their booking date (fixed sites only). 
4.1.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the time taken to achieve 90% from booking to screening (fixed sites 
only). 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.2 Date of first attendance for this episode 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the presenting woman first attended for screening, this episode. 
Context Used for monitoring and planning access, participation and outcome of 
screening. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use For the definition of ‘screening episode’, see the glossary (Appendix 4). 
A screening episode includes all attendances for screening and assessment 
within 6 months relating to a particular episode of screening. This data 
element marks the commencement of the screening episode. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example, if the client first attended on July 1 2000 the Date of first attendance 
should be recorded as 01072000 as specified in the representational layout. 
This data element should have a system prompt for screening unit identifier 
(A.2). 
Verification rules  
Related data 
elements 
A.2 Screening unit identifier 
A.8 Estimated date flag 
B.2 Date of birth 
C.1 Booking date 
Related NAS 
Measures 
1.1.1 (a) The Service and/or SCU monitors and reports the participation rate 
of women aged 50–74 years who participate in screening in the most recent 
24-month period. 
1.1.1 (b) ≥70% of women aged 50–69 years participate in screening in the 
most recent 24-month period. 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
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screening episode within the Program are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below 
that of the overall population, implements specific strategies to encourage 
their participation in screening. Consideration of equitable participation rates 
of at least the following groups is made: women from Indigenous, culturally 
and linguistically diverse, rural/remote and lower socioeconomic 
backgrounds. 
1.2.2 The Service and/or SCU monitors the proportion of women, aged 40–49 
years and 75 years and over who are screened and recalled for assessment. 
(a) screened 
(b) recalled 
2.1.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast 
cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
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2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS. 
2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second 
or subsequent screening episode are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS.  
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.5.1 The Service and/or SCU monitors and reports the percentage of women 
who have up to 4 images per screen, including technical repeats. 
2.5.2 The overall repeat rate for the Service and/or SCU is ≤2% of all 
screening images. 
2.6.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for annual screening. 
2.6.1 (b) ≤10% of women aged 50–69 years attend for annual screening. 
2.6.2 The Service and/or SCU monitors and reports the proportion of women 
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who attend for annual screening, aged 40–49 years and 75 years and over. 
2.6.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode and are 
recalled for assessment. 
2.6.3 (b) <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. 
2.6.4 (a) The Service and/or SCU offers, monitors and reports the proportion 
of women aged 50–74 years who attend for their second or subsequent 
screening episode and are recalled for assessment. 
2.6.4 (b) <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening episode. 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
4.1.1 (a) ≥90% of women aged 50–74 years attend for a screening 
appointment within 28 calendar days of their booking date (fixed sites only). 
4.1.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the time taken to achieve 90% from booking to screening (fixed sites 
only). 
4.1.2 ≥90% of women have a documented notification of the results of 
screening within 14 calendar days of the date of screening. 
4.2.1 (a) ≥90% of women requiring assessment attend an assessment visit 
within 28 calendar days of their screening visit. 
4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the number of days the Service and/or SCU takes to achieve 90%.  
4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and 
report the percentage of women who were offered assessment within 28 
calendar days of their screening visit. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
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received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.3.1 Total number of images used 
Admin. status SUPERSEDES  C.3.1 Total number of films used 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The number of images used to screen a woman during her screening visit(s). 
Context This data element is used for Service provision, monitoring and planning. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative Value 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain Number of films 
Guide for use The total number of images used is the total of all satisfactory and 
unsatisfactory images taken, including technical repeats. 
Technical repeats are the additional image(s) that need to be taken due to 
technically unsatisfactory images at the screening visit. 
This data element should have a system prompt for radiographer identifier 
code of radiographer taking initial images (to be coded in A.6 Service 
provider identifier). 
The number of images used is recorded at the screening visit for the client. 
Verification rules  
Related data 
elements 
A.6 Service provider identifier 
A.7 Machine number 
C.3.2 Technical repeat status 
C.3.3 Number of technical repeats 
Related NAS 
Measures 
2.5.1 The Service and/or SCU monitors and reports the percentage of women 
who have up to 4 images per screen, including technical repeats. 
2.5.2 The overall repeat rate for the Service and/or SCU is ≤2% of all 
screening images. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.3.2 Technical repeat status 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a technical repeat was performed 
Context This data element is used for Service provision, monitoring and planning. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. No technical repeat performed—not required 
2. No technical repeat performed—woman refused 
3. Technical repeat performed—at initial screening visit 
4. Technical repeat performed—at subsequent screening visit 
9. Unknown 
Guide for use Technical repeats are the additional image(s) that need to be taken due to 
technically unsatisfactory images at the screening visit. They are initiated by 
the radiographer or radiologist. The unsatisfactory images are allocated to the 
radiographer who performed the mammography during the screening visit. 
The technical repeats (the additional images) are allocated to the 
radiographer who carried out the technical repeats. This may or may not be 
the initial radiographer. Also, the additional images may be taken during the 
first screening visit, or during a subsequent visit. 
A technical repeat carried out at an assessment centre is still part of the 
screening process and should not be included in the calculation of recall rate, 
unless it results in the client requiring assessment, i.e. a true ‘recall to 
assessment’. Screening is not completed until a set of technically satisfactory 
images is available for reading. 
Women who fail to attend a technical repeat appointment are included in the 
‘refused’ category. 
The technical repeat status is recorded at the screening visit for the client. 
Verification rules  
Related data 
elements 
A.6 Service provider identifier 
A.7 Machine identifier  
C.3.1 Total number of images used 
C.3.3 Number of technical repeats  
Related NAS 
Measures 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.3.3 Number of technical repeats 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The number of additional images taken due to technically unsatisfactory 
images at the screening visit. 
Context The number of technical repeats is used for Service provision, monitoring and 
planning. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative value 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain Number of technical repeats. 
Guide for use Technical repeats are initiated by the radiographer or radiologist, and are due 
to technically unsatisfactory images at the screening visit. The unsatisfactory 
images are allocated to the radiographer who performed the mammography 
during the screening visit. The technical repeats (the additional images) are 
allocated to the radiographer who carried out the technical repeats. This may 
or may not be the initial radiographer. Also, the additional images may be 
taken during the first screening visit, or during a subsequent visit. 
A technical repeat carried out at an assessment centre should not be 
included in the calculation of recall rate, unless it results in the client requiring 
assessment, i.e. a true ‘recall to assessment’. 
This data element should have a system prompt for radiographer identifier 
code of radiographer taking repeat images if different from initial radiographer 
(to be coded in A.6 Service provider identifier). 
Verification rules  
Related data 
elements 
A.6 Service provider identifier 
A.7 Machine number 
C.3.1 Total number of images used 
C.3.2 Technical repeat status 
Related NAS 
Measures 
2.5.2 The overall repeat rate for the Service and/or SCU is ≤2% of all 
screening images 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.4 Screening mammogram reading results 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Each reader’s opinion of the client’s mammogram. 
Context Used for monitoring and planning access, participation and outcome of 
screening. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Normal 
2. Suspicious 
Guide for use Some States & Territories use 5 categories to collect this data element. 
Where this is the case, the following conversion should be used: 
Normal and Benign are to be classified as ‘Normal.’ 
Equivocal, Suspicious and Malignant are to be classified as ‘Suspicious’. 
Where TABAR grades are used to collect this data element, the following 
conversion should be used: 
• Normal and Benign are to be classified as ‘Normal.’ 
• Probably benign, Possibly malignant and Likely Malignant are to be 
classified as ‘Suspicious’. 
This data element should have a system prompt for reader code (to be coded 
in A.6 Service provider identifier). 
The combined reading results are used in determining the screening 
recommendation (C.5). 
BreastScreen Australia requires that two readers are used. If their opinions 
differ, the opinion of a third radiologist is used by most services to determine 
the outcome. Therefore, this field must be completed for at least two and up 
to three readers involved in assessing the screening images. 
For each image reader, indicate opinion of images as either ‘Normal’ or 
‘Suspicious’. A client with a suspicious mammogram is recommended for 
assessment. 
Verification rules This field must be completed for at least two and up to three readers involved 
in reading the screening images. A third reader is entered if the opinions of 
the first two differ. 
Related data 
elements 
A.6 Service provider identifier 
C.5 Recommendation—screening 
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Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.5 Recommendation—screening 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The recommended action following the client’s visit(s) to the screening unit 
for this episode. 
Context Used for monitoring and planning access, participation and outcome of 
screening. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Routine rescreen 2 years 
2. Routine rescreen 1 year 
3. To assessment centre for mammographic recall only 
4. To assessment centre for other reasons (non-mammographic) 
5. To assessment centre for combined recall. 
Guide for use This data element is based on the combined screening mammogram reading 
results and State and Territory policy on assessment of symptomatic women 
without a mammographic abnormality. 
Routine rescreen: 
Under the National Program policy, the routine re-screen interval is two 
years. Under some State and Territory policies, clients in high risk categories 
(as defined by the State and Territory) are recommended for rescreening at 
one year. 
To assessment centre: 
If a client is recommended to attend for assessment, indicate whether this is 
because of a mammographic recall (see C.4), for other reasons (non-
mammographic) or for a combined recall. 
A technically unsatisfactory mammogram is not a reason for assessment, 
even if the technical repeat is carried out at an assessment centre. This data 
element is not completed until the set of technically satisfactory images has 
been read. 
NOTE: Some services have a policy not to invite clients of certain age groups 
for rescreening. This data element should be completed regardless of such a 
policy. If the outcome of the mammogram is ‘normal’, then ‘routine rescreen 2 
years’ is coded. 
Recorded when screening mammogram reading results become available. 
Verification rules  
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Related data 
elements 
B.10 Symptom status  
C.4 Screening mammogram reading result 
C.8 Annual screening flag 
D.1 Reason for assessment 
Related NAS 
Measures 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
1.2.2 The Service and/or SCU monitors the proportion of women, aged 40–49 
years and 75 years and over who are screened and recalled for assessment. 
(b) recalled 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.6.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode and are 
recalled for assessment. 
2.6.3 (b) <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. 
2.6.4 (a) The Service and/or SCU offers, monitors and reports the proportion 
of women aged 50–74 years who attend for their second or subsequent 
screening episode and are recalled for assessment. 
2.6.4 (b) <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
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value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening episode. 
4.2.1 (a) ≥90% of women requiring assessment attend an assessment visit 
within 28 calendar days of their screening visit. 
4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the number of days the Service and/or SCU takes to achieve 90%. 
4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and 
report the percentage of women who were offered assessment within 28 
calendar days of their screening visit. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.6 Date woman notified of screening results 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman was first notified of the outcome of her screening visit(s) 
in writing. 
Context Used for monitoring and planning access, participation and outcome of 
screening. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use When the mammogram outcome is suspicious, the woman is usually notified 
of her screening results both verbally and in writing by mail. The notification 
date for this data element is the date on which the letter was generated. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the woman was notified on 1 July 2000 the Date woman notified of 
screening results should be recorded as 01072000 as specified in the 
representational layout. 
It is recommended that in cases where all components of Date woman 
notified of screening results are not known, a valid date be used together with 
A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
C.2 Date of first attendance for this episode 
C.7.1 Letter to general practitioner about screening results 
C.7.2 Letter to general practitioner about screening results—date 
Related NAS 
Measures 
4.1.2 ≥90% of women have documented notification of the results of 
screening within 14 calendar days of the date of screening. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.7.1 Letter to general practitioner about screening results 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a letter about the outcome of the woman’s attendance for 
screening was sent to her general practitioner. 
Context Used for monitoring and planning access, participation and outcome of 
screening. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use Indicate whether or not the woman’s nominated general practitioner was sent 
a letter about the results of her attendance(s) at the screening unit.  
Notification to general practitioner could be in electronic form (for example, an 
email) and need not be a mailed letter. 
Recorded by the Service when screening results letters are finalised. 
Verification rules  
Related data 
elements 
B.11 General practitioner flag 
C.6 Date woman notified of screening results 
C.7.2 Letter to general practitioner—date 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.7.2 Letter to general practitioner about screening  
results—date 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the letter about the outcome of the woman’s attendance for 
screening was sent to her general practitioner. 
Context Used for monitoring and planning access, participation and outcome of  
screening. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use Indicate on which date the woman’s nominated general practitioner was sent 
written advice, either by hard copy letter or electronically, about the results of 
her attendance(s) at the screening unit. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the letter was sent on 1 July 2000 the date should be recorded as 
01072000 as specified in the representational layout. 
It is recommended that in cases where all components of Letter to general 
practitioner about screening results—date are not known, a valid date be 
used together with A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules This date is to be entered only if entry for C.7.1 Letter to general practitioner 
about screening results is ‘yes’. 
Related data 
elements 
A.8 Estimated date flag 
B.11 General practitioner flag 
C.6 Date woman notified of screening results 
C.7.1 Letter to general practitioner about screening results 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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C.8 Annual screening flag 
Admin. status PROPOSED 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Identifies whether the woman is recommended for annual routine screening. 
Context This data element identifies women who are recommended for annual routine 
screening. This is as a result of the characteristics of the woman (for 
example, a personal history of breast cancer). 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use The annual screening flag should be used as a ‘high-risk’ flag, identifying 
women who are at considerably higher risk for breast cancer. 
There are 3 circumstances that denote that a woman is at higher risk, and is 
therefore recommended for annual routine screening: personal history of 
invasive breast cancer, family history of invasive breast cancer and presence 
or history of pre-cancerous lesion (e.g. papilloma, radial scar, atypical lesion).  
This flag is not intended to be used for women who may receive a ‘one off’ 
recommendation to return in 12 months; rather, it is a permanent flag 
attributed to the woman. 
Verification rules C.5 or D.11.1 or E.12 = 2 
Related data 
elements 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
Related NAS 
Measures 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.3 (a) The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
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2.2.3 (b) The Service and/or SCU monitors and reports the number of women 
aged 50-69 years who attend annually for screening, who are diagnosed with 
DCIS.2.6.1 (a) The Service and/or SCU monitors and reports the proportion 
of women aged 50–74 years who attend for annual screening. 
2.6.1 (b) ≤10% of women aged 50–69 years attend for annual screening. 
2.6.2 The Service and/or SCU monitors and reports the proportion of women 
who attend for annual screening, aged 40–49 years and 75 years and over. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D—Assessment visit segment 
Data dictionary version 1.1 Data dictionary version 1 
D.1 Reason for assessment  D.1 Reason for assessment  
D.2.1 Attendance for assessment D.2.1 Attendance for assessment 
D.2.2 Date of first attendance for 
assessment 
D.2.2 Date of first attendance for 
assessment 
D.2.3 Date of first offered appointment for 
assessment 
  
D.3.1 Nature of mammographic lesion(s) 
to be assessed 
D.3.1 Nature of mammographic lesions to 
be assessed 
D.3.2 Nature of mammographic lesion(s) 
to be assessed—side 
D.3.2 Nature of mammographic lesions to 
be assessed—side 
D.4.1 Nature of clinical symptoms & signs 
to be assessed 
D.4.1 Nature of clinical symptoms/signs to 
be assessed 
D.4.2 Nature of clinical symptoms & signs 
to be assessed—side 
D.4.2 Nature of clinical symptoms/signs to 
be assessed—side 
D.5 Result of mammography D.5 Result of mammography 
D.6.1 Result of clinical examination D.6.1 Result of clinical examination 
D.6.2 Correspondence of clinical 
examination to mammographic 
abnormality  
D.6.2 Correspondence of clinical 
examination to mammographic 
abnormality  
D.7.1 Result of ultrasound D.7  Result of ultrasound 
D.7.2 Description of ultrasound lesion D.8 Description of ultrasound lesion 
D.8.1 Percutaneous needle biopsy 
performed 
  
D.8.2 Percutaneous needle biopsy 
guidance method 
D.9.1 Fine needle cytology method 
D.8.3 Percutaneous needle biopsy result D.9.2 Fine needle cytology result 
  D.10.1  Core biopsy method 
  D.10.2  Core biopsy result 
D.9 Other procedures performed D.11 Other assessment procedures 
performed 
D.10 Final result of assessment visit D.12 Final result of assessment visit 
D.11.1 Recommendation—assessment D.13.1 Recommendation—assessment 
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D.11.2 Recommendation—number of 
months 
D.13.2 Recommendation—number of 
months 
D.11.3 Date recommendation made D.13.3 Date recommendation made 
D.11.4 Assessment visit—date D.13.4 Assessment visit—date 
D.11.5 Results visit—date   
D.12 Discharge from BreastScreen 
Australia following assessment 
D.14 Discharge from program following 
assessment 
D.13.1 Date woman notified in writing of 
assessment results 
D.15 Date woman notified of assessment 
results 
D.13.2 Date woman notified verbally of 
biopsy results 
  
D.14.1 Letter to general practitioner about 
assessment results 
D.16.1 Letter to general practitioner about 
assessment results 
D.14.2 Letter to general practitioner about 
assessment results—date 
D.16.2 Letter to general practitioner about 
assessment results—date 
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D.1 Reason for assessment  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The reason the presenting woman is attending the assessment clinic. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Suspicious mammogram and/or signs/symptoms at screen 
2. Early review 
3. Interval signs/symptoms 
4. Other, please specify 
Guide for use Indicate only one of the four categories. 
Code 1, Suspicious mammogram and/or signs/symptoms at screening 
episode is based on the data element Recommendation—screening (C.5), 
where the recommendation is codes 3 to 5.  
Code 2, Early review is defined as the recall of a woman for further 
assessment within twelve months of the screening date and following an 
equivocal assessment visit (where a decision cannot be made). Early review 
within six months of the screening date is considered part of the screening 
episode and cancers found as a result of the review are considered to be 
screen-detected. Early review carried out at six months or more from the date 
of screening, occurs after the screening episode is complete and cancers 
found are considered to be interval cancers. This code is used if D.11.1 
Recommendation—assessment is coded as 3. 
Code 3, Interval signs/symptoms is used for assessment visits initiated by a 
client who has been screened previously in BreastScreen Australia. The 
client is attending before her next screening episode is due to commence (as 
determined by her routine re-screening interval), and has clinical signs or 
symptoms. This occurs after the previous screening episode is complete; if 
cancer is found it would be counted as an interval cancer. 
Code 4, Other, includes other reasons for recalling women to assessment, for 
example breast implants or a history of breast cancer, without a suspicious 
mammogram and/or signs/symptoms. The reason needs to be specified. 
Recorded for all women who have attended for assessment. 
Verification rules  
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Related data 
elements 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
F.1.3 Cancer diagnosed in BreastScreen Australia status 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
4.2.3 ≥95% of women require no more than two procedural assessment visits 
to receive a definitive recommendation from assessment. 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.2.1 Attendance for assessment 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not the woman attended for assessment. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
9. Unknown 
Guide for use If No then the episode would be closed if >= 6 months from the screening 
date and no further data elements completed. 
Code 9 may be used if it is unknown whether the woman was assessed 
outside BreastScreen Australia. 
If Code 9 (Unknown) then no more data elements are collected in Segment 
D. 
This data element should have a system prompt for A.3 Assessment unit 
identifier. More than one Assessment unit identifier can apply to each 
screening episode. If procedures in this segment occur at more than one 
assessment centre then the system should allow for the coding of 
assessment unit identifier for each set of procedures that can be carried out 
separately. For example, mammographic work-up may occur on a mobile unit 
and other procedures at one or more fixed units. 
Recorded for all women who have attended for assessment. 
Verification rules  
Related data 
elements 
A.3 Assessment unit identifier 
D.2.2 Date of first attendance for assessment 
D.2.3 Date first offered appointment for assessment 
Related NAS 
Measures 
3.3.2 ≥ 95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.6 All women are notified of the results of their assessment in writing within 
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14 calendar days of the date of completion of assessment. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
Comments The location of the screening visit determines the attribution of the outcome 
of assessment. If a woman is assessed in a Screening and Assessment 
Service (SAS) outside the SAS where screening took place or in an 
assessment centre outside BreastScreen Australia or in another state, then 
the information about assessment is relevant only to the NAS Measures that 
measure the efficiency of the assessment unit undertaking the assessment 
process. The final outcome of assessment is attributed to the SAS where 
screening took place. For example if a cancer is detected then it is attributed 
to the screening SAS and NOT counted in the assessment SAS. This also 
applies to the reporting of NAS Measures such as the proportion returning to 
assessment, etc. The fact that the assessment took place outside the 
screening SAS or that the assessment was carried out in more than one 
assessment centre is captured by the Assessment unit identifier. 
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D.2.2 Date of first attendance for assessment 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman first attended for assessment, for this episode. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the client first attended on July 1 2000 the Date of first attendance 
for assessment should be recorded as 01072000 as specified in the 
representational layout. 
Recorded for all women who have attended for assessment. 
It is recommended that in cases where all components of Date of first 
attendance for assessment are not known, a valid date be used together with 
A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules Date of first attendance for assessment is to be entered only if entry for 
Attendance for assessment (D.2.1) is ‘yes’. 
Related data 
elements 
A.8 Estimated date flag 
D.2.1 Attendance for assessment 
D.11.4 Assessment visit—date 
D.11.5 Results visit—date 
Related NAS 
Measures 
4.2.1 (a) ≥90% of women requiring assessment attend an assessment visit 
within 28 calendar days of their screening visit.  
4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the number of days the Service and/or SCU takes to achieve 90%. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.3 ≥95% of women require no more than two procedural assessment visits 
to receive a definitive recommendation from assessment. 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.2.3 Date first offered appointment for assessment 
Admin. status PROPOSED 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman is offered an appointment for assessment, for this 
episode. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the client first attended on July 1 2000 the Date of first attendance 
for assessment should be recorded as 01072000 as specified in the 
representational layout. 
Recorded for all women who are offered an assessment appointment. 
It is recommended that in cases where all components of Date first offered 
appointment for assessment are not known, a valid date be used together 
with A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules Date first offered appointment for assessment is to be entered only if entry for 
D.2.1 Attendance for assessment is ‘yes’. 
Related data 
elements 
A.8 Estimated date flag 
D.2.1 Attendance for assessment 
D.2.2 Date of first attendance for assessment 
Related NAS 
Measures 
4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and 
report the percentage of women who were offered assessment within 28 
calendar days of their screening visit. 
Administrative attributes 
Source document Developed for The BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments This is a new data element that was created to enable calculation of the new 
NAS Measure 4.2.1 (c). 
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D.3.1 Nature of mammographic lesion(s) to be assessed 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT  
Definition The nature of a suspicious mammographic lesion that has generated the 
assessment process. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. No mammographic lesion 
1. Calcification 
2. Stellate lesion 
3. Discrete mass with or without calcification 
4. Multiple masses 
5. Architectural distortion 
6. Non-specific density 
7. Other, please specify 
Guide for use Mammographic data are collected before workup by the radiologist who will 
do the work up at the time of assessment. More than one code may be 
reported. 
Code 0 signifies that there is no mammographic lesion being assessed (i.e. 
the client is being assessed for clinical symptoms/signs only). 
Code dominant category for reporting purposes. 
DEFINITIONS 
Code 1, Calcification 
Deposition or collections of calcium compounds in breast tissue of sufficient 
size to be seen on mammography. Calcifications are characterised by size 
distribution, density and morphology. 
Features which may be suspicious for malignancy include size (0.05—0.5 
mm), distribution, (cluster, multiple cluster, or sometimes scattered) 
pleomorphism and density variation. 
Code 2, Stellate Lesion 
Spiculations of variable length radiating from a central point or mass. When a 
central mass is present, it may be small or large, and of low, mixed or high 
density compared to surrounding breast parenchyma. 
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Code 3, Discrete Mass with or without Calcification 
A mass is a space occupying lesion seen in two projections, and is described 
by density and edge characteristics. 
Density may be high, low or variable compared to normal breast tissue. The 
outline (edge) may be smooth, lobulated, irregular, spiculated, stellate, or 
obscured by superimposed parenchyma. 
Features suspicious for malignancy include increased density and an 
irregular, spiculated or stellate border, or portion of border. 
Code 4, Multiple Masses 
More than one lesion which conforms to the definition of a suspicious mass. 
Code 5, Architectural Distortion 
Abnormal configuration of the ductal and ligamentous structures of breast 
parenchyma compared with the remainder of the breast tissue markings. 
Includes spiculation, focal retraction, distortion of the parenchymal edge, and 
disorganisation of markings. 
Code 6, Non Specific Density 
Asymmetry of breast tissue seen in either one or two planes not accurately 
described by other categories. Additional imaging may reveal normal breast 
parenchymal appearances, or an underlying mass, or definite architectural 
distortion. Includes new densities with poorly defined characteristics. 
Code 7, Other 
Lesions not included or varying from above includes skin thickening or 
abnormality, abnormal axillary lymph modes, vascular abnormalities, nipple 
retraction, diffuse density change, duct abnormality, etc. 
Collect data for up to two mammographic lesions.  
Recorded for all women who have mammographic workup at assessment. 
For suggested coding, see A.5 Lesion number. 
More than one code may be reported. 
Code dominant category for reporting purposes. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
D.3.2 Nature of mammographic lesion to be assessed—side 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
Comments The definitions under the ‘Guide for use’ were supplied by Dr J. Cawson. 
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D.3.2 Nature of mammographic lesion(s) to be assessed—
side  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT  
Definition The breast in which the mammographic lesion detected at screening is 
located. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Character  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout A 
Data domain: R Right 
L Left 
Guide for use Collect data for up to two mammographic lesions.  
Recorded for all women who have mammographic workup at assessment. 
For suggested coding, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
D.3.1 Nature of mammographic lesion to be assessed 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.4.1 Nature of clinical symptoms & signs to be assessed 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT  
Definition The nature of suspicious clinical symptoms/signs reported prior to the 
assessment process. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. None 
1. Lump 
2. Serous nipple discharge 
3. Blood-stained nipple discharge 
4. Other, please specify 
Guide for use Specify symptoms/signs if code 4 is reported. 
Clinical symptoms/signs are based on self-report (of symptoms) or outcome 
of any clinical examination prior to assessment (signs). The ‘none’ category 
(code 0) signifies that there is no clinical symptom/sign being assessed. 
Code dominant category for reporting purposes. 
No lesion number is recorded for this data element as the symptom/sign may 
correlate with a mammographic lesion. This is determined at D.5 Result of 
Mammography. 
Recorded for all women who have clinical symptoms/signs assessed. 
More than one code may be reported. 
Verification rules  
Related data 
elements 
D.4.2 Nature of clinical symptoms & signs to be assessed—side 
D.5 Result of mammography 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.4.2 Nature of clinical symptoms & signs to be assessed—
side 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The breast in which the clinical symptom/sign reported at screening is 
located. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Character  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout A 
Data domain R Right 
L Left 
Guide for use Recorded for all women who have clinical symptoms/signs assessed. 
Verification rules Side is to be entered only if entry for D.4.1 Nature of clinical symptoms/signs 
to be assessed is not ‘0’. 
Related data 
elements 
D.4.1 Nature of clinical symptoms & signs to be assessed 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
  
 BreastScreen Australia data dictionary: version 1.1 113 
D.5 Result of mammography  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT  
Definition The result of further mammography done after the recommendation ‘to 
assessment centre’ was made at the screening visit (see C.5 
Recommendation—screening). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. Not done 
1. No significant abnormality 
2. Benign lesion 
3. Equivocal lesion 
4. Suspicious lesion 
5. Malignant lesion 
9. Unknown 
Guide for use This data element should have a system prompt for reader/radiologist who 
reports results of mammography (to be recorded in A.6 Service provider 
identifier). 
Collected for all women who have mammographic workup at assessment. 
Collect the above for up to two mammographic lesions and additional clinical 
lesions. 
If there is also a clinical symptom/sign being worked up, code Lesion Number 
as follows: 
If it appears to correspond to the mammographic lesion(s) being worked up, 
then report as the Mammographic Lesion Number (M1 or M2); 
If it appears to be distinct from the mammographic lesion being worked up, 
then code as lesion Number = S1. 
If a new mammographic lesion is found during the mammographic work-up 
that does not correspond to those reported prior to assessment, lesion 
number = M3. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
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C.5 Recommendation—screening 
D.4.1 Nature of clinical symptoms & signs to be assessed 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.6.1 Result of clinical examination 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The result of the clinical examination done after the recommendation ‘to 
assessment centre’ was made at the screening visit (see C.5 
Recommendation—screening). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. Not done 
1. No significant abnormality 
2. Benign lesion 
3. Equivocal lesion 
4. Suspicious lesion 
5. Malignant lesion 
9. Unknown 
Guide for use This data element should have a system prompt for clinical examiner provider 
code (to be coded in A.6 Service provider identifier). 
Collected for all women after clinical examination at assessment. 
Collect the above for up to two mammographic lesions and additional clinical 
lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
If there is also a new clinical lesion found at clinical examination that does not 
correspond to mammographic lesion(s), or sign/symptom, code as lesion = 
C1. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
C.5 Recommendation—screening 
D.6.2 Correspondence of clinical examination to mammographic 
 abnormality 
Related NAS 
Measures 
 
 116 BreastScreen Australia data dictionary: version 1.1 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.6.2 Correspondence of clinical examination to 
mammographic abnormality 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not the lesion(s) assessed at clinical examination correspond to a 
mammographic abnormality. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain: 1. Yes 
2. No 
Guide for use Collected for all women after clinical examination at assessment. 
Collect for up to two lesions corresponding to D.6.1 Result of clinical 
examination. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
D.6.1 Result of clinical examination 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.7.1 Result of ultrasound 
Admin. status SUPERSEDES  D.7 Result of ultrasound 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The result of the Ultrasound done after the recommendation ‘to assessment 
centre’ was made at the screening visit (see C.5 Recommendation—
screening). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. Not done 
1. No significant abnormality 
2. Benign lesion 
3. Equivocal lesion 
4. Suspicious lesion 
5. Malignant lesion 
9. Unknown 
Guide for use This data element should have a system prompt for ultrasound interpreter 
provider code (to be coded in A.6 Service provider identifier). 
Collected for all women who have ultrasound at assessment. 
Report one code only for each lesion. 
Collect the above for up to two mammographic lesions and additional clinical 
lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
If there is a new lesion found at ultrasound that does not correspond to 
mammographic or clinical lesions previously identified, code as lesion = U1. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
C.5 Recommendation—screening 
D.7.2 Description of ultrasound lesion 
Related NAS 
Measures 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.7.2 Description of ultrasound lesion 
Admin. status SUPERSEDES  D.8 Description of ultrasound lesion 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The description of the lesion based on ultrasound findings. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. Not done 
1. Normal breast 
2. Cystic 
3. Solid, probably benign 
4. Solid, probably malignant 
5. Indeterminate 
6. Other, please specify 
9. Unknown 
Guide for use Collected for all women who have ultrasound at assessment. 
Report one code only for each lesion. 
Indicate [0] not done, or one classification from [1] to [9]. 
For suggested coding of lesions, see A.5 Lesion number. 
Collect for up to two lesions corresponding to D.7.1 Result of ultrasound. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
D.7.1 Result of ultrasound 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.8.1 Percutaneous needle biopsy performed 
Admin. status PROPOSED 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a percutaneous needle biopsy was performed, including 
details of the type of needle biopsy performed or the reason why a needle 
biopsy was not performed. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes, fine needle aspiration 
2. Yes, core biopsy, non-vacuum assisted 
3 Yes, core biopsy, vacuum assisted 
4. No– woman’s decision 
5.  No– clinical decision 
9. Unknown 
Guide for use Record whether a percutaneous needle biopsy was performed. 
Collected for all women who have attended assessment. 
Verification rules If this Data Element = 1,2 or 3 then 
C.5 = 3, 4, or 5 
If this Data Element = 1, 2, or 3 then  
D.8.2 = not null 
D.8.3 = not null 
Related data 
elements 
A.5 Lesion number 
C.5 Recommendation—screening 
D.8.2 Percutaneous needle biopsy guidance method 
D.8.3 Percutaneous needle biopsy result 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.8.2 Percutaneous needle biopsy guidance method 
Admin. status SUPERSEDES  D.9.1 Fine needle cytology method  
   D.10.1 Core biopsy method 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The method used to direct needle position for percutaneous needle biopsy. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Palpation 
2. Ultrasound 
3. Mammographic—stereotactic 
9. Unknown 
Guide for use This data element should have a system prompt for needle biopsy operator 
provider code (to be coded in A.6 Service provider identifier). 
Collected for all women who have a percutaneous needle biopsy performed 
at assessment. 
Report one code for each percutaneous needle biopsy procedure. 
Verification rules D.8.1 Percutaneous biopsy performed = 1 or 2 or 3 
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
D.8.1 Percutaneous needle biopsy performed 
D.8.3 Percutaneous needle biopsy result 
Related NAS 
Measures 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.8.3 Percutaneous needle biopsy result 
Admin. status SUPERSEDES  D.9.2 Fine needle cytology results  
   D.10.2 Core biopsy result 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The result of the percutaneous needle biopsy. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 2 Representational layout N 
Data domain 1. Inadequate specimen (specify reason) 
2. Benign 
3. Atypical/equivocal 
4. Suspicious 
5. Malignant 
9. Unknown 
Guide for use In case of inadequate specimen, record reasons (may be recorded in the 
percutaneous needle biopsy report). 
This data element should have a system prompt for percutaneous needle 
biopsy interpreter provider code (to be coded in A.6 Service provider 
identifier). 
Collected for all women who have a percutaneous needle biopsy performed 
at assessment. 
Report one code only for each needle biopsy procedure. 
Indicate one opinion from [1] to [5] for each procedure. Unknown [9] to be 
used only after attempts to seek a result have failed. 
Specify reason if code = 1 (inadequate specimen). 
Collect data for up to 2 lesions, corresponding to Percutaneous needle biopsy 
guidance method (D.8.2). 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules Blank if D.8.2 Percutaneous needle biopsy result is blank 
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
D.8.1 Percutaneous needle biopsy performed 
D.8.2 Percutaneous needle biopsy guidance method 
 124 BreastScreen Australia data dictionary: version 1.1 
Related NAS 
Measures 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
4.2.4 ≥85% of women are verbally given the results of percutaneous needle 
biopsy within seven calendar days of the assessment procedure. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.9 Other procedures performed 
Admin. status SUPERSEDES  D.11 Other assessment procedures performed 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether other procedures were used to assess the mammographic lesion(s). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Cyst aspiration 
2. Other, please specify 
Guide for use Recorded for all women who have procedures other than percutaneous 
needle biopsy performed at assessment. 
More than one procedure can be coded. 
Specify procedures used if code =2 (‘other’). 
Code for up to two lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.10 Final result of assessment visit 
Admin. status SUPERSEDES  D.12 Final result of assessment visit 
Identifying and definitional attributes 
Data element type DATA ELEMENT  
Definition The combined result of all procedures carried out during the assessment of a 
woman. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 0. Incomplete assessment 
1. No significant abnormality 
2. Benign lesion 
3. Equivocal lesion 
4. Suspicious lesion 
5. Malignant lesion 
9. Unknown 
Guide for use This data element should have a system prompt for Assessment coordinator 
provider code (to be coded in A.6 Service provider identifier). 
Collected for all women who have attended for assessment. 
Report one code only. 
Indicate [0] if assessment was not completed, or one opinion from [1] to [5]. 
Unknown [9] to be used only after attempts to seek a result have failed. 
Verification rules  
Related data 
elements 
A.6 Service provider identifier 
Related NAS 
Measures 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.11.1 Recommendation—assessment 
Admin. status SUPERSEDES  D.13.1 Recommendation—assessment 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The recommended action following the assessment workup for this screening 
episode. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Routine rescreen at 2 years 
2. Routine rescreen at 1 year 
3. Early review 
4. Definitive treatment for cancer 
5. Diagnostic open biopsy 
Guide for use Code 3, Early review is the recall of a woman for further assessment within 
twelve months of the screening date and following an equivocal assessment 
visit (where a decision cannot be made). Early review within six months of the 
screening date is considered part of the screening episode and cancers 
found as a result of the review are considered to be screen-detected. Early 
review carried out at six months or more from the date of screening occurs 
after the screening visit is complete and cancers found are considered to be 
interval cancers. 
Code 4, Definitive treatment: for breast cancer only—not treatment for other 
abnormalities. 
Code 5, Diagnostic open biopsy, relates to excision for the purpose of making 
a definitive histological diagnosis. 
Definitive treatment: for breast cancer only—not treatment for other 
abnormalities. 
The aim of diagnostic open biopsy is to form definitive histology. 
This data element records the recommendation following assessment 
although the recommendation may not be adhered to due to a 
woman’s/doctor’s decision or State and Territory policy. 
Examples include: 
Some services have a policy not to invite clients of certain age-groups for 
rescreening. This data element should be completed regardless of such a 
policy. If the outcome of the mammogram is ‘normal’, then ‘routine rescreen 2 
years’ is coded (code 1). 
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A recommendation for excision is made but this does not occur. An example 
would be an older woman, whose FNA/Core biopsy result is highly suspicious 
or malignant, but she is too frail to undergo surgery—in the first case 
(suspicious) code 5 is used, in the second case (malignant) code 4 is used.  
Collected for all women who have attended for assessment. 
Report one code only. 
This data element cannot be coded until the assessment is complete, unless 
the recommendation is Early review in which case segment D is repeated. 
If recommendation is Early Review (Reason for assessment D.1=2), repeat 
all data elements in Assessment Visit Segment until definitive assessment 
recommendation is made, codes 1,2, 4 or 5 in this data element (routine re-
screen, definitive treatment or diagnostic open biopsy). 
Verification rules  
Related data 
elements 
C.8 Annual screening flag 
D.1 Reason for assessment 
D.11.2 Recommendation—number of months 
D.11.3 Date recommendation made 
Related NAS 
Measures 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.6.7 <0.2% women who attend for screening are recommended for early 
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review for further assessment. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provide the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.3 ≥95% of women require no more than two procedural assessment visits 
to receive a definitive recommendation from assessment. 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.11.2 Recommendation—number of months  
Admin. status SUPERSEDES  D.13.2 Recommendation—number of months 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The number of months to the time when the Early review is recommended to 
take place. 
Context Used for monitoring the assessment and diagnosis of breast cancer. This 
data element is used for monitoring purposes and for the call back of women 
to the early review visit. It also determines whether an Early review occurs 
within or after a screening episode. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative value 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain Number of months 
Guide for use Early review is the recall of a woman for further assessment within twelve 
months of the screening date and following an equivocal assessment visit 
(where a decision cannot be made). Early review within six months of the 
screening date is considered part of the screening episode and cancers 
found as a result of the review are considered to be screen-detected. Early 
review carried out at six months or more from the date of screening occurs 
after the screening visit is complete and cancers found are considered to be 
interval cancers. 
Collected following completion of assessment for all women who are 
recommended to return to assessment for early review. 
Verification rules Number of months is to be entered only if entry for D.11.1 
Recommendation—assessment is code 3. 
Related data 
elements 
D.11.1 Recommendation—assessment 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.11.3 Date recommendation made 
Admin. status SUPERSEDES  D.13.3 Date recommendation made 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the recommendation after the assessment work up for this 
screening episode was made. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the recommendation was made on 1 July 2000 the date should be 
recorded as 01072000 as specified in the representational layout. 
Collected for all women who have attended for assessment.  
This data element cannot be completed until the assessment is complete, 
unless the recommendation is early review, in which case segment D is 
repeated after the early review visit. 
It is recommended that in cases where all components of Date 
recommendation made are not known, a valid date be used together with A.8 
Estimated date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
D.11.1 Recommendation—assessment 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
3.3.2 ≥ 95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
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visit. 
4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment 
visit. 
4.2.6 All women are notified of the results of their assessment in writing within 
14 calendar days of the date of completion of assessment. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.11.4 Assessment visit—date 
Admin. status SUPERSEDES  D.13.4 Assessment visit—date 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman attended for a procedural visit during this assessment 
episode. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
This data element is used in the calculation of the number of procedural visits 
a woman makes within an assessment episode. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element is coded for each procedural visit relating to an 
assessment episode that is excluding results visits. For the definition of 
‘assessment episode’, see the glossary. 
A date field is required wherever a separate procedural visit may occur during 
the assessment episode. 
The date recorded is the date on which the woman attended for each 
assessment visit. For example, a woman may attend for a mammographic 
work-up on a mobile unit and for further work-up elsewhere on a separate 
date. In this case two dates should be recorded. 
If the woman returns to the assessment clinic for an appointment with the 
counsellor only, for example to receive her results, such a visit should be 
recorded under D.11.5 Results visit—date. 
Multiple visits can also apply to Early review. Early review is considered to be 
a second assessment with all data elements in segment D repeated, 
commencing at D.1 Reason for assessment. 
Collected after all procedural visits at assessment are completed. 
Verification rules  
Related data 
elements 
D.2.2 Date of first attendance for assessment 
D.11.5 Results visit—date 
Related NAS 
Measures 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
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false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
3.1.7 ≥95% of all lesions are correctly identified at first excision. 
3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provides the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
4.2.3 ≥95% of women require no more than two procedural assessment visits 
to receive a definitive recommendation from assessment. 
4.2.4 ≥85% of women are verbally given the results of percutaneous needle 
biopsy within seven calendar days of the assessment procedure. 
4.2.6 All women are notified of the results of their assessment in writing within 
14 calendar days of the date of completion of assessment. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.11.5 Results visit—date 
Admin. status PROPOSED 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman attended for a results visit during this assessment 
episode. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
This data element is used in the calculation of the number of visits a woman 
makes within an assessment episode. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element is coded for each visit in which a woman receives results 
of her assessment. There should be no procedures performed at this visit. 
Collected following the woman’s assessment results visit. 
Verification rules  
Related data 
elements 
D.2.2 Date of first attendance for assessment 
D.11.4 Assessment visit—date 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.12 Discharge from BreastScreen Australia following 
assessment 
Admin. status SUPERSEDES  D.14 Discharge from program following assessment 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a woman was discharged from BreastScreen Australia 
following the outcome of assessment. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use If the woman has been discharged from BreastScreen Australia she will not 
receive a routine recall invitation. A 'Yes' code includes women discharged 
permanently from BreastScreen Australia as well as those women suspended 
from BreastScreen Australia for some years (for example, some services 
reinvite women diagnosed with breast cancer after five years).  
The most common reason for discharge will be a diagnosis of breast cancer, 
and in most cases the decision to discharge will be made after open biopsy. If 
a woman is recommended for open biopsy, this data element is coded as 2 
(No) and information is recorded in E.1, E.11, E.12 and E.13 (Discharge from 
BreastScreen Australia following open biopsy). Code 1 (Yes) in this data 
element is used for women diagnosed with cancer from the FNA/Core biopsy 
and not recommended for open biopsy. 
Women may be discharged for other reasons, being either the woman’s own 
decision or the service’s recommendation, for example discharge due to a 
pre-malignant lesion.  
Collected for all women who have attended for assessment. 
Verification rules  
Related data 
elements 
 
 
Related NAS 
Measures 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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D.13.1 Date woman notified in writing of assessment 
results 
Admin. status SUPERSEDES  D.15 Date woman notified of assessment results 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman was first notified in writing of the outcome of her 
assessment visit(s). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use The woman is usually notified of her assessment results verbally (in person 
or by phone). A letter may be handed to her at the same time, or it may be 
sent to her by mail or in electronic form (for example, over email). The 
notification date is the date on which the letter was generated.  
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the woman was notified on 1 July 2000 the Date woman notified of 
assessment results should be recorded as 01072000 as specified in the 
representational layout.  
Collected for all women who have attended for assessment.  
It is recommended that in cases where all components of the Date woman 
notified of assessment results are not known, a valid date be used together 
with A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
D.14.1 Letter to general practitioner about assessment results 
D.14.2 Letter to general practitioner about assessment results—date 
Related NAS 
Measures 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
4.2.6 All women are notified of the results of their assessment in writing within 
14 calendar days of the date of completion of assessment. 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.13.2 Date woman notified verbally of biopsy results 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the woman was verbally notified of the outcome of her cytology or 
pathology assessment result(s). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use The woman is usually notified of her assessment results verbally (in person 
or by phone). This notification date is the date on which the woman was 
notified of her results verbally. How the woman was notified must be 
documented, for example, details of the phone call recorded. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the woman was notified on 1 July 2000 the Date woman notified of 
assessment results should be recorded as 01072000 as specified in the 
representational layout. 
Collected for all women who have attended for assessment and had 
percutaneous needle biopsy performed. 
It is recommended that in cases where all components of Date woman 
notified verbally of biopsy results are not known, a valid date be used 
together with A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
D.14.1 Letter to general practitioner about assessment results 
D.14.2 Letter to general practitioner about assessment results—date 
Related NAS 
Measures 
4.2.4 ≥85% of women are verbally given the results of percutaneous needle 
biopsy within seven calendar days of the assessment procedure. 
4.2.5 ≥95% of women complete all assessment within 15 calendar days. 
 142 BreastScreen Australia data dictionary: version 1.1 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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D.14.1 Letter to general practitioner about assessment 
results 
Admin. status SUPERSEDES  D.16.1 Letter to general practitioner about  
   assessment results 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a letter about the outcome of the woman’s attendance for 
assessment was sent to her general practitioner. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use Indicate whether or not the woman’s nominated general practitioner was sent 
a letter about the results of her attendance(s) at the assessment unit. 
Notification to general practitioner could be in electronic form (for example, an 
email) and need not be a mailed letter. 
Collected for all women who have attended for assessment. 
Verification rules  
Related data 
elements 
B.11 General practitioner flag 
D.13.1 Date woman notified in writing of assessment results 
D.13.2 Date woman notified verbally of biopsy results 
D.14.2 Letter to general practitioner about assessment results—date 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
  
 144 BreastScreen Australia data dictionary: version 1.1 
D.14.2 Letter to general practitioner about assessment 
results—date 
Admin. status SUPERSEDES  D.16.2 Letter to general practitioner about  
   assessment results—date 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date the letter about the outcome of the woman’s attendance for 
assessment was sent to her general practitioner. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use Indicate on which date the woman’s nominated general practitioner was sent 
a letter or was contacted electronically about the results of her attendance(s) 
at the assessment unit. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the letter was sent on 1 July 2000 the date should be recorded as 
01072000 as specified in the representational layout. 
Collected for all women who have attended for assessment. 
It is recommended that in cases where all components of Letter to general 
practitioner about assessment results—date are not known, a valid date be 
used together with A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules This date is to be entered only if entry for D.14.1 Letter to general practitioner 
about assessment results is code 1 (yes). 
Related data 
elements 
A.8 Estimated date flag 
B.11 General practitioner flag 
D.13.1 Date woman notified in writing of assessment results 
D.13.2 Date woman notified verbally of biopsy results 
D.14.1 Letter to general practitioner about assessment results 
Related NAS 
Measures 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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E—Local excision of lesion segment 
Data dictionary version 1.1 Data dictionary version 1 
E.1 Local excision performed E.1 Local excision performed 
E.2 Date excision performed E.2 Date local excision performed 
E.3 Funding of local excision E.3 Funding of local excision 
E.4.1 Marking method E.4 Marking method 
E.4.2 Localisation technique E.5 Localisation technique 
E.5 Palpability of lesion   
E.6 Frozen section E.6 Frozen section 
E.7 Specimen x-ray E.7 Specimen x-ray 
E.8.1 Lesion removal E.8.1 Lesion identified in specimen 
E.8.2 Further surgery recommended E.8.2 Further surgery recommended 
E.9 Local excision result  E.9 Local excision result  
E.10 Number of excisions E.10 Number of excisions 
E.11 Date of definitive diagnosis E.11 Date of definitive diagnosis 
E.12 Recommendation—definitive E.12 Recommendation—definitive 
E.13 Discharge from BreastScreen 
Australia following local excision 
E.13 Discharge from Program following local 
excision 
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E.1 Local excision performed 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a local excision was performed for a woman recommended 
for diagnostic open biopsy or treatment. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use Record whether local excision was performed. If no, complete the following 
data elements: 
E.11 Date of definitive diagnosis 
E.12 Recommendation—definitive 
E.13 Discharge from BreastScreen Australia following local excision 
The decision not to perform the excision may be the woman’s or the 
surgeon’s. 
If the woman underwent surgery more than once, or was recommended to 
undergo surgery more than once, this and related data elements are 
repeated. 
This data element should have a system prompt for Surgeon provider code 
(to be coded in A.6 Service provider identifier) and A.4 Surgical unit identifier. 
Collected for all women recommended for diagnostic open biopsy or 
treatment. 
Verification rules  
Related data 
elements 
A.4 Surgical unit identifier 
A.6 Service provider identifier 
D.12 Discharge from BreastScreen Australia following assessment 
E.8.2 Further surgery recommended 
E.11 Date of definitive diagnosis 
E.12 Recommendation—definitive 
E.13 Discharge from BreastScreen Australia following local excision 
Related NAS 
Measures 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
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3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
3.1.7 ≥95% of all lesions are correctly identified at first excision. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.2 Date excision performed 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date on which the local excision was performed. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date. 
Guide for use If the woman underwent surgery more than once, this data element is to be 
collected for each occasion of surgery. 
The first date is used in the calculation of NAS Measures 3.1.7. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the client underwent surgery on 1 July 2000 the Date excision 
performed should be recorded as 01072000 as specified in the 
representational layout. 
Collected for all women who had a local excision performed.  
It is recommended that in cases where all components of the Date excision 
performed are not known, a valid date be used together with A.8 Estimated 
date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
E.8.2 Further surgery recommended 
G.2 Date of commencement of treatment 
Related NAS 
Measures 
3.1.7 ≥95% of all lesions are correctly identified at first excision. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.3 Funding of local excision 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not the local excision of lesion(s) detected by BreastScreen 
Australia was paid for by BreastScreen Australia funds. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
BreastScreen Australia can fund up to and including the cytological or 
histological diagnosis. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes—funded within BreastScreen Australia 
2. No—funded outside BreastScreen Australia 
Guide for use If the woman underwent surgery more than once, this data element is to be 
collected for each occasion of surgery. 
Collected for all women who had a local excision performed. 
Verification rules  
Related data 
elements 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.4.1 Marking method 
Admin. status SUPERSEDES  E.4 Marking method 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The marking method used to localise the lesion during surgical excision. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. None (palpation) 
2. Hookwire/needle 
3. Carbon 
Guide for use For palpation record ‘none’ (code 1). 
Collected for all women who had a local excision performed. 
Collect for up to two lesions. 
Lesion number corresponds to the numbering used for lesions recorded at 
assessment. If a new lesion has been identified at local excision, it is given a 
new lesion number (E.1). 
See A.5 Lesion number for suggested coding. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
E.4.2 Localisation technique 
E.5 Palpability of lesion 
E.6 Frozen section 
E.7 Specimen imaging 
E.8.1 Lesion removal 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.4.2 Localisation technique 
Admin. status SUPERSEDES  E.5 Localisation technique 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The technique used to localise the lesion during surgical excision. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Mammographic—non stereotactic 
2. Ultrasound 
3. Mammographic—stereotactic 
Guide for use If hookwire or carbon method is used, then record technique used (one 
category). If method is none, technique is not collected. 
Collected for all women who had a local excision performed. 
Collect for up to two lesions corresponding to E.4.1 Marking method. 
Verification rules ‘Localisation technique’ is to be entered only if entry for E.4.1 Marking 
method is ‘Hookwire/needle’ or ‘Carbon’. 
Related data 
elements 
A.5 Lesion number 
E.4.1 Marking method 
E.5 Palpability of lesion 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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E.5 Palpability of lesion 
Admin. status PROPOSED 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not the lesion was palpable or impalpable at assessment. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Palpable 
2. Impalpable 
9. Unknown 
Guide for use Collected for all women who had a local excision performed. 
Collect for up to two lesions. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
E.4.1 Marking method 
E.4.2 Localisation technique 
Related NAS 
Measures 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments At the meeting of the National Quality Management Committee (NQMC) held 
on 22 November 2013, members considered a number of queries in relation 
to specimen imaging from Breast Surgeons of Australia and New Zealand.  
The NQMC directed: 
That specimen imaging is to be undertaken and recorded for a screen 
detected abnormality that is impalpable pre operatively; 
That specimen imaging is to be undertaken and recorded for any localised 
procedure; and 
That specimen imaging is to be undertaken and recorded if a lump becomes 
palpable during an operation. 
In line with this directive, the definition of this data element is ‘Whether or not 
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the lesion was palpable or impalpable at assessment’ to make it clear that, 
even if the lesion subsequently becomes palpable at surgery, it should be 
classified as impalpable (and is therefore relevant for NAS Measure 3.1.6 
which requires specimen imaging to be recorded if any lesion that was 
impalpable at assessment and becomes palpable during an operation or if a 
lesion is localised intraoperatively). 
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E.6 Frozen section 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a frozen section was taken during surgical excision for 
pathology purposes. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use Collected for all women who had a local excision performed. 
Collect for up to two lesions corresponding to E.4.1 Marking method.  
Verification rules  
Related data 
elements 
A.5 Lesion number 
E.4.1 Marking method 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.7 Specimen imaging  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a specimen image was obtained during surgical excision. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Specimen radiography permits a degree of certainty that a lesion has been 
satisfactorily removed and is also useful for establishing the completeness of 
excision in treatment biopsies. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use Collected for all women who had a local excision performed. 
Collect for up to two lesions corresponding to E.4.1 Marking method. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
E.4.1 Marking method 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
3.1.6 All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.8.1 Lesion removal 
Admin. status SUPERSEDES  E.8.1 Lesion identified in specimen 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether the screen detected lesion has been removed through needle 
biopsy or surgery. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use Generally, the answer will be based on specimen imaging (although 
sometimes small lesions may be removed by needle biopsy). If lesion was 
not identified, indicate whether (a) further surgery will be performed (in data 
element E.8.2 Further surgery recommended) or (b) if further surgical 
surveillance is recommended. 
Collect for up to two lesions corresponding to E.4.1 Marking method. 
Collected for all women who had a local excision performed. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
E.4.1 Marking method 
E.8.2 Further surgery recommended 
Related NAS 
Measures 
3.1.7 ≥95% of all lesions are correctly identified at first excision 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.8.2 Further surgery recommended 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not, following surgical excision, further surgery is recommended. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use If lesion was not identified, indicate whether further surgery is recommended. 
If further surgery is performed, then repeat the following data elements: 
A.4 Surgical unit identifier 
A.6 Service provider identifier  
E.1 Local excision performed 
E.2 Date local excision performed 
E.3 Funding of local excision 
E.4.1 Marking method 
E.4.2 Localisation technique 
E.6 Frozen section 
E.7 Specimen x-ray 
before completing the data element E.9 Local excision result. 
Collected for all women who had a local excision performed where E.8.1 
Lesion Removal is ‘No’. 
Collect for up to two lesions. 
Verification rules This data element applies only where E.8.1 Lesion Removal is ‘No’ 
Related data 
elements 
A.4 Surgical unit identifier 
A.6 Service provider identifier 
E.1 Local excision performed 
E.2 Date local excision performed 
E.3 Funding of local excision 
E.4.1 Marking method 
E.4.2 Localisation technique 
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E.6 Frozen section 
E.7 Specimen x-ray 
E.8.1 Lesion removal 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.9 Local excision result  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether lesion(s) for which a woman underwent local excision was/were 
malignant or non-malignant. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Malignant 
2. Non malignant 
3. No definitive result 
Guide for use Malignant includes DCIS. For a full list of types of lesions included under non-
malignant and malignant lesions, refer to the data elements F.3 
Histopathology of non-malignant lesions and F.4 Histopathology of malignant 
lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
If a new lesion is identified at local excision (i.e. not identified at assessment), 
then the suggested code lesion number = E.1. 
No definite result applies where the sample obtained does not permit definite 
diagnosis and where further biopsy will not be performed. The decision not to 
perform further biopsy may be the woman’s or the surgeon’s. 
Collected for all women who had a local excision performed. 
Collect for up to two lesions. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
E.11 Date of definitive diagnosis 
F.3 Histopathology of non-malignant lesions 
F.4 Histopathology of malignant lesions 
Related NAS 
Measures 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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E.10 Number of excisions 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Number of occasions on which a woman underwent surgery before a 
definitive histological diagnosis was made. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative value 
Field size Min.  Max.  Representational layout N 
Data domain Number of occasions 
Guide for use The number of occasions is based on separate days on which the woman 
underwent surgery. Collected for all women who had a local excision 
performed. 
Verification rules  
Related data 
elements 
 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.11 Date of definitive diagnosis 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Date of histological diagnosis, or where histological diagnosis was not 
obtained, the date of the cytological diagnosis. 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use If local excision was recommended but not performed, or entry for E.9 Local 
excision result is ‘no definitive result’, then use the code 88/88/8888 to 
indicate that a definitive diagnosis was unable to be made.  
This data element combines the results of all lesions where the 
recommendation following assessment was definitive treatment or diagnostic 
open biopsy. 
If histological diagnosis was not obtained, this date refers to the date 
cytological diagnosis was made. 
It is recommended that in cases where all components of the date of 
definitive diagnosis are not known, a valid date be used together with A.8 
Estimated date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
D.12 Discharge from BreastScreen Australia following assessment 
E.1 Local excision performed 
E.9 Local excision result 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.12 Recommendation—definitive 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The definitive recommendation given to the woman, following excision of 
lesion(s). 
Context Used for monitoring the assessment and diagnosis of breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Routine rescreen 2 years 
2. Routine rescreen 1 year 
3. Early review 
4. Referral for treatment 
Guide for use This data element is completed when the episode is complete, even where 
definitive diagnosis is not available.  
This data element records the recommendation following local excision 
although the recommendation may not be adhered to due to a 
woman’s/doctor’s decision or State and Territory policy. Examples include: 
Some services have a policy not to invite clients of certain age-groups for 
rescreening. This data element should be completed regardless of such a 
policy. If the outcome of the mammogram is ‘normal’, then ‘routine rescreen 2 
years’ is coded (code 1). 
A recommendation for treatment is made but this does not occur. An example 
would be an older woman too frail to undergo surgery—in this case code 4 is 
used. 
Some services may discharge women who are not diagnosed with cancer, for 
example those with pre-malignant lesions. In this case ‘routine rescreen 2 
years’ is coded (code 1) according to national policy. The discharge is 
recorded in data element E.13 Discharge from BreastScreen Australia 
following local excision. 
Collected for all women where the recommendation following assessment 
was referral for definitive treatment or referral for diagnostic open biopsy. This 
data element records the final outcome following treatment. 
Only one category can be coded. 
Early review: record number of months. 
Verification rules  
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Related data 
elements 
C.8 Annual screening flag 
D.12 Discharge from BreastScreen Australia following assessment 
E.1 Local excision performed 
E.13 Discharge from BreastScreen Australia following local excision 
Related NAS 
Measures 
1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within 
the Program who are rescreened within 27 months. 
1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 months. 
1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent 
screening episode within the Program who are rescreened within 27 months 
of their previous screening episode. 
1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second and 
subsequent screens within the Program are rescreened within 27 months of 
their previous screening episode. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.6.7 <0.2% women who attend for screening are recommended for early 
review for further assessment. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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E.13 Discharge from BreastScreen Australia following local 
excision  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a woman was discharged from BreastScreen Australia 
following the outcome of E.12 Recommendation—Definitive. 
Context  
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use If the woman has been discharged from BreastScreen Australia; she will not 
receive a routine recall invitation. A 'Yes' code includes women discharged 
permanently from BreastScreen Australia as well as those women suspended 
from BreastScreen Australia for some years (for example, some services 
reinvite women diagnosed with breast cancer after five years). 
In most cases, women discharged will be those with cancer. However, 
women may be discharged for other reasons, being either the woman’s own 
decision or the service’s recommendation, for example discharge due to a 
pre-malignant lesion.  
Collected for all women where the recommendation following assessment 
was referral for definitive treatment or referral for diagnostic open biopsy. This 
data element is recorded when E.12 Recommendation—definitive is known. 
Verification rules  
Related data 
elements 
D.12 Discharge from BreastScreen Australia following assessment 
E.1 Local excision performed 
E.12 Recommendation—definitive 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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F—Histopathology segment 
Data dictionary version 1.1 Data dictionary version 1 
F.1.1 Reason for histopathology F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis F.1.2 Date of diagnosis 
F.1.3 Cancer diagnosed in 
BreastScreen Australia  
F.1.3 Cancer diagnosed in Program 
F.2.1 Axillary dissection  F.2.1 Axillary dissection  
F.2.2 Sentinel node biopsy performed F.2.2 Sentinel node biopsy performed 
F.2.3 Axillary dissection—total number 
of nodes  
F.2.3 Axillary dissection—total number of 
nodes  
F.2.4 Axillary dissection—number of 
nodes positive 
F.2.4 Axillary dissection—number of nodes 
positive 
F.3 Histopathology of non-malignant 
lesions 
F.3 Histopathology of non-malignant 
lesions 
F.4 Histopathology of malignant 
lesions 
F.4 Histopathology of malignant lesions 
F.5 Size of tumour F.5 Size of tumour 
F.6 Histological grade F.6 Histological grade 
F.7 Dominant lesion identifier number F.7 Dominant lesion identifier number 
  
 BreastScreen Australia data dictionary: version 1.1 167 
F.1.1 Reason for histopathology 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether histopathology relates to cancer diagnosed after completion of the 
last screening episode in the Program or lesion(s) detected as part of the 
current screening episode. 
Context Used in relation to monitoring breast cancer detection, small invasive breast 
cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Interval cancer or cancer in a non-attender for rescreen 
2. Lesion detected as part of the current screening episode 
Guide for use This data element is completed in relation to histopathology for lesions 
tracked through a screening episode and for all known cancers in women 
screened at least once in the State/Territory Program. For the purposes of 
this data element, both invasive and non-invasive (DCIS) cancers are 
recorded. 
Code 1 means that the histopathology relates to either an interval cancer or 
cancer in a non-attender for rescreen. For reporting purposes, the date of 
diagnosis will be used to determine whether it is an interval cancer or a 
cancer in a non-attender for rescreen. Both invasive and non-invasive 
cancers are collected (see comment). Definitions for both invasive and non-
interval invasive cancer are included in the glossary. 
Code 2 means that the histopathology relates to a lesion(s) detected as part 
of the current screening episode. 
A cancer is defined as ‘interval’ if it is diagnosed within 24 months of the 
screening date of a negative screening episode, unless the woman is 
recommended for annual rescreen in which case only cancers diagnosed 
within 12 months of a negative screening episode are included. 
For further clarification of an interval cancer definition, see Kavanagh et al 
1999. 
A cancer in a non-attender for rescreen is diagnosed following a negative 
screening episode and after 24 months from the date of the previous screen, 
unless the woman is recommended for annual rescreen in which case 
cancers diagnosed after 12 months of a negative screening episode are 
included. Non-attenders for rescreen are: 
• Women who have been sent one or more invitations for rescreening, but 
have failed to attend or declined. 
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• Women who have not been sent an invitation for rescreening due to 
State/Territory screening policy and have not returned for screening.  
If cancer was diagnosed after the date of completion of the last screening 
episode, record F.1.2 Date of diagnosis of interval cancer and whether the 
woman had cancer diagnosed in BreastScreen Australia (F.1.3 Cancer 
diagnosed in BreastScreen Australia). 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
The question on the histopathology form needs to read: ‘Does the 
histopathology relate to cancer diagnosed after the date of completion of the 
last screening episode in BreastScreen Australia’ or ‘Does the histopathology 
relate to interval cancer’. 
Verification rules  
Related data 
elements 
F.1.2 Date of diagnosis 
F.1.3 Cancer diagnosed in BreastScreen Australia 
Related NAS 
Measures 
2.1.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast 
cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
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diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS.  
2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second 
or subsequent screening episode are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening episode. 
3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provide the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments The national indicators relating to interval cancers only include invasive 
cancers. In relation to screen-detected malignancies, there are national 
indicators and accreditation requirements for both invasive cancers and 
DCIS. For BreastScreen Australia monitoring and evaluation purposes and 
comparison of screen detected malignancies with non-screen-detected 
malignancies it is important to collect information on interval DCIS. 
  
 BreastScreen Australia data dictionary: version 1.1 171 
F.1.2 Date of diagnosis of interval cancer 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type: DATA ELEMENT 
Definition: The date on which an interval cancer or cancer in a non-attender for rescreen 
was diagnosed. That is, a cancer diagnosed after completion of the last 
screening episode. 
Context: Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
This date is collected on the histopathology forms used by the services. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use This data element is completed for all non-screen-detected cancers 
diagnosed, within or outside BreastScreen Australia, in women ever screened 
in BreastScreen Australia. 
For reporting purposes, the date of diagnosis will be used to determine 
whether it is an interval cancer or a cancer in a non-attender for rescreen. 
Where the date of diagnosis is within 24 months of the screening date, the 
cancer is regarded as an interval cancer. Those diagnosed at more than 24 
months of the screening date are regarded as non-attenders for rescreen. 
For definitions of interval cancer and non-attender for rescreen, see F.1.1 
Reason for histopathology. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the diagnosis was made on July 1 2000 the date of diagnosis 
should be recorded as 01072000 as specified in the representational layout. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
It is recommended that in cases where all components of Date of diagnosis 
are not known, a valid date be used together with A.8 Estimated date flag to 
indicate that it is an estimate. 
Verification rules Date of diagnosis is to be entered only if entry for F.1.1 Reason for 
histopathology is ‘interval cancer or cancer in a non-attender for rescreen’ 
(code 1). 
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Related data 
elements 
A.8 Estimated date flag 
F.1.1 Reason for histopathology 
F.1.3 Cancer diagnosed in BreastScreen Australia 
Related NAS 
Measures 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.1.3 Cancer diagnosed in BreastScreen Australia 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not a cancer diagnosed after completion of the last screening 
episode (i.e. an interval cancer or cancer in a non-attender for rescreen) was 
diagnosed in BreastScreen Australia. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
Guide for use If ‘Yes’, the woman will have attended between 0 and 24 months of her 
previous screening episode with interval signs/symptoms (refer to D.1 
Reason for assessment). 
If ‘No’, the woman will have had breast cancer detected within 0 and 24 
months of her previous screening episode outside BreastScreen Australia or 
she is a non-attender for rescreen. 
For definitions of interval cancer and non-attender for rescreen, see F.1.1 
Reason for histopathology.  
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Verification rules Cancer diagnosed in BreastScreen Australia is to be entered only if entry for 
F.1.1 Reason for histopathology  is ‘interval cancer or cancer in a non-
attender for rescreen’ (code 1). 
Related data 
elements 
D.1 Reason for assessment 
F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis 
Related NAS 
Measures 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.2.1 Axillary dissection  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether an axillary dissection was performed and, if so, the type of 
dissection. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Axillary Dissection not performed 
2. Level II/III Axillary Dissection 
3. Level I Axillary Dissection 
4. Sentinel Node Biopsy 
9. Unknown 
Guide for use Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Code for up to two lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
If the two lesions being reported are located in the same breast, the same 
information is entered for both lesions. 
If histopathology relates to an interval cancer or cancer in a non-attender for 
rescreen (Yes in F.1.1 Reason for histopathology) suggested lesion number 
is 1. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
F.1.1 Reason for histopathology 
F.2.2 Sentinel node biopsy performed 
F.2.3 Axillary dissection—total number of nodes 
F.2.4 Axillary dissection—number of nodes positive 
G.6.1 Metastasis—distant 
Related NAS 
Measures 
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Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.2.2 Sentinel node biopsy performed  
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether a sentinel node biopsy was performed. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes 
2. No 
9. Unknown 
Guide for use Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Code for up to two lesions corresponding to F.2.1 Axillary dissection. 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
F.2.1 Axillary dissection 
F.2.3 Axillary dissection—total number of nodes 
F.2.4 Axillary dissection—number of nodes positive 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.2.3 Axillary dissection—total number of nodes 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition This data element records the total number of lymph nodes identified and 
examined. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative value 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain Number of lymph nodes. 
Guide for use Indicate how many lymph nodes were identified and examined. Code 0 if 
none. 
In some cases an axillary dissection is not performed, but a number of lymph 
nodes have been identified and examined. The intention is not to perform a 
dissection but nodes are collected, for example, intramammary lymph nodes 
or as part of an upper outer quadrant excision. These should be reported as 
they may turn out to be positive. Provision should be made to record this data 
element, even if an axillary dissection has not been performed. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Code for up to two lesions corresponding to F.2.1 Axillary dissection. 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
F.2.1 Axillary dissection 
F.2.2 Sentinel node biopsy performed 
F.2.4 Axillary dissection—number of nodes positive 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.2.4 Axillary dissection—number of nodes positive 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The number of positive lymph nodes found. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative value 
Field size Min. 1 Max. 2 Representational layout NN 
Data domain Number of positive lymph nodes 
Guide for use  
Verification rules The number of positive lymph nodes should be equal to or less than the 
number of nodes examined (see F.2.3). 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Code for up to two lesions corresponding to F.2.1 Axillary dissection. 
For suggested coding of lesions, see A.5 Lesion number. 
Related data 
elements 
A.5 Lesion number 
F.2.1 Axillary dissection 
F.2.2 Sentinel node biopsy performed 
F.2.3 Axillary dissection—total number of nodes 
G.6.1 Metastasis—distant 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.3 Histopathology of non-malignant lesions 
Admin. status SUPERSEDES  F.3 Histopathology of non-malignant lesions 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The type of non-malignant lesion identified during histopathology. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 2 Representational layout NN.N 
Data domain 1. Lobular carcinoma in situ 
1.1 Classical lobular carcinoma in situ 
1.2 Pleomorphic lobular carcinoma in situ 
2. Atypical lobular hyperplasia 
3. Ductal hyperplasia with atypia 
4. Phyllodes tumour (benign) 
5. Ductal hyperplasia without atypia 
6. Fibroadenoma 
7. Radial scar/complex sclerosing lesion 
8. Sclerosing adenosis 
9. Cyst 
10. Other, please specify 
Guide for use Code all applicable categories. 
Code dominant category for reporting purposes. 
The categories under ‘1’ in the data domain for this data element have been 
updated. Lobular carcinoma has been separated into 1.1 Classical lobular 
carcinoma in situ and 1.2 Pleomorphic lobular carcinoma in situ to allow the 
collection of information on pleomorphic lobular carcinoma as a distinct 
category. It is desirable to be able to collect data on this rare lesion due to its 
atypia, molecular profile and association with more advanced lesions. 
This item should have a system prompt for pathologist provider code (to be 
coded in A.6 Service provider identifier). 
Other variants of LCIS should be recorded as PLCIS. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
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diagnostic or therapeutic treatment procedures have been performed. 
Categories are not mutually exclusive. 
Specify the type of non-malignant lesion identified at code=10 (other). 
Code for up to two lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
E.9 Local excision result 
F.4 Histopathology of malignant lesions 
F.5 Size of tumour 
Related NAS 
Measures 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments Dominant category is determined by the pathologist interpreting the 
histopathology, based on known risk factors for breast cancer. This may be 
difficult for non-malignant lesions, but generally atypical lesions and lobular 
carcinoma in situ would be considered more significant.  
The separate coding of pleomorphic lobular carcinoma in situ allows for this 
rare lesion to contribute to the non-invasive breast malignancy ductal 
carcinoma in situ category for BreastScreen Australia reporting purposes if 
this is desired, which may be appropriate given that current management 
recommendations for pleomorphic lobular carcinoma in situ are similar to 
those for ductal carcinoma in situ. 
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F.4 Histopathology of malignant lesions 
Admin. status SUPERSEDES  F.4 Histopathology of malignant lesions 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The type of malignant lesion identified during histopathology. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 3 Max. 4 Representational layout NN.N 
Data domain 1 Invasive breast malignancies 
1.1 Invasive ductal N.O.S 
1.2 Tubular 
1.3 Cribriform 
1.4 Mucinous (colloid) 
1.5 Medullary 
1.6 Lobular classical 
1.7 Lobular variant 
1.8 Mixed ductal/lobular 
1.9 Phyllodes tumour (malignant subtype only—not borderline or benign 
 variants) 
1.10 Other, primary invasive breast malignancy (specify) 
1.11 Other, primary malignancy, not defined as breast cancer (specify.) 
1.12 Other, secondary malignancy (specify). 
2 Non-invasive breast malignancies 
2.1 DCIS, High Grade 
2.2 DCIS, Intermediate Grade 
2.3 DCIS, Low Grade 
2.4 Other DCIS (specify) 
Guide for use Atypical medullary should not be recorded as a separate item, but should be 
identified as invasive duct carcinoma N.O.S. 
For the purposes of BreastScreen reporting, DCIS with microinvasion is 
classified as an invasive breast malignancy, and is therefore included in the 
total cases of invasive breast cancer detected through BreastScreen. 
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Equivocal invasive tumours are to be diagnosed as DCIS. 
Categorisation of intracystic papillary carcinoma as either an invasive breast 
malignancy or non-invasive breast malignancy is problematic, as uncertainty 
exists among specialists as to whether it is an unusual form of invasive breast 
cancer or DCIS. Current management recommendations for intracystic 
papillary carcinoma are similar to those for DCIS, and it is included as DCIS 
for BreastScreen reporting purposes (as 2.4 Other DCIS). 
Phyllodes borderline is considered a pre-malignant tumour, and is therefore 
coded as a non-malignant lesion in F.3 Histopathology of non-malignant 
lesions. 
For Phyllodes Tumour include malignant subtype only—not borderline or 
benign variants include metastatic carcinoma and variants. 
Other, primary invasive breast malignancy includes sarcoma. It also includes 
Paget’s disease of the breast or nipple if an invasive component is present. 
Other, primary malignancy, not defined as breast cancer includes lymphoma. 
Code the dominant category for reporting purposes. Some lesions have both 
invasive and non-invasive components. Where both invasive and non-
invasive categories are recorded, record the prognostically more significant 
category. 
Lymphoma is not counted as a breast cancer detected through BreastScreen. 
However, malignancy in lymph nodes is counted if indicative of a primary 
breast cancer. 
‘Other DCIS’ includes Papillary carcinoma and Paget’s disease in the 
absence of an invasive component or any other DCIS. Paget’s diease in the 
absence of an invasive compenent or DCIS is a very rare occurrence, but as 
Paget’s disease is essentially DCIS of the breast ducts near the nipple, it has 
been determined that these few cases should be classified as ‘Other DCIS’. 
The categories under ‘2’ in the data domain for this data element have been 
updated. These categories are not directly translatable from the previous 
categories used in the BreastScreen Australia Minimum Data Set. Generally, 
‘Comedo DCIS’ is associated with High DCIS. However, the previous 
category of ‘Non-comedo DCIS’ may sometimes correspond to Low DCIS 
and sometimes to Intermediate DCIS. 
This item should have a system prompt for pathologist provider code (to be 
coded in A.6 Service provider identifier). 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
A lesion may have both an invasive and non-invasive component, thus both 1 
and 2 may be coded. However, within each group only one category should 
be coded. 
Specify the type of malignant lesion identified if code=1.10, 1.11 or 1.12 or 
code=2.4. 
Code for up to two lesions. 
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For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
E.9 Local excision result 
F.3 Histopathology of non-malignant lesions 
F.5 Size of tumour 
Related NAS 
Measures 
2.1.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast 
cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS. 
2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
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screening episode who are diagnosed with DCIS. 
2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second 
or subsequent screening episode are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 0–12 months following a negative 
screening episode. 
2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 0–12 months following 
a negative screening episode. 
2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with 
an interval invasive breast cancer 13–24 months following a negative 
screening episode. 
2.3.2 (b) ≤15  per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. 
2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their first screening episode. 
2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS 
in women aged 50–74 years who attend for their second or subsequent 
screening. 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have a 
false positive cancer diagnosis, when the definitive needle biopsy result is 
achieved after performance of the final needle biopsy at an assessment 
episode(s). A false positive FNA which is followed by a true negative core 
biopsy, prior to recommendation for surgery or treatment, is not considered to 
be a false positive ‘percutaneous needle biopsy’ for the purpose of this 
standard. 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
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3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provide the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
5.1.1 ≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments When this data element is used for the calculation of breast malignancy 
detection, 1.1–1.10 are included as cases of invasive breast cancer (1.11 
refers to lymphomas which are often secondary to a primary breast 
malignancy; 1.12 refers to a malignancy that has metastasised to the 
breast—both cases are excluded from invasive breast malignancies detected 
through BreastScreen), 2.1–2.4 are included as cases of ductal carcinoma in 
situ. 
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F.5 Size of tumour 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The size, in millimetres, of the malignant tumour. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form Quantitative value 
Field size Min. 1 Max. 4 Representational layout NNNN 
Data domain Size in millimetres 
Guide for use Although size estimates are subject to errors, no matter which method is 
used to assess them, a single measurement of the greatest dimension of the 
tumour from either the fixed or fresh specimen should be adopted. 
Specify whether the reported size is for DCIS, Invasive cancer or Both DCIS 
and Invasive. If both, code size for both components. Measurements also 
encompass those cases of DCIS in which only microscopic foci of invasion 
are present. In the case of multiple microinvasive foci, the largest size should 
be reported. Summing of the sizes of these foci is not performed. 
Where size has not been specified for invasive lesions but a description of 
‘microinvasive’ is recorded, then use code ‘8888’. It is preferred that the use 
of the term ‘microinvasive’ be discouraged and all tumours are sized. For the 
purpose of the data set the pathology committee (of the MDS, 1994) felt that 
any inclusion of Extensive Intraduct Component (EIC) was not relevant, 
especially given both the lack of agreed definitions of EIC and the variable 
use made of the information in the clinical practice. It was felt that EIC was 
more appropriately dealt with by individual practices with close clinico-
pathological agreement. 
This data element is recorded for malignant lesions only. 
If the size of the malignant tumour is not known, record as ‘9999’. 
If the size is reported as ‘Micro invasive’, record as ‘8888’. 
This data element should have a system prompt for pathologist provider code 
(to be coded in A.6 Service provider identifier). 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Collect for up to two lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
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Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
F.3 Histopathology of non-malignant lesions 
F.4 Histopathology of malignant lesions 
Related NAS 
Measures 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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F.6 Histological grade 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The level of malignancy based on histological factors. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Grade 1 
2. Grade 2 
3. Grade 3 
Guide for use Indicate overall grade using the modified Bloom and Richardson System in 
Elston C.W, ‘Grading of invasive carcinoma of the breast’ in Page D.L, 
Anderson T.J, ‘Diagnostic Histopathology of the breast’. (Edinburgh; Churchill 
Livingstone. 1987; 300–311). 
Recorded for malignant lesions only. 
This data element should have a system prompt for pathologist provider code 
(to be coded in A.6 Service provider identifier). 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
Only one category should be coded. 
Code for up to two lesions. 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
A.6 Service provider identifier 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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F.7 Dominant lesion identification number 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The lesion number that corresponds to the dominant lesion. 
Context Histopathology information used in relation to monitoring breast cancer 
detection, small invasive breast cancer detection, interval breast cancers. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 2 Max. 2 Representational layout AN 
Data domain Lesion number 
Guide for use For lesions tracked through the Assessment and Local Excision Segments 
record the lesion number that turns out to be the most significant. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, or for interval cancers, after 
diagnostic or therapeutic treatment procedures have been performed. 
For suggested coding of lesions, see A.5 Lesion number. 
Verification rules  
Related data 
elements 
A.5 Lesion number 
Related NAS 
Measures 
2.1.1 (a)The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with invasive breast cancer. 
2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with invasive breast cancer. 
2.1.2 (a)The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast 
cancer. 
2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with small (≤15mm) invasive breast 
cancer. 
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2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for screening 
are diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are 
diagnosed with small (≤15mm) invasive breast cancer. 
2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are 
diagnosed with invasive breast cancer. 
2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who 
are diagnosed with DCIS. 
2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their first 
screening episode are diagnosed with DCIS. 
2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent 
screening episode who are diagnosed with DCIS. 
2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their second 
or subsequent screening episode are diagnosed with DCIS. 
2.2.3 The Service and/or SCU monitors and reports the number of women 
aged 50–74 years who attend annually for screening, who are diagnosed with 
DCIS. 
3.1.4 ≤0.35% of women who attend for their first screening episode are found 
not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
3.1.5 ≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without the 
need for excision. 
3.1.8 (b) Where part (a) is not met, the Service and/or SCU provide the 
proportion of breast cancers that are diagnosed as invasive and DCIS without 
the need for excision. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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G—Primary treatment segment 
Data dictionary version 1.1 Data dictionary version 1 
G.1 Nature of primary treatment G.1 Primary treatment form 
G.2 Date of commencement of 
treatment 
G.2 Date of commencement of treatment 
G.3 Side of malignancy G.3 Side of malignancy 
G.4 Surgical treatment G.4 Surgical treatment 
G.5.1 Radiotherapy G.5 Adjuvant radiotherapy 
G.5.2 Chemotherapy   
G.6.1 Metastasis—distant G.6.1 Metastasis—distant 
G.6.2 Site of metastasis G.6.2 Site of metastasis 
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G.1 Nature of primary treatment 
Admin. status SUPERSEDES  G.1 Primary treatment form 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The nature of primary treatment. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Surgical 
2. Radiotherapy 
3. Chemotherapy 
4. No treatment 
9. Unknown 
Guide for use Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Verification rules  
Related data 
elements 
 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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G.2 Date of commencement of treatment 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The date on which primary treatment commenced. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use If the diagnostic open biopsy is also the treatment, then the date of 
commencement of treatment is the date on which the diagnostic open biopsy 
was performed (see E.2 Date excision performed). 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the treatment commenced on July 1 2000 the Date of 
commencement of treatment should be recorded as 01072000 as specified in 
the representational layout. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Recorded for all women where G.1 Nature of Primary Treatment is 1, 2 or 3. 
It is recommended that in cases where all components of Date of 
commencement of treatment are not known, a valid date be used together 
with A.8 Estimated date flag to indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
E.2 Date excision performed 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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G.3 Side of malignancy 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether the malignancy for which the woman was treated is in the left or the 
right breast, or whether both breasts are involved. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Left 
2. Right 
3. Both 
Guide for use Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Indicate which breast is involved and if bilateral indicate ‘both’ (code 3). 
Verification rules  
Related data 
elements 
 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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G.4 Surgical treatment 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The definitive outcome of the surgical treatment. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. No surgery—woman’s decision 
2. No surgery—surgeon’s decision 
3. Level II/III Axillary Dissection 
4. Level I Axillary Dissection 
5. Axillary Node Sampling (non-directed) 
6. Sentinel Node Biopsy 
7. Complete local excision 
8. Total mastectomy 
9. Unknown 
Guide for use Unknown (code 9) is to be used only after attempts to seek a result have 
failed. 
This data element refers to surgery as part of primary treatment. 
This data element describes the definitive surgical treatment, for example if a 
local excision is performed and this is followed by a mastectomy, code 8 
(Total mastectomy) is used. Axillary dissection or node sampling should only 
be coded if this was the definitive treatment (i.e. no excision or mastectomy 
performed). 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Verification rules G.1 Nature of primary treatment should be 1. 
Related data 
elements 
 
Related NAS 
Measures 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
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percutaneous needle biopsy is >90%. 
 5.1.1 ≥95% of data dictionary compliant surgical histopathology information 
is received by the Service and/or SCU. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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G.5.1 Radiotherapy 
Admin. status SUPERSEDES  G.5 Adjuvant radiotherapy 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not radiotherapy was given as a part of the treatment regime. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes, primary 
2. Yes, adjuvant 
3. No 
9. Unknown 
Guide for use Unknown (code 9) to be used only after attempts to seek a result have failed. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Verification rules  
Related data 
elements 
 
Related NAS 
Measures 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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G.5.2 Chemotherapy 
Admin. status PROPOSED 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not chemotherapy was given as a part of the treatment regime. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Yes, primary 
2. Yes, adjuvant 
3. No 
9. Unknown 
Guide for use Unknown (code 9) to be used only after attempts to seek a result have failed. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Verification rules  
Related data 
elements 
 
Related NAS 
Measures 
3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. 
3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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G.6.1 Metastasis—distant 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition Whether or not there was evidence of distant metastasis at the time of 
primary treatment. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min. 1 Max. 1 Representational layout N 
Data domain 1. Present 
2. Not present 
9. Unknown 
Guide for use ‘Not present’ means tests have been done and no lesion demonstrated. 
Unknown (code 9) means no investigations were performed. 
If metastasis present, please specify the site (see G.6.2 Site of metastasis). 
This information is to be completed by surgeon at the time of initial surgical 
treatment. 
Regional metastasis (axilla) is collected in data elements F.2.1 to F.2.4. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Verification rules  
Related data 
elements 
F.2.1 Axillary dissection 
F.2.4 Axillary dissection—number of nodes positive 
G.6.2 Site of metastasis 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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G.6.2 Site of metastasis 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition A description of the site of the metastasis at the time of primary treatment. 
Context Used for monitoring collection of treatment information about women with 
breast cancer. 
Relational and representational attributes 
Datatype Text  Representational form  
Field size Min.  Max.  Representational layout  
Data domain Site of metastasis 
Guide for use To be completed by surgeon at the time of initial surgical treatment. 
Collected from histopathology information for all women referred for treatment 
or for diagnostic open biopsy at assessment, after diagnostic or therapeutic 
treatment procedures have been performed. 
Verification rules Site of metastasis is to be entered only if entry for G.6.1 Metastasis—distant 
is ‘Present’ (code 1). 
Related data 
elements 
G.6.1 Metastasis—distant 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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H—Death segment 
Data dictionary version 1.1 Data dictionary version 1 
H.1 Date of death H.1 Date of death 
H.2 Underlying cause of death H.2 Underlying cause of death 
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H.1 Date of death 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The woman’s date of death 
Context  
Relational and representational attributes 
Datatype Numeric  Representational form DATE 
Field size Min. 8 Max. 8 Representational layout DDMMYYYY 
Data domain Valid date 
Guide for use Record the date the woman died. 
This data element should always be recorded as an 8 digit valid date 
comprising day, month and year. Year should always be recorded in its full 4 
digit format. For days and months with a numeric value of less than 10, zeros 
should be used to ensure that the date contains the required 8 digits. For 
example if the woman died on 1 July 2000 the Date of death should be 
recorded as 01072000 as specified in the representational layout. 
It is recommended that in cases where all components of Date of death are 
not known, a valid date be used together with A.8 Estimated date flag to 
indicate that it is an estimate. 
Verification rules  
Related data 
elements 
A.8 Estimated date flag 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia  
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H.2 Underlying cause of death 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type DATA ELEMENT 
Definition The underlying cause of death of the woman. 
Context  
Relational and representational attributes 
Datatype Numeric  Representational form CODE 
Field size Min.  Max.  Representational layout  
Data domain 1. Breast cancer 
2. Other 
Guide for use  
Verification rules  
Collection methods Information to be obtained from the cancer registry or births, deaths and 
marriages registry in that state or territory, if legislation allows. 
Related data 
elements 
 
Related NAS 
Measures 
 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments Note that at present not all BreastScreen reigisters are able to access cause 
of death data, and as this data element is not required for any of the NAS 
Measures, the collection of this data element is purely on a voluntary basis. 
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4 Performance indicators  
Indicator 1—Participation 
Indicator 2—Rescreening  
Indicator 3—Recall to assessment  
Indicator 4—Invasive breast cancer detection  
Indicator 5—Ductal carcinoma in situ detection 
Indicator 6a—Interval cancers  
Indicator 6b—Program sensitivity 
Indicator 7a—Invasive breast cancer incidence 
Indicator 7b—Ductal carcinoma in situ incidence 
Indicator 8—Mortality 
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Indicator 1—Participation 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition Percentage of women screened through BreastScreen Australia in a  
24-month period by 5-year age groups (40–44, 45–49, 50–54, 55–59,  
60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target age group  
(50–74 years). 
Related Standard Standard 1 Access and participation: Appropriate levels of access and 
participation in BreastScreen Australia are achieved in the target and eligible 
populations 
Context BreastScreen Australia aims to achieve substantial reductions in mortality 
from breast cancer among Australian women by maximising the participation 
of women in the target age group of 50-74 years. A high participation rate 
also helps maximise the efficient use of the physical infrastructure and 
specialist staff resources required for the population based breast cancer 
screening program. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 3 Representational layout NNN 
Data domain Percentage 
Formula 
Number of women screened by age group 
ABS ERP by age group 
 
x 100 
Numerator The number of individual women screened during a 24-month period by age 
group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identifier number 
A.9 State identifier 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
B.4 Main language other than English spoken at home 
B.5 Indigenous status 
C.2 Date of first attendance for this episode 
Denominator The number of women for each State/Territory/Australia, remoteness area, 
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socioeconomic status, Indigenous status and main language spoken at 
home, using Australian Bureau of Statistics (ABS) estimated resident female 
population(s) as at 30 June averaged over the relevant 24 months by age 
group. This value will represent the estimated population at the midpoint of 
the reference period. 
Data collection Australian Bureau of Statistics 
Source ABS Estimated Resident Population 
Specifications • Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, 
then only the last screening episode is to be counted. 
• Indicator is expressed per 100 women in the population. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age is determined by subtracting date of birth from date of first 
attendance for this episode. 
• Data are presented by the following stratifications: 
 State/Territory –
 Remoteness area  –
 Socioeconomic status –
 Indigenous status –
 Main language spoken at home –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
Comments Remoteness area 
The ABS Australian Statistical Geography Standard Remoteness Area 
classification or ASGS RA (ABS 2011) is a classification that allocates one of 
five remoteness categories to areas. Areas are classified as Major cities, 
Inner regional, Outer regional, Remote or Very remote. 
The calculation of this measure will produce five results for the five different 
remoteness areas. 
See Appendix 2 for more information. 
Socioeconomic status 
The IRSD is one of four SEIFAs developed by the Australian Bureau of 
Statistics (ABS 2011c). This index is based on factors such as average 
household income, education levels and unemployment rates. Rather than 
being a person-based measure, the IRSD is an area-based measure of 
socioeconomic status in which small areas of Australia are classified on a 
continuum from disadvantaged to affluent. This information is used as a proxy 
for the socioeconomic status of people living in those areas and may not be 
correct for each person in that area. 
The calculation of this measure will produce five results (low to high 
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socioeconomic status) across the five quintiles. 
See Appendix 2 for more information. 
Indigenous status 
Women are allocated to one of the following categories: ‘Indigenous’, ‘Non-
Indigenous’, ‘Not stated’.  
The ABS provides estimates of the Indigenous and non-Indigenous 
population by five year age groups, sex and state/territory. 
Cultural and linguistic diversity 
Women are allocated to one of the following categories: ‘English’, ‘Non-
English’, ‘Not stated’. 
The ABS estimated resident population is not stratified by language spoken 
at home. In these cases the denominator is calculated by applying the age–
specific distribution of language spoken at home from the most recent ABS 
Census to the relevant age specific estimated resident population counts. 
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Indicator 2—Rescreening 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition Proportion of all women screened in a given index year whose screening 
outcome was a recommendation to return for screening in two years who 
returned for a screen within 27 months. This rate is reported by 5-year age 
groups (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 
85+) and for the target age group (50–72 years). 
Related Standard Standard 1 Access and participation: Appropriate levels of access and 
participation in BreastScreen Australia are achieved in the target and eligible 
populations 
Context If BreastScreen Australia is to achieve its potential in terms of mortality 
benefit, women in the target age group must be rescreened on a regular 
basis to increase the likelihood that breast cancers are detected as early as 
possible. The screening interval needs to be short enough to detect cancers 
before they are clinically apparent so they can be treated earlier, providing 
improved survival.  The interval needs to be long enough so that any potential 
harms of the screening program are minimised for participants (BreastScreen 
Australia 2009a). 
The long-term effectiveness of the breast cancer screening programs 
depends on women in the target age group continuing to be screened at 
regular intervals. Unless high rescreening rates are maintained, overall 
participation rates will decline. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 3 Representational layout NNN 
Data domain Percentage 
Formula 
Number of women who returned for a screen within  
27 months by age group 
Number of women who were screened whose screening 
outcome was a recommendation to return for screening  
in two years by age group 
 
 
x 100 
Numerator The number of women screened in a given index year who returned for a 
screen within 27 months stratified by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
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Data element A.1 Client identifier number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
Denominator The number of women who were screened in the relevant index year whose 
screening outcome was a recommendation to return for screening, stratified 
by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identifier number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
E.12 Recommendation—definitive 
Specifications • Age is age at the time of screen in the index year. 
• Screening round classified as ‘First round’, ‘Second round’ or ‘Third and 
subsequent rounds’. 
• Indicator is expressed per 100 women. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• In principle the denominator for this rate should be adjusted to remove 
women who either died or developed an interval cancer after their screen 
in the index year. However, this would be too complex to collect. 
• Data are presented by the following stratifications: 
 Screening round (first, second and third and subsequent) –
 State/Territory –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 3—Recall to assessment 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The proportion of all women screened in a given calendar year who were 
recalled for assessment by 5-year age groups (40–44, 45–49, 50–54, 55–59, 
60–64, 65–69, 70–74, 75–79, 85+) and for the target age group  
(50–74 years). 
Related Standard Standard 2 Cancer detection: Breast cancer detection is maximised in the 
target population and harm is minimised. 
Context Population based breast cancer screening is offered to a well population of 
women with the aim of detecting asymptomatic breast cancer at an early 
stage. It is important that BreastScreen Australia balances maximising cancer 
detection, particularly small cancer detection, with minimising the potential 
harm that may be caused to the women screened, by unnecessary recall to 
assessment or investigations. An effective breast cancer screening program 
will limit any unnecessary investigations by minimising the proportion of 
women recalled for further assessment without impacting on achieving a high 
breast cancer detection rate. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 3 Representational layout N 
Data domain Percentage 
Formula 
Number of women who were recalled for assessment  
by age group 
Number of women screened by age group 
 
 
x 100 
Numerator The number of women who were recalled for assessment in the relevant 
calendar year. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identification number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
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Denominator The number of women screened in a given calendar year. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identification number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
Specifications • Recall for assessment counts: 
a) mammographic recall only (C.5 = 3 or 5) 
b) recall for other reasons (non–mammographic) (C.4 = 4) and/or 
c) combined recall (C.5 = 3 & 4 & 5) 
• Screening round should be classified as ‘First round’ and ‘Subsequent 
rounds’ 
• Indicator is expressed per 100 women. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Data are presented by the following stratifications: 
 Screening round (first and subsequent) –
 State/Territory –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 4—Invasive breast cancer detection 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The number of women with invasive breast cancer detected through 
BreastScreen Australia per 10,000 women screened in a 12-month period by 
5-year age groups (40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74,  
75–79, 80–84, 85+) and for the target age group (50–74 years). The rate is 
reported for breast cancers of all sizes, as well as for a subset of breast 
cancers that are small (having a diameter ≤15 mm). 
Related Standard Standard 2 Cancer detection: Breast cancer detection is maximised in the 
target population and harm is minimised. 
Context BreastScreen Australia aims to achieve significant reductions in morbidity 
and mortality attributable to breast cancer by maximising the early detection 
of breast cancer in the target population. Early detection will lead to better 
treatment options and improved chances of survival for women screened in 
BreastScreen Australia. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 5 Representational layout  NN 
Data domain Rate 
 
Number of women with invasive breast cancer by age group 
Number of women screened by age group 
 
x 10,000 
 
Number of women with small (≤15 mm) invasive breast cancer 
by age group 
Number of women screened by age group 
 
x 10,000 
Numerator The number of women with all size as well as small diameter (≤15 mm) 
invasive breast cancer detected in BreastScreen Australia in a 12-month 
period by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identification number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
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C.2 Date of first attendance for this episode 
F.4 Histopathology of malignant lesions 
F.5 Size of tumour 
F.7 Dominant lesion identification number 
Denominator The number of women screened by BreastScreen Australia over the relevant 
12 months by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identifier number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
Specifications • Count is of individual women, not tumours. 
• Include invasive tumours only. 
• Indicator is expressed per 10,000 women screened. 
• Use a woman’s last screen in the 12-month period. 
• A small cancer is one that is pathologically defined as ≤15 mm. 
• A screen–detected breast cancer is a cancer that is histopathologically 
confirmed as a breast cancer before completion of an episode of 
screening at BreastScreen Australia. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• If a small invasive breast cancer was detected for a woman at separate 
screening episodes during the reporting period, both cases should be 
included in the numerator. 
• Microinvasive tumours are included. 
• Cancer detected at early review is excluded. 
• Invasive cancer diagnosed at early rescreen where the woman presents 
with a breast lump and/or clear or blood–stained nipple discharge in the 
breast in which the cancer was diagnosed is excluded. 
• Paget’s disease is only included if an invasive component is present. 
• Data are presented by the following stratifications: 
 Tumour size: ≤15 mm and all sizes –
 Screening round (first and subsequent) –
 State/Territory –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 5—Ductal carcinoma in situ detection 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type: Performance indicator 
Definition The number  of women diagnosed with ductal carcinoma in situ per 10,000 
women screened in a 12-month period by 5-year age groups (40–44, 45–49, 
50–54,55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85+) and for the target 
age group (50–74 years). 
Related Standard Standard 2 Cancer detection: Breast cancer detection is maximised in the 
target population and harm is minimised. 
Context Women who have DCIS detected are at increased risk of developing invasive 
breast cancer (AIHW 2010a; World Health Organisation and the International 
Agency of Research in Cancer 2002). It is not currently possible to predict 
which DCIS cases will progress to invasive breast cancer. However, given 
the increased risk of invasive breast cancer after a diagnosis of DCIS, and 
that the detection and subsequent treatment of high grade DCIS is likely to 
prevent deaths from invasive breast cancer, BreastScreen Australia aims to 
maximise the detection of DCIS.   
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 4 Representational layout NNN.N 
Data domain Rate 
Formula 
Number of women with DCIS by age group 
Number of women screened by age group 
 
x 10,000 
Numerator The number of women with ductal carcinoma in situ detected in BreastScreen 
Australia in a 12-month period by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identifier number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.4 Histopathology of malignant lesions 
F.7 Dominant lesion identification number 
Denominator The number of women screened by BreastScreen Australia over the relevant 
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12 months by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identifier number 
A.9 State identifier 
B.5 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
Specifications • Count is of individual women, not tumours. 
• Indicator is expressed per 10,000 women screened. 
• Symptomatic women are included in both the numerator and the 
denominator. 
• In case of a simultaneous diagnosis of DCIS and LCIS, the case should 
be counted as DCIS. 
• In case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive. 
• If there is a microinvasive lesion in the presence of DCIS, the lesion with 
the microinvasion is the dominant lesion over DCIS. 
• Only the first case of DCIS in a woman should be counted. 
• Data are presented by the following stratifications: 
 Screening round (first and subsequent) –
 State/Territory –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 6a—Interval cancers 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The number of invasive breast cancers detected in women screened through 
BreastScreen Australia that arise during an interval between two screening 
rounds, per 10,000 women-years in a defined period by  10-year age groups 
(40-49, 50-59, 60-69, 70-79, 80+) and for the target age group (50-74 years). 
Related Standard Standard 2 Cancer detection: Breast cancer detection is maximised in the 
target population and harm is minimised. 
Context BreastScreen Australia aims to have a high proportion of invasive breast 
cancers detected within a screening episode and a low proportion diagnosed 
after a screening episode detected no cancer. A cancer is defined as 'interval' 
if it is diagnosed in the interval between a negative screening episode and 
the next screening examination. 
Interval cancer rates are a key performance indicator of the likely success of 
BreastScreen Australia to reduce mortality from breast cancer. Women who 
have their cancer diagnosed as an interval cancer may have a poorer 
outcome compared to women who have their cancer detected at their 
screening episode. If too many breast cancers are missed at screening and 
are found in the interval between screening episodes, the opportunity to 
prevent death is compromised. It is therefore important to monitor the rate of 
interval cancers by the Program at a national, State and Territory level. The 
interval cancer rate should also be monitored at Service level, as it is strong 
indicator of the quality and performance of individual Services and screen 
readers in particular.   
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 4 Representational layout NNN.N 
Data domain Rate 
Formula 
Number of interval invasive breast cancers by age group 
Number of women—years at risk by age group 
 
x 10,000 
Numerator The number of women with an interval invasive breast cancer in a 24-month 
period by age group. 
Data collection State and Territory Cancer registries and BreastScreen Australia 
Source State and Territory Cancer registries and BreastScreen Australia 
Data element A1 Client identifier number 
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A.5 Lesion number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number— State/Territory program 
B.10 Symptom status 
C.2 Date of first attendance for this episode 
C.5 Recommendation— screening 
D.1 Reason for assessment 
D.2.2 Date of first attendance for assessment 
D.11.1 Recommendation—assessment 
D.11.2 Recommendation—number of months 
D.11.3 Date recommendation made 
D.11.4 Assessment visit—date 
E.12 Recommendation—definitive 
F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis 
F.4 Histopathology of malignant lesions 
Denominator The number of women–years at risk in the specified period by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identification number 
A.9 State identifier 
B.2 Date of birth 
B.7.1 Previous history of breast cancer 
B.9.1 Round number—State/Territory program 
B.10 Symptom status 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
Specifications • Count is of individual women, not tumours. 
• Include invasive tumours only. 
• Indicator is expressed per 10,000 women screened. 
• Screening round should be classified as ‘First round’ and ‘Subsequent 
rounds’. 
• Data are presented by the following stratifications: 
 Time since screening (0–364 days and 365–729 days) –
 Screening round (first and subsequent) –
 State/Territory –
• See NAS Measures 2.3.1 and 2.3.2 for definitions of interval cancers. 
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Collection methods Data are collected on the women screened through BreastScreen Australia 
and the interval cancers are identified by linking this information with that of 
the State and Territory cancer registries. 
BreastScreen Australia State and Territory Programs have developed a 
process of matching to their own State/Territory cancer registries in a way 
that is suitable to the size of their screening populations. For example, States 
with large population sizes have larger numbers of women to match with the 
cancer registries. In these cases, the volume of matching needs to be 
facilitated by an automated matching program. Smaller State/Territories may 
be able to do their matching manually with the aid of SQL–based queries. 
Regardless of method, it is important that each State and Territory uses a 
comparable set of variables for their matches. The recommended variables 
(Kavanagh et al. 1999) to extract from both BreastScreen data bases and the 
cancer registry databases are, at a minimum: 
• first name 
• last name 
• date of birth 
• address (including number, street, suburb/town and postcode in separate 
fields) 
• date of cancer diagnosis 
• date of last contact  (and date of death if separate field to date of last 
contact) 
Other variables suggested for matching include: 
• second given name 
• alias and/or maiden name 
• tumour details (including histology, laterality, behaviour, staging (TNM), 
grade) 
Additional information required from the BreastScreen Australia databases 
include: 
• date of screen 
• outcome of screening episode (routine recall, lesion detected or early 
review). 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 6b—Program sensitivity 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The percentage of women with screen–detected invasive breast cancer 
amongst all Program–screened women diagnosed with invasive breast 
cancer in a defined period (screen–detected and interval cancers) by 10-year 
age groups (40–49, 50–59, 60–69, 70–79 and 80+) and for the target age 
group (50–74 years). 
Related Standard None. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 3 Representational layout NN 
Data domain Percentage 
Formula 
Number of invasive screen–detected breast cancers 
 by age group 
Number of invasive screen–detected breast cancer plus 
number of interval invasive breast cancers by age group 
 
 
x 100 
Numerator The number of women with screen–detected invasive breast cancer in a  
24-month period by age group. 
Data collection BreastScreen Australia data dictionary 
Source BreastScreen Australia 
Data element A.1 Client identification number 
A.5 Lesion number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
D.2.2 Date of first attendance for assessment 
D.11.2 Recommendation—number of months 
D.11.3 Date recommendation made 
D.11.4 Assessment visit—date 
F.1.1 Reason for histopathology 
F.1.2 Date of Diagnosis 
F.1.3 Cancer diagnosed in BreastScreen Australia 
F.4 Histopathology of malignant lesions 
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Denominator The number of women with screen–detected invasive breast cancer plus the 
number of Program–screened women with interval invasive breast cancer in 
the specified period by age group. 
Data collection BreastScreen Australia and State and Territory Cancer registries 
Source BreastScreen Australia and State and Territory Cancer registries 
Data element A.1 Client identification number 
A.9 State identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
F.4 Histopathology of malignant lesions 
F.7 Dominant lesion identification number 
Specifications • Count is of individual women, not tumours. 
• Include invasive tumours only. 
• Screen detected cancers are as defined for Indicator 4. 
• Interval cancers are defined as for Indicator 6a. 
• Indicator is expressed as a percentage 
• Screening round should be classified as ‘First round’ and ‘Subsequent 
rounds’. 
• Data are presented by the following stratifications: 
 Time since screening (0–364 days and 365–729 days) –
 Screening round (first or subsequent) –
 State/Territory –
Collection methods Data are collected at point of screening and by the State/Territory cancer 
registry. 
Refer to Indicator 6a, Interval cancers, (BreastScreen Australia indicator 6a) 
for an outline of the matching process used to identify interval cancers. 
For further information on Program sensitivity, please refer to Kavanagh et al 
1999. 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version1.1 
Source organisation BreastScreen Australia 
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Indicator 7a—Invasive breast cancer incidence 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The number of new cases of invasive breast cancer per 100,000 estimated 
female resident population in a 12-month period by 5-year age groups  
(40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 85+) and for the 
target age group (50–74 years). 
Related Standard None. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 4 Representational layout NNN.N 
Data domain Rate 
Formula 
Number of new cases of breast cancer by age group 
Population by age 
 
x 100,000 
Numerator The number of new cases of breast cancer by age group. 
Data collection State and Territory Cancer Registries 
Source AIHW Australian Cancer Database 
Denominator The number of women in that particular age group, using Australian Bureau 
of Statistics estimated resident female mid–year population. 
Data collection Australian Bureau of Statistics 
Source Australian Bureau of Statistics Estimated Resident Population 
Specifications • All invasive breast cancer is defined as ICD-10 code C50. 
• Indicator is expressed per 100,000 women age–standardised to the 2001 
total Australian population using direct standardisation. 
• This indicator is derived from the AIHW holdings of cancer registry 
incidence data (AIHW Australian Cancer Database). 
• Reporting period to be the latest available years. 
• Data are presented by the following stratifications: 
 State/Territory –
 Remoteness area  –
 Socioeconomic status –
 Indigenous status. –
 
 BreastScreen Australia data dictionary: version 1.1 223 
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 7b—Ductal carcinoma in situ incidence 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The number of new cases of ductal carcinoma in situ (DCIS) per 100,000 
estimated female resident population in a 12-month period by 10-year age 
groups (40–49, 50–59, 60–69, 70–79 and 80+) and for the target age group 
(50–74 years). 
Related Standard None. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 4 Representational layout NNN.N 
Data domain Rate 
Formula 
Number of new cases of DCIS by age group 
Population by age group 
 
x 100,000 
Numerator The number of new cases of DCIS in a 12-month period by age group. 
Data collection State and Territory Cancer Registries 
Source AIHW Australian Cancer Database 
Denominator The number of women in that particular age group, using Australian Bureau 
of Statistics estimated resident female mid-year population. 
Data collection Australian Bureau of Statistics 
Source Australian Bureau of Statistics Estimated Resident Population 
Specifications • Indicator is expressed per 100,000 women. 
• Count is of individual women, not tumours. 
• The following should be excluded from the data set: 
 Lobular Carcinoma In Situ (LCIS) –
 Women with a previous invasive breast cancer –
• In case of a simultaneous diagnosis of DCIS and LCIS, the case should 
be counted as DCIS. 
• In case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive. 
• Only the first case of DCIS in a woman should be counted. 
• Paget’s disease either in the presence or absence of DCIS should be 
included as DCIS unless there is an invasive component. 
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• Data are presented by the following stratifications: 
 State/Territory –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation BreastScreen Australia 
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Indicator 8—Mortality 
Admin. status CURRENT 
Identifying and definitional attributes 
Data element type Performance indicator 
Definition The number of deaths from breast cancer per 100,000 estimated female 
resident population in a 12-month period by 5-year age groups (40–44,  
45–49, 50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 85+) and for the target 
age group (50–74 years). 
Related Standard None. 
Relational and representational attributes 
Datatype Numeric Representational form Quantitative value 
Field size Min. 1 Max. 4 Representational layout NNN.N 
Data domain Rate 
Formula 
Number of deaths from breast cancer by age group 
Population by age group 
 
x 100,000 
Numerator The number of deaths from breast cancer by age group. 
Data collection AIHW National Mortality database 
Source AIHW National Mortality database 
Denominator The number of women in that particular age group, using Australian Bureau 
of Statistics estimated resident female mid–year population. 
Data collection Australian Bureau of Statistics 
Source Australian Bureau of Statistics Estimated Resident Population 
Specifications • Indicator is expressed per 100,000 women. 
• This indicator is derived from the AIHW holdings of cancer registry 
mortality data (National Mortality database). 
• Data are presented by the following stratifications: 
 State/Territory –
 Remoteness area –
 Indigenous status –
Administrative attributes 
Source document BreastScreen Australia data dictionary, version 1.1 
Source organisation: BreastScreen Australia 
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5 National Accreditation Standards 
Measures—data specifications 
5.1 Usage guide 
The following algorithms should be used where the data dictionary data elements match the 
data elements in the various program databases. Where the data elements do not match and 
the Service can use alternative or more effective data elements, the algorithms should be 
used as a guide to ensure the correct measurement of the standards.  
In most instances the denominator should be calculated first as the numerator is a subset of 
the denominator. 
Unless otherwise stated, both symptomatic and asymptomatic women are to be included in 
the numerator and the denominator. 
Use A.1 Client identification number and B.9.1 Round number—State/Territory program to ensure 
correct linking of data elements. 
For standards relating to assessment measures, include all women assessed by the Service 
even if screened elsewhere. Assessments or assessment procedures performed outside the 
Service are to be excluded. 
For standards relating to cancer detection, include all cancers detected for women screened 
by the Service even if they were not assessed by the Service. 
For standards that relate to performance in relation to the screening episode, which includes 
cancer detection, the reference period relates to the most recent 12-month period (either 
calendar or financial year) for which data are available using data element C.2 Date of first 
attendance for this episode (between start date and end date). 
For standards that relate to performance in relation to the assessment visit, the reference 
period relates to the most recent 12-month period (either calendar or financial year) for 
which data are available, using data element D.2.2 Date of first attendance for assessment 
(between start date and end date). Where a woman has multiple visits, it is important to 
include all visits associated with that round. 
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NAS Measures—Data Specifications  
 NAS Measures—Data Specifications 
1. Access and Participation Standard 
Criterion 1.1—The Service and/or SCU maximises the participation of women in the target 
age groups for screening and rescreening. 
NAS Measure 1.1.1 (a) The Service and/or SCU monitors and reports the participation 
rate of women aged 50–74 years who participate in screening in the most recent  
24-month period. ..............................................................................................................233 
NAS Measure 1.1.1 (b) ≥70% of women aged 50–69 years participate in screening in the 
most recent  24-month period. .........................................................................................235 
NAS Measure 1.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their first screening episode within the Program 
who are rescreened within 27 months. ............................................................................237 
NAS Measure 1.1.2 (b) ≥75% of women aged 50–67 years who attend for their first 
screening episode within the Program are rescreened within 27 months. ......................239 
NAS Measure 1.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–72 years who attend for their second and subsequent screen within the 
Program who are rescreened within 27 months of their previous screening episode. ....241 
NAS Measure 1.1.3 (b) ≥90% of women aged 50–67 years who attend for their second 
and subsequent screens within the Program are rescreened within 27 months of their 
previous screening episode. ............................................................................................243 
Criterion 1.2—BreastScreen services are accessible to the target and eligible populations, 
especially women from Indigenous; culturally and linguistically diverse; rural/remote; and 
lower socioeconomic backgrounds and women with a disability.  
NAS Measure 1.2.1 (a) The Service and/or SCU monitors and reports participation of 
women aged 50–74 years from special groups and where rates are below that of the 
overall population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the following groups is 
made: women from Indigenous, culturally and linguistically diverse, rural/remote and 
lower socio-economic backgrounds. ................................................................................245 
NAS Measure 1.2.1 (b) The Service and/or SCU monitors and reports participation of 
women aged 50–69 years from special groups and where rates are below that of the 
overall population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the following groups is 
made: women from Indigenous, culturally and linguistically diverse, rural/remote and 
lower socio-economic backgrounds. ................................................................................247 
NAS Measure 1.2.2 The Service and/or SCU monitors the proportion of all women in the 
Service who are screened and recalled for assessment, aged 40–49 years and  
75 years and over. 
(a) women who are screened ..........................................................................................261 
(b) women who are recalled for assessment ...................................................................263 
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2. Cancer Detection Standard 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive breast cancer 
in the target population.  
NAS Measure 2.1.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who are diagnosed 
with invasive breast cancer. .............................................................................................265 
NAS Measure 2.1.1 (b) ≥50 per 10,000 women aged 50–69 years who attend for their 
first screening episode are diagnosed with invasive breast cancer. ................................267 
NAS Measure 2.1.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent screening episode 
who are diagnosed with invasive breast cancer. .............................................................269 
NAS Measure 2.1.2 (b) ≥35 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with invasive breast cancer. ..271 
NAS Measure 2.1.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode who are diagnosed 
with small (≤15mm) invasive breast cancer. ....................................................................273 
NAS Measure 2.1.3 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent screening episode 
who are diagnosed with small (≤15mm) invasive breast cancer. ....................................275 
NAS Measure 2.1.3 (c) ≥25 per 10,000 women aged 50–69 years who attend for 
screening are diagnosed with small (≤15mm) invasive breast cancer. ...........................278 
NAS Measure 2.1.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are diagnosed with 
invasive breast cancer. ....................................................................................................281 
NAS Measure 2.1.4 (b) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend annually for screening, who are diagnosed with 
small (≤15mm) invasive breast cancer. ...........................................................................283 
NAS Measure 2.1.4 (c) The Service and/or SCU monitors and reports the proportion of 
women aged 40–49 years who attend annually for screening, who are diagnosed with 
invasive breast cancer. ....................................................................................................286 
Criterion 2.2—The Service and/or SCU maximises the detection of ductal carcinoma in situ 
(DCIS).  
NAS Measure 2.2.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged  50–74 years who attend for their first screening episode who are diagnosed 
with DCIS. ........................................................................................................................288 
NAS Measure 2.2.1 (b) ≥12 per 10,000 women aged 50–69 years who attend for their 
first screening episode are diagnosed with DCIS. ...........................................................290 
NAS Measure 2.2.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent screening episode 
who are diagnosed with DCIS. .........................................................................................292 
NAS Measure 2.2.2 (b) ≥7 per 10,000 women aged 50–69 years who attend for their 
second or subsequent screening episode are diagnosed with DCIS. .............................294 
NAS Measure 2.2.3 The Service and/or SCU monitors and reports the number of women 
aged  50–74 years who attend annually for screening, who are diagnosed with DCIS. .296 
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Criterion 2.3—The Service and/or SCU minimises the number of interval invasive breast 
cancers.  
NAS Measure 2.3.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with an interval 
invasive breast cancer 0–12 months following a negative screening episode. ...............298 
NAS Measure 2.3.1 (b) <7.5 per 10,000 women aged 50–69 years who attend for 
screening are diagnosed with an interval invasive breast cancer 0–12 months following a 
negative screening episode. ............................................................................................304 
NAS Measure 2.3.2 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for screening who are diagnosed with an interval 
invasive breast cancer 13–24 months following a negative screening episode. .............310 
NAS Measure 2.3.2 (b) ≤15 per 10,000 women aged 50–69 years who attend for 
screening are diagnosed with an interval invasive breast cancer 13–24 months following 
a negative screening episode. .........................................................................................315 
Criterion 2.4—The Service and/or SCU ensures high quality screen reading.  
NAS Measure 2.4.1 All screen readers read at least 2,000 mammographic screening 
cases within the Program per year. .................................................................................320 
Criterion 2.5—The Service and/or SCU ensures high quality imaging.  
NAS Measure 2.5.1 The Service and/or SCU monitors and reports the percentage of 
women who have up to 4 images per screen, including technical repeats. ....................321 
NAS Measure 2.5.2 The overall repeat rate for the Service and/or SCU is ≤2% of all 
screening images. ............................................................................................................323 
Criterion 2.6—Investigations and recall for assessment of non-malignant lesions is 
minimised.  
NAS Measure 2.6.1 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for annual screening. ..........................................325 
NAS Measure 2.6.1 (b) ≤10% of women aged 50–69 years attend for annual screening.327 
NAS Measure 2.6.2 The Service and/or SCU monitors and reports the proportion of 
women who attend for annual screening, aged 40–49 years and 75 years and over. ....329 
NAS Measure 2.6.3 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their first screening episode and are recalled for 
assessment. .....................................................................................................................331 
NAS Measure 2.6.3 (b) <10% of women aged 50–69 years who attend for their first 
screening episode are recalled for assessment. .............................................................333 
NAS Measure 2.6.4 (a) The Service and/or SCU monitors and reports the proportion of 
women aged 50–74 years who attend for their second or subsequent screening episode 
and are recalled for assessment. .....................................................................................335 
NAS Measure 2.6.4 (b) <5% of women aged 50–69 years who attend for their second or 
subsequent screening episode are recalled for assessment. ..........................................337 
NAS Measure 2.6.5 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS in women 
aged 50–74 years who attend for their first screening episode. ......................................339 
 BreastScreen Australia data dictionary: version 1.1 231 
NAS Measure 2.6.6 The Service and/or SCU monitors and reports the positive predictive 
value of a recall to assessment for detecting invasive breast cancer or DCIS in women 
aged 50–74 years who attend for their second or subsequent screening episode. ........342 
NAS Measure 2.6.7 <0.2% of women who attend for screening are recommended for 
early review for further assessment. ................................................................................345 
3. Assessment Standard 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment.  
NAS Measure 3.1.1 <5% of all percutaneous needle biopsies of malignant breast lesions 
are classified as benign or inadequate/insufficient. .........................................................347 
NAS Measure 3.1.2 0% of benign lesions assessed by percutaneous needle biopsy have 
a false positive cancer diagnosis, when the definitive needle biopsy result is achieved 
after performance of the final needle biopsy at an assessment episode(s). A false positive 
FNA which is followed by a true negative core biopsy, prior to recommendation for 
surgery or treatment, is not considered to be a false positive ‘percutaneous needle 
biopsy’ for the purpose of this standard. ..........................................................................349 
NAS Measure 3.1.3 The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. .............................................................................351 
NAS Measure 3.1.4 ≤0.35% of women who attend for their first screening episode are 
found not to have invasive breast cancer or DCIS after diagnostic open biopsy. ...........353 
NAS Measure 3.1.5 ≤0.16% of women who attend for their second or subsequent 
screening episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. .....................................................................................................................355 
NAS Measure 3.1.6 All women with impalpable lesions undergoing excision have 
specimen imaging recorded. ............................................................................................357 
NAS Measure 3.1.7 ≥95% of all lesions are correctly identified at first excision. ............359 
NAS Measure 3.1.8 (a) ≥85% of invasive breast cancers or DCIS are diagnosed without 
the need for excision. .......................................................................................................361 
NAS Measure 3.1.8 (b) Where part (a) is not met, the Service and/or SCU provides the 
proportion of breast cancers that are diagnosed as invasive and DCIS without the need 
for excision. ......................................................................................................................363 
4. Timeliness Standard 
Criterion 4.1—The Service and/or SCU ensures that women progress through the 
screening pathway in a timely manner.  
NAS Measure 4.1.1 (a) ≥90% of women aged 50–74 years attend for a screening 
appointment within 28 calendar days of their booking date (fixed sites only). ................365 
NAS Measure 4.1.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the time taken to achieve 90% from booking to screening (fixed sites only). ......367 
NAS Measure 4.1.2 ≥90% of women have a documented notification of the results of 
screening within 14 calendar days of the date of screening. ...........................................369 
Criterion 4.2—The Service and/or SCU ensures that women progress through the 
assessment pathway in a timely manner.  
NAS Measure 4.2.1 (a) ≥90% of women requiring assessment attend an assessment visit 
within 28 calendar days of their screening visit. ..............................................................371 
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NAS Measure 4.2.1 (b) Where part (a) is not met, the Service and/or SCU records and 
reports the number of days the Service and/or SCU takes to achieve 90%. ..................373 
NAS Measure 4.2.1 (c) Where part (a) is not met, the Service and/or SCU records and 
reports the percentage of women who were offered assessment within 28 calendar days 
of their screening visit. .....................................................................................................375 
NAS Measure 4.2.2 ≥95% of women not requiring percutaneous needle biopsy at 
assessment receive a definitive recommendation at their first assessment visit. ...........377 
NAS Measure 4.2.3 ≥95% of women require no more than two procedural assessment 
visits to receive a definitive recommendation from assessment. .....................................379 
NAS Measure 4.2.4 ≥85% of women are verbally given the results of percutaneous 
needle biopsy within seven calendar days of the assessment procedure. ......................381 
NAS Measure 4.2.5 ≥95% of women complete all assessment within 15 calendar days.383 
NAS Measure 4.2.6 All women are notified of the results of their assessment in writing 
within 14 calendar days of the date of completion of assessment. .................................385 
5. Data Management and Information Systems Standard 
Criterion 5.1—The Service and/or SCU ensures the collection of treatment information 
about women with breast cancer.  
NAS Measure 5.1.1 ≥95% of data dictionary compliant surgical histopathology information 
is received by the Service and/or SCU. ...........................................................................387 
NAS Measure 5.1.2 ≥95% of data dictionary compliant primary treatment information is 
received by the Service and/or SCU. ...............................................................................389 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.1—The Service and/or SCU maximises the participation of women in 
the target age groups for screening and rescreening. 
NAS Measure 1.1.1 (a) 
The Service and/or SCU monitors and reports the participation rate of women 
aged 50–74 years who participate in screening in the most recent 24-month 
period. 
Data Dictionary Measure 
The percentage of women aged 50–74 years in the Service and/or SCU catchment area who are 
screened by BreastScreen Australia during the most recent 24-month period. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Post code of usual residence 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–74 years residing in the Service and/or 
SCU catchment area screened by BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, C.2 
Denominator Number of women aged 50–74 years resident in the catchment area using 
Australian Bureau of Statistics estimated resident female population(s). This value 
will represent the estimated population at the midpoint of the reference period. If 
the reference period is based on calendar years, the population figure will be an 
average of the two corresponding Estimated Residential Populations (ERPs) as at 
30 June. When the reference period is based on financial years, the population 
value will be the ERP for the year wholly contained within the reference period. 
Where Service and/or SCU boundaries cross ABS population boundaries, 
calculation of resident women to be made on a proportional basis. 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
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• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Age is calculated as the age at the date of first attendance for the screening 
episode selected. 
• Interstate women are excluded from the numerator. 
Algorithm 
[A.1 & ((last C.2 between start date & end date) &  
(last C.2—B.2≥50 & ≤74) &  
(B.3.1 or B.3.2 for Service and/or SCU catchment area))] 
ABS ERP 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population using 
appropriate estimated resident populations (ERPs) as defined by the 
Australian Bureau of Statistics. 
• The calculation of this measure will produce one result. National collection 
collects data by calendar years. 
Former NAS 1.1.1 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.1—The Service and/or SCU maximises the participation of women in 
the target age groups for screening and rescreening. 
NAS Measure 1.1.1 (b) 
≥70% of women aged 50–69 years participate in screening in the most recent  
24-month period. 
Data Dictionary Measure 
The percentage of women aged 50–69 years in the Service and/or SCU catchment area who are 
screened by BreastScreen Australia during the most recent 24-month period. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
C.2  Date of first attendance for this episode 
Numerator Number of individual women aged 50–69 years residing in the Service and/or 
SCU catchment area screened by BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, C.2 
Denominator Number of women aged 50–69 years resident in the catchment area using 
Australian Bureau of Statistics estimated resident female population(s). This value 
will represent the estimated population at the midpoint of the reference period. If 
the reference period is based on calendar years, the population figure will be an 
average of the two corresponding Estimated Residential Populations (ERPs) as at 
30 June. When the reference period is based on financial years, the population 
value will be the ERP for the year wholly contained within the reference period. 
Where Service and/or SCU boundaries cross ABS population boundaries, 
calculation of resident women to be made on a proportional basis. 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
 236 BreastScreen Australia data dictionary: version 1.1 
• Age is calculated as the age at the date of first attendance for the screening 
episode selected. 
• Interstate women are excluded from the numerator. 
Algorithm 
 [A.1 & ((last C.2 between start date & end date) &  
(last C.2—B.2≥50 & ≤69) &  
(B.3.1 or B.3.2 for Service and/or SCU catchment area))] 
ABS ERP 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population using 
appropriate estimated resident populations (ERPs) as defined by the 
Australian Bureau of Statistics. 
• The calculation of this measure will produce one result. 
Former NAS 1.1.1 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.1—The Service and/or SCU maximises the participation of women in 
the target age groups for screening and rescreening. 
NAS Measure 1.1.2 (a)  
The Service and/or SCU monitors and reports the proportion of women aged 
50–72 years who attend for their first screening episode within the Program 
who are rescreened within 27 months. 
Data Dictionary Measure 
The percentage of women aged 50–72 years who are rescreened within 27 months of their first 
screening episode. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data, 
including 27 months of follow-up data, are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
Numerator Number of individual women aged 50–72 years who attend for their first screening 
episode and then return within 27 months. 
A.1, B.9.1, C.2 
Denominator Number of individual women aged 50–72 years who attend for their first screening 
episode at the Service and/or SCU and are recommended for rescreening at 12 or 
24 months. 
A.1, A.2, B.2, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period (index year). 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Women aged 50–72 years only are included instead of women aged 50–74 
years because of policy variations between programs in relation to the age 
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that women continue to be reinvited for rescreening. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Interstate women are excluded from the numerator and the denominator. 
• This algorithm is applicable for calculation where the reference period is a 
calendar year or financial year. If using a different reference period, the 
number of months in the numerator may have to be adjusted. 
• When calculating this standard, be aware that States/Territories may have 
different policies in relation to eligibility for rescreen that may need to be taken 
into consideration when interpreting the results. 
Algorithm 
[(A.1 & B.9.1 & ((C.2 for B.9.1=2)—(C.2 for B.9.1=1)) ≤821 days)] 
[A.1 & B.9.1=1 & ((C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤72) & (C.5 or D.11.1 or E.12=1 or 2)) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of all women rescreened. 
• The calculation of this measure will produce one result. 
• If BreastScreen programs develop the capability of sharing information in the 
future, for example through eHealth, then this NAS Measure should include 
women rescreened at another Service and/or SCU within BreastScreen 
Australia in the numerator. 
• In principle the denominator should be adjusted to remove women who have 
died, been discharged from BreastScreen Australia or developed an interval 
cancer. However, this information may not be possible for some services. 
Where this information is not available, the denominator will include all women 
recommended for rescreen, which only excludes women who were diagnosed 
with a screen-detected breast cancer at their previous screen. 
Former NAS 1.2.1 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.1—The Service and/or SCU maximises the participation of women in 
the target age groups for screening and rescreening. 
NAS Measure 1.1.2 (b) 
≥75% of women aged 50–67 years who attend for their first screening episode 
within the Program are rescreened within 27 months. 
Data Dictionary Measure 
The percentage of women aged 50–67 years who are rescreened within 27 months of their first 
screening episode. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data, 
including 27 months of follow-up data, are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
Numerator Number of individual women aged 50–67 years who attend for their first screening 
episode and then return within ≤27 months. 
A.1, B.9.1, C.2 
Denominator Number of individual women aged 50–67 years who attend for their first screening 
episode at the Service and/or SCU and are recommended for rescreening at 12 or 
24 months. 
A.1, A.2, B.2, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period (index year). 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Women aged 50–67 years only are included instead of women aged 50–69 
years because of policy variations between programs in relation to the age 
that women continue to be reinvited for rescreening. 
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• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Interstate women are excluded from the numerator and the denominator. 
• This algorithm is applicable for calculation where the reference period is a 
calendar year or financial year. If using a different reference period, the 
number of months in the numerator may have to be adjusted. 
• When calculating this standard, be aware that States/Territories may have 
different policies in relation to eligibility for rescreen that may need to be taken 
into consideration when interpreting the results. 
Algorithm 
[(A.1 & B.9.1 & ((C.2 for B.9.1=2)—(C.2 for B.9.1=1)) ≤821 days)] 
[A.1 & B.9.1=1 & ((C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤67) & (C.5 or D.11.1 or E.12=1 or 2)) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of all women rescreened. 
• The calculation of this measure will produce one result. 
• If BreastScreen programs develop the capability of sharing information in the 
future, for example through eHealth, then this NAS Measure should include 
women rescreened at another Service and/or SCU within BreastScreen 
Australia in the numerator. 
• In principle the denominator should be adjusted to remove women who have 
died, been discharged from BreastScreen Australia or developed an interval 
cancer. However, this information may not be possible for some services. 
Where this information is not available, the denominator will include all women 
recommended for rescreen, which only excludes women who were diagnosed 
with a screen-detected breast cancer at their previous screen. 
Former NAS 1.2.1 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.1—The Service and/or SCU maximises the participation of women in 
the target age groups for screening and rescreening. 
NAS Measure 1.1.3 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–72 years who attend for their second and subsequent screen within the 
Program who are rescreened within 27 months of their previous screening 
episode. 
Data Dictionary Measure 
The percentage of women aged 50–72 years who attend for subsequent rescreens within 27 months 
of their previous screening episode. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which  
27 months of follow-up data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
Numerator Number of women aged 50–72 years who attend for a second or subsequent 
screening episode and return within ≤27 months. 
A.1, B.9.1, C.2 
Denominator Number of women aged 50–72 years who attend for a second or subsequent 
screening episode and are recommended for rescreening at 12 or 24 months. 
A.1, A.2, B.2, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period (index year). 
• Count is of women. 
• Women aged 50–72 years only are included instead of women aged 50–74 
years because of policy variations between programs in relation to the age 
that women continue to be reinvited for rescreening. 
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• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in the numerator 
and the denominator. 
• Age is recorded as the age at the time of screening in the index year. 
• Interstate women are excluded from the numerator and the denominator. 
• This algorithm is applicable for calculation where the reference period is a 
calendar year or financial year. If using a different reference period, the 
number of months in the numerator may have to be adjusted. 
• When calculating this standard, be aware that States/Territories have different 
policies in relation to eligibility for rescreen that may need to be taken into 
consideration when interpreting the results. 
Algorithm 
[A.1 & B.9.1 ((C.2 for B.9.1=(x+1))—(last C.2 for B.9.1=x)) ≤821 days] 
[A.1 & B.9.1=x & ((last C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤72) & (C.5 or D.11.1 or E.12=1 or 2)) at A.2] 
where x = index year round number of 2 or more 
 
x 100 
Notes • Indicator is expressed as a proportion of women rescreened. 
• The calculation of this measure will produce one result. 
• If BreastScreen programs develop the capability of sharing information in the 
future, for example through eHealth, then this NAS Measure should include 
women rescreened at another Service and/or SCU within BreastScreen 
Australia in the numerator. 
• Count each woman once. 
• In principle the denominator should be adjusted to remove women who have 
died, been discharged from BreastScreen Australia or developed an interval 
cancer. However, this information may not be possible for some services. 
Where this information is not available, the denominator will include all women 
recommended for rescreen, which only excludes women who were diagnosed 
with a screen-detected breast cancer at their previous screen. 
Former NAS 1.2.2 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.1—The Service and/or SCU maximises the participation of women in 
the target age groups for screening and rescreening. 
NAS Measure 1.1.3 (b) 
≥90% of women aged 50–67 years who attend for their second and subsequent 
screens within the Program are rescreened within 27 months of their previous 
screening episode. 
Data Dictionary Measure 
The percentage of women aged 50–67 years who attend for subsequent rescreens within 27 months 
of their previous screening episode. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which  
27 months of follow-up data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
Numerator Number of women aged 50–67 years who attend for their second or subsequent 
screening episode and then return within 27 months. 
A.1, B.9.1, C.2 
Denominator Number of women aged 50–67 years who attend for their second or subsequent 
screening episode and are recommended for rescreening at 12 or 24 months. 
A.1, A.2, B.2, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period (index year). 
• Count is of women in the reference period. 
• Women aged 50–67 years only are included instead of women aged 50–69 
years because of policy variations between programs in relation to the age 
that women continue to be reinvited for rescreening. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
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i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in the numerator 
and the denominator. 
• Age is recorded as the age at the time of screening in the index year. 
• Interstate women are excluded from the numerator and the denominator. 
• This algorithm is applicable for calculation where the reference period is a 
calendar year or financial year. If using a different reference period, the 
number of months in the numerator may have to be adjusted. 
• When calculating this standard, be aware that States/Territories have different 
policies in relation to eligibility for rescreen that may need to be taken into 
consideration when interpreting the results. 
Algorithm 
[A.1 & B.9.1 ((C.2 for B.9.1=(x+1))—(last C.2 for B.9.1=x)) ≤821 days] 
[A.1 & B.9.1=x & ((last C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤67) & (C.5 or D.11.1 or E.12=1 or 2)) at A.2] 
where x = index year round number of 2 or more. 
 
x 100 
Notes • Indicator is expressed as a proportion of women rescreened. 
• The calculation of this measure will produce one result. 
• If BreastScreen programs develop the capability of sharing information in the 
future, for example through eHealth, then this NAS Measure should include 
women rescreened at another Service and/or SCU within BreastScreen 
Australia in the numerator. 
• Count each woman once. 
• In principle the denominator should be adjusted to remove women who have 
died, been discharged from BreastScreen Australia or developed an interval 
cancer. However, this information may not be possible for some services. 
Where this information is not available, the denominator will include all women 
recommended for rescreen, which only excludes women who were diagnosed 
with a screen-detected breast cancer at their previous screen. 
Former NAS 1.2.2 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (a) (i) 
The Service and/or SCU monitors and reports participation of women aged  
50–74 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(i) Indigenous women: 
Data Dictionary Measure 
The percentage of women aged 50–74 years who are screened by BreastScreen Australia during the 
most recent 24-month period disaggregated by Indigenous status. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
B.5 Indigenous status 
C.2 Date of first attendance for this episode 
Numerator Number of individual Aboriginal and Torres Strait Islander women aged 50–74 
years residing in the Service and/or SCU catchment area screened by any Service 
and/or SCU in BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, B.5, C.2 
Denominator The ABS provides estimates of the Aboriginal and Torres Strait Islander and  
non-Indigenous population by five year age groups, sex and state/territory. 
The number of Aboriginal or Torres Strait Islander women aged 50–74 years 
resident in the catchment area using Australian Bureau of Statistics estimated 
Aboriginal and Torres Strait Islander female population(s). 
Formula Numerator / Denominator x 100 
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Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Women for whom Indigenous status is not stated or missing are excluded 
from the numerator. 
Algorithm [A.1 & ((last C.2 between start date & end date) &  
(B.5=1 or 2 or 3) & (last C.2—B.2≥50 & ≤74) &  
(B.3.1 or B.3.2 for Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
x 100 
Notes • Indicator is expressed as a proportion of Aboriginal and Torres Strait Islander 
women in the population. 
• The calculation of this measure will produce one result. 
Former NAS 1.3.5 (b) 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (b) (i) 
The Service and/or SCU monitors and reports participation of women aged  
50–69 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(i) Indigenous women: 
Data Dictionary Measure 
The percentage of women aged 50–69 years who are screened by BreastScreen Australia during the 
most recent 24-month period disaggregated by Indigenous status. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
B.5 Indigenous status 
C.2 Date of first attendance for this episode 
Numerator Number of individual Aboriginal and Torres Strait Islander women aged 50–69 
years residing in the Service and/or SCU catchment area screened by any Service 
and/or SCU in BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, B.5, C.2 
Denominator The ABS provides estimates of the Aboriginal and Torres Strait Islander and  
non-Indigenous population by five year age groups, sex and state/territory. 
The number of Aboriginal or Torres Strait Islander women aged 50–69 years 
resident in the catchment area using Australian Bureau of Statistics estimated 
Aboriginal and Torres Strait Islander female population(s). 
Formula Numerator / Denominator x 100 
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Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Women for whom Indigenous status is not stated or missing are excluded 
from the numerator. 
Algorithm 
[A.1 & (last C.2 between start date & end date) &  
(B.5=1 or 2 or 3) & (last C.2—B.2≥50 & ≤69) &  
(B.3.1 or B.3.2 for Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
x 100 
Notes • Indicator is expressed as a proportion of Aboriginal and Torres Strait Islander 
women in the population. 
• The calculation of this measure will produce one result. 
Former NAS 1.3.5 (b) 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (a) (ii) 
The Service and/or SCU monitors and reports participation of women aged  
50–74 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds 
(ii) women from culturally and linguistically diverse backgrounds: 
Data Dictionary Measure 
The percentage of women aged 50–74 years who are screened by BreastScreen Australia during the 
most recent 24-month period by women with a language other than English spoken at home. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
B.4 Main language other than English spoken at home 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–74 years with language other than English 
spoken at home residing in the Service and/or SCU catchment area screened by 
any Service and/or SCU in BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, B.4, C.2 
Denominator The ABS estimated resident population is not stratified by language spoken at 
home. In this case the denominator is calculated by applying the age-specific 
distribution of language spoken at home calculated from the most recent ABS 
Census to the relevant age specific estimated resident population counts. 
Formula Numerator / Denominator x 100 
Specifications • Count is of individual women, not screening episodes. 
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• Select on reference period. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Women for whom language spoken at home is not stated or missing are 
excluded from the numerator. 
Algorithm 
[A.1 & (last C.2 between start date & end date) & 
 (B.4 ≠ ‘English’) & (last C.2—B.2≥50 & ≤74) & 
 (B.3.1 or B.3.2 for Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population with 
language other than English spoken at home. 
• The calculation of this measure will produce one result. 
• See Appendix 2 for more information. 
Former NAS 1.3.5 (a) 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (b) (ii) 
The Service and/or SCU monitors and reports participation of women aged  
50–69 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(ii) women from culturally and linguistically diverse backgrounds: 
Data Dictionary Measure 
The percentage of women aged 50–69 years who are screened by BreastScreen Australia during the 
most recent 24-month period by women with a language other than English spoken at home. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
B.4 Main language other than English spoken at home 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–69 years with language other than English 
spoken at home residing in the Service and/or SCU catchment area screened by 
any Service and/or SCU in BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, B.4, C.2 
Denominator The ABS estimated resident population is not stratified by language spoken at 
home. In this case the denominator is calculated by applying the age-specific 
distribution of language spoken at home calculated from the most recent ABS 
Census to the relevant age specific estimated resident population counts. 
Formula Numerator / Denominator x 100 
Specifications • Count is of individual women, not screening episodes. 
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• Select on reference period. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Women for whom language spoken at home is not stated or missing are 
excluded from the numerator. 
Algorithm 
[A.1 & (last C.2 between start date & end date) & 
 (B.4 ≠ ‘English’) & (last C.2—B.2≥50 & ≤69) & 
 (B.3.1 or B.3.2 for Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population with 
language other than English spoken at home. 
• The calculation of this measure will produce one result. 
• For more information see Appendix 2. 
Former NAS 1.3.5 (a) 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (a) (iii) 
The Service and/or SCU monitors and reports participation of women aged  
50–74 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(iii) women residing across different remoteness areas: 
Data Dictionary Measure 
The percentage of women aged 50–74 years who are screened by BreastScreen Australia during 
the most recent 24-month period disaggregated according to the level of remoteness of the area in 
which a woman resides. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–74 years residing in the five remoteness 
categories in the Service and/or SCU catchment area screened by any Service 
and/or SCU in BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, C.2 
Denominator Number of women aged 50–74 years resident in the catchment area using 
Australian Bureau of Statistics estimated resident female population(s). This value 
will represent the estimated population at the midpoint of the reference period. If 
the reference period is based on calendar years, the population figure will be an 
average of the two corresponding Estimated Residential Populations (ERPs) as at 
30 June. When the reference period is based on financial years, the population 
value will be the ERP for the year wholly contained within the reference period. 
Where Service and/or SCU boundaries cross ABS population boundaries, 
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calculation of resident women to be made on a proportional basis. 
Allocate women to regions using the ABS Australian Statistical Geography 
Standard Remoteness Area classification or ASGS RA (ABS 2011, see notes 
below). 
For further information see http://www.abs.gov.au/ausstats 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Each woman is to be counted only once, regardless of whether she has more 
than one screening episode in the 24 month period. 
Algorithm 
[A.1 & (last C.2 between start date & end date) &  
(last C.2—B.2≥50 & ≤74) & (B.3.1 or B.3.2 = corresponding ASGS RA 
classification in Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population. 
• The ABS Australian Statistical Geography Standard Remoteness Area 
classification or ASGS RA (ABS 2011) is a classification that allocates one of 
five remoteness categories to areas. Areas are classified as Major cities, Inner 
regional, Outer regional, Remote or Very remote. 
• The calculation of this measure will produce five results for five different 
remoteness areas. 
• See Appendix 2 for more information. 
Former NAS 1.3.5 (c)  
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (b) (iii) 
The Service and/or SCU monitors and reports participation of women aged  
50–69 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(iii) women residing across different remoteness areas: 
Data Dictionary Measure 
The percentage of women aged 50–69 years who are screened by BreastScreen Australia during the 
most recent 24-month period disaggregated according to the level of remoteness of the area in which 
a woman resides. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–69 years residing in the five remoteness 
categories in the Service and/or SCU catchment area screened by any Service 
and/or SCU in BreastScreen Australia. 
A.1, B.2, B.3.1 or B.3.2, C.2 
Denominator Number of women aged 50–69 years resident in the catchment area using 
Australian Bureau of Statistics estimated resident female population(s). This value 
will represent the estimated population at the midpoint of the reference period. If 
the reference period is based on calendar years, the population figure will be an 
average of the two corresponding Estimated Residential Populations (ERPs) as at 
30 June. When the reference period is based on financial years, the population 
value will be the ERP for the year wholly contained within the reference period. 
Where Service and/or SCU boundaries cross ABS population boundaries, 
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calculation of resident women to be made on a proportional basis. 
Allocate women to regions using the ABS Australian Standard Geographic 
Classification Remoteness Area classification or ASGS RA (ABS 2011, see notes 
below). 
For further information see http://www.abs.gov.au/ausstats 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• If a woman has been screened more than once in a 24-month period, then 
only the last screening episode is to be counted. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
• Each woman is to be counted only once, regardless of whether she has more 
than one screening episode in the 24-month period. 
Algorithm 
[A.1 & (last C.2 between start date & end date) &  
(last C.2—B.2≥50 & ≤69) & (B.3.1 or B.3.2 = corresponding ASGS RA 
classification in Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population. 
• The ABS Australian Statistical Geography Standard Remoteness Area 
classification or ASGS RA (ABS 2011) is a classification that allocates one of 
five remoteness categories to areas. Areas are classified as Major cities, Inner 
regional, Outer regional, Remote or Very remote. 
• The calculation of this measure will produce five results for five different 
remoteness areas. 
• See Appendix 2 for more information. 
Former NAS 1.3.5 (c) 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (a) (iv) 
The Service and/or SCU monitors and reports participation of women aged  
50–74 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(iv) women residing across different socioeconomic locations: 
Data Dictionary Measure 
The percentage of women aged 50–74 years who are screened by BreastScreen Australia during the 
most recent 24-month period disaggregated according to the socioeconomic profile of the area in 
which a woman resides. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–74 years residing in the Service and/or 
SCU catchment area screened by any Service and/or SCU in BreastScreen 
Australia by Index of Relative Socio-Economic Disadvantage (IRSD). 
Use the latest ABS Census Socio-Economic Indexes for Areas (SEIFA) Index of 
IRSD to map SA2 to socioeconomic quintiles. 
Apply the mapping of SA2 to socioeconomic quintiles to the number of individual 
women screened aged 50–74 years to determine women screened for each 
quintile. 
A.1, B.2, B.3.1 or B.3.2, C.2 
Denominator Determine the number of women aged 50–74 years resident in the catchment 
area using Australian Bureau of Statistics estimated resident female population(s). 
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This value will represent the estimated population at the midpoint of the reference 
period. If the reference period is based on calendar years, the population figure 
will be an average of the two corresponding Estimated Residential Populations 
(ERPs) as at 30 June. When the reference period is based on financial years, the 
population value will be the ERP for the year wholly contained within the reference 
period. Where Service and/or SCU boundaries cross ABS population boundaries 
calculation of resident women to be made on a proportional basis. 
Allocate women to regions using Australian Statistical Geography Standard 
(ASGS) ABS 2011. Apply the mapping of SA2 to socioeconomic quintiles to the 
relevant ERP for the 50–74 years age group to determine the relevant ERP for 
each quintile.  
For further information see http://www.abs.gov.au/ausstats 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• Each woman is to be counted only once, regardless of whether she has more 
than one screening episode in the 24-month period. If a woman has been 
screened more than once in a 24-month period, then only the last screening 
episode is to be counted. 
• Age is calculated as the age at the screening episode selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
Algorithm 
[A.1 & (last C.2 between start date & end date) &  
(last C.2—B.2≥50 & ≤74) & (B.3.1 or B.3.2 = corresponding SEIFA  
index classification in Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population. 
• The IRSD is one of four SEIFAs developed by the Australian Bureau of 
Statistics (ABS 2011c). This index is based on factors such as average 
household income, education levels and unemployment rates. Rather than 
being a person-based measure, the IRSD is an area-based measure of 
socioeconomic status in which small areas of Australia are classified on a 
continuum from disadvantaged to affluent. This information is used as a proxy 
for the socioeconomic status of people living in those areas and may not be 
correct for each person in that area.  
• The calculation of this measure will produce five results (low to high 
socioeconomic status across five quintiles).  
• See Appendix 2 for more information. 
Former NAS • 1.3.5 (d) 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.1 (b) (iv) 
The Service and/or SCU monitors and reports participation of women aged  
50–69 years from special groups and where rates are below that of the overall 
population, implements specific strategies to encourage their participation in 
screening. Consideration of equitable participation rates of at least the 
following groups is made: women from Indigenous, culturally and linguistically 
diverse, rural/remote and lower socioeconomic backgrounds. 
(iv) women residing across different socioeconomic locations: 
Data Dictionary Measure 
The percentage of women aged 50–69 years who are screened by BreastScreen Australia during the 
most recent 24-month period disaggregated according to the socioeconomic profile of the area in 
which a woman resides. 
Reference 
period 
The most recent 24-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.2 Date of birth 
B.3.1 Area of usual residence (SA2) 
B.3.2 Postcode of usual residence 
C.2 Date of first attendance for this episode 
Numerator Number of individual women aged 50–69 years residing in the Service and/or 
SCU catchment area screened by any Service and/or SCU in BreastScreen 
Australia by Index of Relative Socio-Economic Disadvantage (IRSD). 
Use the latest ABS Census Socio-Economic Indexes for Areas (SEIFA) IRSD to 
map SA2 to socioeconomic quintiles. 
Apply the mapping of SA2 to socioeconomic quintiles to the number of individual 
women screened aged 50–69 years to determine women screened for each 
quintile. 
A.1, B.2, B.3.1 or B.3.2, C.2 
Denominator Determine the number of women aged 50–69 years resident in the catchment 
area using Australian Bureau of Statistics estimated resident female population(s). 
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This value will represent the estimated population at the midpoint of the reference 
period. If the reference period is based on calendar years, the population figure 
will be an average of the two corresponding Estimated Residential Populations 
(ERPs) as at 30 June. When the reference period is based on financial years, the 
population value will be the ERP for the year wholly contained within the reference 
period. Where Service and/or SCU boundaries cross ABS population boundaries 
calculation of resident women to be made on a proportional basis. 
Allocate women to regions using Australian Statistical Geography Standard 
(ASGS) (ABS 2011). Apply the mapping of SA2 to socioeconomic quintiles to the 
relevant ERP for the 50–69 years age group to determine the relevant ERP for 
each quintile. For further information see http://www.abs.gov.au/ausstats. 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes. 
• Each woman is to be counted only once, regardless of whether she has more 
than one screening episode in the 24-month period. If a woman has been 
screened more than once in a 24-month period, then only the last screening 
episode is to be counted. 
• Age is calculated as the age at the screening episode selected. 
• Both symptomatic and asymptomatic women to be counted in the numerator. 
Algorithm 
[A.1 & (last C.2 between start date & end date) &  
(last C.2—B.2≥50 & ≤69) & (B.3.1 or B.3.2 = corresponding SEIFA  
index classification in Service and/or SCU catchment area)] 
ABS population as specified in denominator above 
 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women in the population. 
• The IRSD is one of four SEIFAs developed by the Australian Bureau of 
Statistics (ABS 2011c). This index is based on factors such as average 
household income, education levels and unemployment rates. Rather than 
being a person-based measure, the IRSD is an area-based measure of 
socioeconomic status in which small areas of Australia are classified on a 
continuum from disadvantaged to affluent. This information is used as a proxy 
for the socioeconomic status of people living in those areas and may not be 
correct for each person in that area. 
• The calculation of this measure will produce five results (low to high 
socioeconomic status across five quintiles). 
• See Appendix 2. 
Former NAS 1.3.5 (d) 
  
 BreastScreen Australia data dictionary: version 1.1 261 
1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.2 (a) 
The Service and/or SCU monitors the proportion of all women in the Service 
who are screened and recalled for assessment, aged 40–49 years and 75 years 
and over. 
(a) women who are screened: 
Data Dictionary Measure 
The proportion of women screened who were aged 40–49 years and 75 years and over in the most 
recent 12-month period for which data are available. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
C.2 Date of first attendance for this episode 
Numerator (i) Number of screening episodes among women aged 40–49 years. 
(ii) Number of screening episodes among women aged 75 years and over. 
A.1, A.2, B.2, C.2 
Denominator Total number of screening episodes. 
A.1, A.2, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• The intent of this element is to monitor the impact out of target age group 
women are having on resources. Accordingly, the count is of screening 
episodes and not women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age is calculated on date of last screening episode in this period. 
• Women whose ages have not been recorded to be included in a not stated 
category and are to be included in the denominator. 
Algorithms Standard 1.2.2 (a) (i) 
[A.1 & (C.2—B.2≥40 & ≤49) at A.2] 
[A.1 & (C.2 between start date & end date) at A.2] 
 
 
x 100 
 Standard 1.2.2 (a) (ii) 
[A.1 & (C.2—B.2≥75) at A.2] 
[A.1 & (C.2 between start date & end date) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of screening episodes. 
• The calculation of this measure will produce two results. 
Former NAS 1.1.2 
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1. Access and Participation Standard 
Appropriate levels of access and participation in BreastScreen Australia are 
achieved in the target and eligible populations. 
Criterion 1.2—BreastScreen services are accessible to the target and eligible 
populations, especially women from Indigenous; culturally and linguistically 
diverse; rural/remote; and lower socioeconomic backgrounds and women with 
a disability. 
NAS Measure 1.2.2 (b) 
The Service and/or SCU monitors the proportion of all women in the Service 
who are screened and recalled for assessment, aged 40–49 years and 75 years 
and over. 
(b) women who are recalled for assessment: 
Data Dictionary Measure 
The proportion of women recalled for assessment screened who were aged 40–49 years and 75 
years and over in the most recent 12-month period for which data are available. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
Numerator (i) Number of screening episodes among women aged 40–49 years recalled 
to  an assessment centre for a mammographic recall (C.5 = 3 or 5). 
(ii) Number of screening episodes among women aged 75 years and over 
 recalled to an assessment centre for a mammographic recall  
 (C.5 = 3 or 5). 
A.1, B.2, B.9.1, C.2  
Denominator Number of screening episodes among women recalled to an assessment centre 
for a mammographic recall (C.5 = 3 or 5). 
A.1, A.2, B.9.1, C.2, C.5 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• The intent of this element is to monitor the impact out of target age group 
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women are having on resources. Accordingly, the count is of screening 
episodes and not women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected (C.2—B.2). 
• Women whose ages have not been recorded to be included in a not stated 
category and included in the denominator. 
• If calculating for multiple services at a service level, use A.2 to select service. 
Algorithms Standard 1.2.2 (b) (i) 
[A.1 & B.9.1 & (C.2—B.2≥40 & ≤49)] 
[A.1 & B.9.1 & ((C.5=3 or 5) &  
(C.2 between start date & end date)) at A.2] 
 
 
x 100 
 Standard 1.2.2 (b) (ii) 
[A.1 & B.9.1 & (C.2—B.2≥75)] 
[A.1 & B.9.1 & ((C.5=3 or 5) &  
(C.2 between start date & end date)) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of screening episodes among women 
recalled for assessment. 
• The calculation of this measure will produce two results. 
Former NAS 2.6.3 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.1 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their first screening episode who are diagnosed 
with invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend for their first screening episode who are 
diagnosed with invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years attending for their first screening episode 
who are diagnosed with invasive breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.7 
Denominator Number of women aged 50–74 years attending for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date to be included. 
Exclusions: 
• Invasive cancer detected at early review ≥6 months from the initial screening 
date. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1=1 & ((F.1.1=2) & (F.7 = (F.4=1.1 to 1.10)))] 
[A.1 & B.9.1=1 & ((C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74)) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.1.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.1 (b) 
≥50 per 10,000 women aged 50–69 years who attend for their first screening 
episode are diagnosed with invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–69 years who attend for their first screening episode who are 
diagnosed with invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–69 years attending for their first screening episode 
who are diagnosed with invasive breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.7 
Denominator Number of women aged 50–69 years attending for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
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• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date to be included. 
Exclusions: 
• Invasive cancer detected at early review ≥6 months from the initial screening 
date. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1=1 & ((F.1.1=2) & (F.7 = (F.4=1.1 to 1.10)))] 
[A.1 & B.9.1=1 & ((C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69)) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.1.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.2 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their second or subsequent screening episode who 
are diagnosed with invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend for their second or subsequent screening 
episode who are diagnosed with invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years attending for a second or subsequent 
screening episode who are diagnosed with an invasive breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.7 
Denominator Number of women aged 50–74 years attending for a second or subsequent 
screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected (C.2—B.2). 
• If a woman has two screening episodes that meet the criteria both should be 
counted. Further, if BreastScreen Australia’s policy is to invite women for 
rescreening after a diagnosis of breast cancer and a woman attends within the 
same reporting period, it will be necessary to identify if more than one breast 
cancer was diagnosed for that woman at separate screening episodes during 
that period. While a rare event, if breast cancer was detected for a woman at 
separate screening episodes during the reporting period, both cases of 
invasive breast cancer should be included in the numerator and both 
screening episodes should be counted in the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Invasive cancer detected at early review ≥6 months from the initial screening 
date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1≥2 & ((F.1.1=2) & (F.7 = (F.4=1.1 to 1.10)))] 
[A.1 & B.9.1≥2 & ((C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74)) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.1.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.2 (b) 
≥35 per 10,000 women aged 50–69 years who attend for their second or 
subsequent screening episode are diagnosed with invasive breast cancer. 
The number of women aged 50–69 years who attend for their second or subsequent screening 
episode who are diagnosed with invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2  Date of first attendance for this episode 
F.1.1 Reason for histopathology  
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–69 years attending for a second or subsequent 
screening episode who are diagnosed with invasive breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.7 
Denominator Number of women aged 50–69 years attending for a second or subsequent 
screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
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numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected (C.2—B.2). 
• If a woman has two screening episodes that meet the criteria both should be 
counted. Further, if BreastScreen Australia’s policy is to invite women for 
rescreening after a diagnosis of breast cancer and a woman attends within the 
same reporting period, it will be necessary to identify if more than one breast 
cancer was diagnosed for that woman at separate screening episodes during 
that period. While a rare event, if breast cancer was detected for a woman at 
separate screening episodes during the reporting period, both cases of breast 
cancer should be included in the numerator and both screening episodes 
should be counted in the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Invasive cancer detected at early review ≥6 months from the initial screening 
date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1≥2 & ((F.1.1=2) & (F.7 = (F.4=1.1 to 1.10)))] 
[A.1 & B.9.1≥2 & ((C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69)) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.1.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.3 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their first screening episode who are diagnosed 
with small (≤15mm) invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend for their first screening episode who are 
diagnosed with small (≤15mm) invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.5 Size of tumour 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years attending for their first screening episode 
who are diagnosed with small (≤15mm in diameter) invasive breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.5, F.7 
Denominator Number of women aged 50–74 years attending for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
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data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected (C.2—B.2). 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
• In cases of multiple lesions, size is of dominant lesion only. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review ≥6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1=1 & (F.1.1=2) & (F.7 = (F.4=1.1 to 1.10 & F.5≤15)))] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤74) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• When micro-invasion is noted, size should be stated as ≤1mm. 
• The calculation of this measure will produce one result. 
Former NAS 2.2.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.3 (b) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their second or subsequent screening episode who 
are diagnosed with small (≤15mm) invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend for their second or subsequent screening 
episode who are diagnosed with small (≤15mm) invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.5 Size of tumour 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years attending for a second or subsequent 
screening episode who are diagnosed with small (≤15mm in diameter) invasive 
breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.5, F.7 
Denominator Number of women aged 50–74 years attending for a second or subsequent 
screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
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are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected (C.2—B.2). 
• If a woman has two screening episodes that meet the criteria both should be 
counted. Further, if BreastScreen Australia’s policy is to invite women for 
rescreening after a diagnosis of breast cancer and a woman attends within the 
same reporting period, it will be necessary to identify if more than one breast 
cancer was diagnosed for that woman at separate screening episodes during 
that period. While a rare event, if breast cancer was detected for a woman at 
separate screening episodes during the reporting period, both cases of breast 
cancer should be included in the numerator and both screening episodes 
should be counted in the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
• In cases of multiple lesions, size is of dominant lesion only. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Invasive cancer detected at early review ≥6 months from the initial screening 
date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1≥2 & ((F.1.1=2) & (F.7 = (F.4=1.1 to 1.10 & F.5≤15)))] 
[A.1 & B.9.1≥2 & ((C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74)) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
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• When micro-invasion is noted, size should be stated at ≤1mm. 
• The calculation of this measure will produce one result. 
Former NAS 2.2.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.3 (c) 
≥25 per 10,000 women aged 50–69 years who attend for screening are 
diagnosed with small (≤15mm) invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–69 years who attend for screening who are diagnosed with small 
(≤15mm) invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.5 Size of tumour 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–69 years who attend for screening who are diagnosed 
with small (≤15mm in diameter) invasive breast cancer. 
A.1, B.9.1, F.1.1, F.4, F.5, F.7 
Denominator Number of women aged 50–69 years who attend for screening. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Do not disaggregate by screening round but use all screening rounds.  
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected (C.2—B.2). 
• If a woman has two screening episodes that meet the criteria both should be 
counted. Further, if BreastScreen Australia’s policy is to invite women for 
rescreening after a diagnosis of breast cancer and a woman attends within the 
same reporting period, it will be necessary to identify if more than one breast 
cancer was diagnosed for that woman at separate screening episodes during 
that period. While a rare event, if breast cancer was detected for a woman at 
separate screening episodes during the reporting period, both cases of breast 
cancer should be included in the numerator and both screening episodes 
should be counted in the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
• In cases of multiple lesions, size is of dominant lesion only. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review ≥6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1 & ((F.1.1=2) & (F.7= (F.4=1.1 to 1.10 & F.5≤15)))] 
[A.1 & B.9.1 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤69) at A.2] 
 
x 10,000 
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Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
• When micro-invasion is noted, size should be stated as ≤1mm 
Former NAS 2.2.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.4 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend annually for screening, who are diagnosed with 
invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend annually for screening who are diagnosed with 
invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of attendance for this episode 
C.8 Annual screening flag 
F.1.1 Reason for histopathology  
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years recommended and attending for annual 
rescreening who are diagnosed with invasive breast cancer. 
A.1, B.9.1, C.2, F.1.1, F.4, F.7 
Denominator Number of women aged 50–74 years recommended for annual rescreening who 
attend for screening in the reference period. 
A.1, A.2, B.2, B.9.1, C.2, C.8 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Annual screening is determined by characteristics of the woman at the time of 
screening (for example, a strong family history of breast cancer or a personal 
history of breast cancer), which necessitates that this counts women not 
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screening episodes. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. Note that all the 
data elements specified in the denominator are not restated in the numerator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• If a woman has been screened more than once in the reference period, then 
only the last screening episode is to be selected. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review >6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1 (((C.2 for B.9.1=(x+1))—(C.2 for B.9.1=x)) ≤15 months) & 
(F1.1=2 (F.7=(F.4=1.1 to 1.10)))]] 
[A.1 & B.9.1>1 ((C.2 between start date & end date) &  
(C.8=1 & (C.2—B.2≥50 & ≤74))) at A.2] 
Where x = index year round number of 1 or more 
 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women attending for annual rescreening. 
• The calculation of this measure will produce one result. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.4 (b) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend annually for screening, who are diagnosed with small 
(≤15mm) invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend annually for screening who are diagnosed with 
small (≤15mm) invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round—State/Territory program 
C.2 Date of first attendance for this episode 
C.8 Annual screening flag 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.5 Size of tumour 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years recommended and attending for annual 
rescreening who are diagnosed with small (≤15mm in diameter) invasive breast 
cancer. 
A.1, B.9.1, C.2, F.1.1, F.4, F.5, F.7 
Denominator Number of women aged 50–74 years recommended for annual rescreening who 
attend for screening in the reference period. 
A.1, A.2, B.2, B.9.1, C.2, C.8 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Annual screening is determined by characteristics of the woman at the time of 
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screening (for example, a strong family history of breast cancer or a personal 
history of breast cancer), which necessitates that this counts women not 
screening episodes. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. Note that all the 
data elements specified in the denominator are not restated in the numerator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• If a woman has been screened more than once in the reference period, then 
only the last screening episode is to be selected. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review ≥6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1& (((C.2 for B.9.1=(x+1))—(C.2 for B.9.1=x)) ≤15 months) 
& ((F1.1=2) & (F.7=(F.4=1.1 to 1.10 & F.5 ≤15)))] 
[A.1 & B.9.1 & ((C.2 between start date & end date) &  
(C.8=1) & (last C.2—B.2≥50 & ≤74)) at A.2]  
Where x = index year round number 1 or more. 
 
 
x 10,000 
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Notes • Indicator is expressed per 10,000 women attending for annual rescreening. 
• When micro-invasion is noted, size should be stated at ≤1mm. 
• The calculation of this measure will produce one result. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.1—The Service and/or SCU maximises the detection of invasive 
breast cancer in the target population. 
NAS Measure 2.1.4 (c) 
The Service and/or SCU monitors and reports the proportion of women aged 
40–49 years who attend annually for screening, who are diagnosed with 
invasive breast cancer. 
Data Dictionary Measure 
The number of women aged 40–49 years who attend annually for screening who are diagnosed with  
invasive breast cancer per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of attendance for this episode 
C.8 Annual screening flag 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 40–49 years recommended and attending for annual 
rescreening who are diagnosed with invasive breast cancer. 
A.1, B.9.1, C.2, F.1.1, F.4, F.7 
Denominator Number of women aged 40–49 years recommended for annual rescreening who 
attend for screening in the reference period. 
A.1, A.2, B.2, B.9.1, C.2, C.8 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Annual screening is determined by characteristics of the woman at the time of 
screening (for example, a strong family history of breast cancer or a personal 
history of breast cancer), which necessitates that this counts women not 
 BreastScreen Australia data dictionary: version 1.1 287 
screening episodes. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. Note that all the 
data elements specified in the denominator are not restated in the numerator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• If a woman has been screened more than once in the reference period, then 
only the last screening episode is to be selected. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review >6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
Algorithm 
[A.1 & B.9.1 (((C.2 for B.9.1=(x+1))—(C.2 for B.9.1=x)) ≤15 months) 
& (F1.1=2 (F.7=(F.4=1.1 to 1.10)))] 
[A.1 & B.9.1 ((C.2 between start date & end date) &  
(C.8=1 & (C.2—B.2≥40 & ≤49))) at A.2] 
Where x = index year round number 1 or more. 
 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women attending for annual rescreening. 
• The calculation of this measure will produce one result. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.2—The Service and/or SCU maximises the detection of ductal 
carcinoma in situ (DCIS). 
NAS Measure 2.2.1 (a) 
The Service and/or SCU monitors and reports the proportion of women aged  
50–74 years who attend for their first screening episode who are diagnosed 
with DCIS. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend for their first screening episode who are 
diagnosed with DCIS per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years attending for their first screening episode 
who are diagnosed with DCIS. 
A.1, B.9.1, F.1.1, F.4, F.7, 
Denominator Number of women aged 50–74 years attending for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A woman should only be counted once in the numerator and denominator. 
• A screen-detected DCIS is one that is histologically confirmed as DCIS before 
completion of an episode of screening at BreastScreen Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• In the case of a simultaneous diagnosis of DCIS and LCIS the case should be 
counted as DCIS. 
• In the case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive for the purpose of this indicator and 
therefore not included in the DCIS data set. 
• Women diagnosed with DCIS at early review are not included in the DCIS 
detection rates if it is detected in the period 6–12 months after the completion 
of the screening episode. 
• Although intracystic papillary carcinoma is regarded by some pathologists to 
be an unusual form of invasive cancer, most authorities advocate its treatment 
along the lines of DCIS. Therefore it is included in the count of DCIS. 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’). 
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1=1 & ((F.1.1=2) & (F.7 = (F.4=2.1 to 2.4)))] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.3.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.2—The Service and/or SCU maximises the detection of ductal 
carcinoma in situ (DCIS). 
NAS Measure 2.2.1 (b) 
≥12 per 10,000 women aged 50–69 years who attend for their first screening 
episode are diagnosed with DCIS. 
Data Dictionary Measure 
The number of women aged 50–69 years who attend for their first screening episode who are 
diagnosed with DCIS per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–69 years attending for their first screening episode 
who are diagnosed with DCIS. 
A.1, B.9.1, F.1.1, F.4, F.7, 
Denominator Number of women aged 50–69 years attending for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of individual women as a woman can only have one first screening 
episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
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• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A woman should only be counted once in the numerator and denominator. 
• A screen-detected DCIS is one that is histologically confirmed as DCIS before 
completion of an episode of screening at BreastScreen Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• In the case of a simultaneous diagnosis of DCIS and LCIS the case should be 
counted as DCIS. 
• In the case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive for the purpose of this indicator and 
therefore not included in the DCIS data set. 
• Women diagnosed with DCIS at early review are not included in the DCIS 
detection rates if it is detected in the period 6–12 months after the completion 
of the screening episode. 
• Although intracystic papillary carcinoma is regarded by some pathologists to 
be an unusual form of invasive cancer, most authorities advocate its treatment 
along the lines of DCIS. Therefore it is included in the count of DCIS. 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’). 
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1=1 & ((F.1.1=2) & (F.7 = (F.4=2.1 to 2.4)))] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.3.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.2—The Service and/or SCU maximises the detection of ductal 
carcinoma in situ (DCIS). 
NAS Measure 2.2.2 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their second or subsequent screening episode who 
are diagnosed with DCIS. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend for their second or subsequent screening 
episode who are diagnosed with DCIS per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years attending for a subsequent screening 
episode who are diagnosed with DCIS. 
A.1, B.9.1, F.1.1, F.4, F.7 
Denominator Number of women aged 50–74 years attending for a subsequent screening 
episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• If a woman has two screening episodes that meet the criteria both should be 
counted. Further, if, BreastScreen Australia’s policy is to invite women for 
rescreening after a diagnosis of breast cancer and a woman attends within the 
same reporting period, it will be necessary to identify if more than one breast 
cancer was diagnosed for that woman at separate screening episodes during 
that period. While a rare event, if breast cancer was detected for a woman at 
separate screening episodes during the reporting period, both cases of breast 
cancer should be included in the numerator and both screening episodes 
should be counted in the denominator. 
• A screen-detected DCIS is one that is histologically confirmed as DCIS before 
completion of an episode of screening at BreastScreen Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• In the case of a simultaneous diagnosis of DCIS and LCIS, the case should 
be counted as DCIS. 
• In the case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive for the purpose of this indicator and 
therefore not included in the DCIS data set. 
• Women diagnosed with DCIS at early review are not included in the DCIS 
detection rates if it is detected in the period 6–12 months after the completion 
of the screening episode. 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’). 
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1≥2 & ((F.1.1=2) & (F.7 = (F.4=2.1 to 2.4)))] 
[A.1 & B.9.1≥2 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤74) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.3.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.2—The Service and/or SCU maximises the detection of ductal 
carcinoma in situ (DCIS). 
NAS Measure 2.2.2 (b) 
≥7 per 10,000 women aged 50–69 years who attend for their second or 
subsequent screening episode are diagnosed with DCIS. 
Data Dictionary Measure 
The number of women aged 50–69 years who attend for their second or subsequent screening 
episode who are diagnosed with DCIS per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–69 years attending for a subsequent screening 
episode who are diagnosed with DCIS. 
A.1, B.9.1, F.1.1, F.4, F.7 
Denominator Number of women aged 50–69 years attending for a subsequent screening 
episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
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• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• If a woman has two screening episodes that meet the criteria both should be 
counted. Further, if, BreastScreen Australia’s policy is to invite women for 
rescreening after a diagnosis of breast cancer and a woman attends within the 
same reporting period, it will be necessary to identify if more than one breast 
cancer was diagnosed for that woman at separate screening episodes during 
that period. While a rare event, if breast cancer was detected for a woman at 
separate screening episodes during the reporting period, both cases of breast 
cancer should be included in the numerator and both screening episodes 
should be counted in the denominator. 
• A screen-detected DCIS is one that is histologically confirmed as DCIS before 
completion of an episode of screening at BreastScreen Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• In the case of a simultaneous diagnosis of DCIS and LCIS, the case should 
be counted as DCIS. 
• In the case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive for the purpose of this indicator and 
therefore not included in the DCIS data set. 
• Women diagnosed with DCIS at early review are not included in the DCIS 
detection rates if it is detected in the period 6–12 months after the completion 
of the screening episode. 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’). 
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1≥2 & ((F.1.1=2) & (F.7 = (F.4=2.1 to 2.4)))] 
[A.1 & B.9.1≥2 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤69) at A.2] 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.3.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.2—The Service and/or SCU maximises the detection of ductal 
carcinoma in situ (DCIS). 
NAS Measure 2.2.3 
The Service and/or SCU monitors and reports the number of women aged  
50–74 years who attend annually for screening, who are diagnosed with DCIS. 
Data Dictionary Measure 
The number of women aged 50–74 years who attend annually for screening who are diagnosed with 
DCIS per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round—State/Territory program 
C.2 Date of first attendance for this episode 
C.8 Annual screening flag 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identifier number 
Numerator Number of women aged 50–74 years on annual screening who are diagnosed 
with DCIS. 
A.1, B.9.1, C.2, F.1.1, F.4, F.7 
Denominator Number of women aged 50–74 years recommended for annual rescreening who 
attend for screening in the reference period. 
A.1, A.2, B.2, B.9.1, C.2, C.8 
Formula Numerator / Denominator x 10,000 
Specifications • Select on reference period. 
• Count is of women. 
• Annual screening is determined by characteristics of the woman at the time of 
screening (for example, a strong family history of breast cancer or a personal 
history of breast cancer), which necessitates that this counts women not 
screening episodes. 
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• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. Note that all the 
data elements specified in the denominator are not restated in the numerator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A screen-detected DCIS is one that is histologically confirmed as DCIS before 
completion of an episode of screening at BreastScreen Australia. 
• This standard relates to all women screened by the Service and/or SCU even 
if they are assessed elsewhere. 
• In the case of a simultaneous diagnosis of DCIS and LCIS the case should be 
counted as DCIS. 
• In the case of a simultaneous diagnosis of DCIS and invasive disease, the 
case should be counted as invasive for the purpose of this indicator and 
therefore not included in the DCIS data set. 
• Women diagnosed with DCIS at early review are not included in the DCIS 
detection rates if it is detected in the period 6–12 months after the completion 
of the screening episode. 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’).  
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1 ≥2 (((C.2 for B.9.1=(x+1))— 
(C.2 for B.9.1=x)) ≤15 months) &  
(F1.1=2 (F.7=(F.4=2.1 to 2.4)))] 
[A.1 & B.9.1 & ((C.2 between start date & end date) &  
(C.8=1 & (C.2—B.2≥50 & ≤74)) at A.2] 
Where x = index year round number of 1or more. 
 
 
 
x 10,000 
Notes • Indicator is expressed per 10,000 women attending for annual rescreening. 
• The calculation of this measure will produce one result. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.3—The Service and/or SCU minimises the number of interval 
invasive breast cancers. 
NAS Measure 2.3.1 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for screening who are diagnosed with an interval 
invasive breast cancer in the first calendar year following a negative screening 
episode. 
Data Dictionary Measure 
The number of women aged 50–74 years who are diagnosed with an interval invasive breast cancer 
between 0 and 364 days following a negative screening episode per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.5 Lesion number 
B.2 Date of birth 
B.7.1 Previous history of breast cancer 
B.9.1 Round number—State/Territory program 
B.10 Symptom status 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.1 Reason for assessment 
D.11.1 Recommendation—assessment 
D.11.2 Recommendation—number of months 
D.11.3 Date recommendation made 
E.12 Recommendation—definitive 
F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis 
F.4 Histopathology of malignant lesion 
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More information on interval cancers 
Interval cancers are invasive breast cancers that are diagnosed in the interval 
between the completion of a negative screening episode and the commencement 
of the next screening episode. For most women, the next screening episode will 
occur around 24 months after her previous negative screening episode, as the 
recommended screening interval for most women in BreastScreen Australia is 24 
months. The exception to this is women on annual screens, for whom the next 
screening episode will occur around 12 months after her previous negative 
screening episode. 
An interval cancer may be:  
• an aggressive breast cancer that emerges and grows very rapidly in the 
period between screening episodes  
• a breast cancer that, due to the characteristics of the cancer or the breast 
tissue, is not visible on screening mammography and therefore not able to be 
detected 
• a breast cancer that can be retrospectively detected on the previous screening 
mammogram.  
The first two types of interval cancer described above are true interval cancers, 
and therefore do not represent any failure in detection; the third represents a 
failure of the screening process. Through the BreastScreen accreditation process, 
state and territory BreastScreen programs are required to audit interval cancers. 
On investigation, more than 80% are found to be true interval cancers. 
Interval cancers may be detected outside BreastScreen Australia or through 
BreastScreen Australia, depending on the policies for screening symptomatic 
women that exist in each State and Territory. 
Interval cancers diagnosed outside BreastScreen Australia 
The majority of interval cancers are detected outside BreastScreen Australia. In 
this scenario, following the completion of a negative screening episode, if a 
woman develops signs or symptoms of breast cancer, she will typically visit her 
General Practitioner and from there be assessed privately in a diagnostic clinic. If 
it is found that she has developed breast cancer, details of this diagnosis will be 
provided to the cancer register in that state or territory. BreastScreen registers link 
to the cancer register in their state or territory on an annual basis, which allows 
them to discover any invasive breast cancers that were diagnosed in screened 
women outside BreastScreen Australia. If this cancer was diagnosed within 729 
days of the date of attendance of her previous negative screen (or within 364 days 
of the date of attendance of her previous negative screen for women on annual 
screens), this will be categorised as an interval cancer. 
Interval cancers diagnosed within BreastScreen Australia— early rescreen 
More rarely, if a woman develops signs or symptoms of breast cancer following 
the completion of a negative screening episode, rather attending a private 
diagnostic clinic, she may return to BreastScreen Australia early to have her 
breast symptoms assessed through the Program.  
This is called an ‘early rescreen’ if her date of attendance for this screen is <730 
days after the date of attendance of her previous screen (or <365 days after the 
date of attendance of her previous screen for women on annual screens). 
If a woman attends BreastScreen Australia <730 days after the date of attendance 
of her previous negative screen AND presents with a breast lump and/or clear or 
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blood-stained nipple discharge AND has an invasive breast cancer detected in 
that same breast, this cancer will be categorised as an interval cancer. 
Invasive breast cancers that are found in women who attend BreastScreen 
Australia <730 days after the date of attendance of her previous negative screen 
but do not adhere to the above conditions are categorised as screen-detected 
cancers, not interval cancers (that is, there needs to be a breast lump or clear or 
blood-stained nipple discharge in the breast in which the cancer was detected, not 
just a cancer detected in a woman at early rescreen). Women with no breast 
symptoms are likely to be attending an early rescreen because it is more 
convenient for her to attend at that time, or for reasons related to available 
resources (for instance that may be when a mobile clinic is available). 
Note that policies for screening symptomatic women differ across States and 
Territories; some will redirect women with symptoms down a diagnostic pathway 
outside BreastScreen Australia, whereas others will accept a woman for an early 
rescreen through BreastScreen Australia. The specifications above are to ensure 
that these cancers are captured and counted as interval cancers regardless of 
whether their detection is in a private diagnostic clinic or through BreastScreen 
Australia. 
Interval cancers diagnosed within BreastScreen Australia— early review 
Also rarely, women who attend BreastScreen Australia for early review may have 
an invasive breast cancer detected. Early review is the recall of a woman for 
further assessment within 364 days of the screening date and following an 
equivocal assessment visit (where a decision cannot be made). Early review 
within 182 days of the screening date is considered to be part of the screening 
episode and invasive breast cancers found as a result of the review are 
considered to be screen-detected. Early review carried out at 183 days or more 
from the date of screening (but less than 365 days), occurs after the screening 
episode is complete and invasive breast cancers found are considered to be 
interval cancers.  
Interval cancers, regardless of where they are detected, are separated into those 
that are diagnosed in the first calendar year (0–364 days) following a negative 
screening episode, and those that are diagnosed in the second calendar year 
(365–729 days) following a negative screening episode.  
This measure counts interval cancers that are diagnosed in the first calendar year 
following a negative screening episode. 
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Numerator Sum all cases i to iii to derive the numerator. 
i. The number of women aged 50–74 years with an invasive breast cancer 
diagnosed outside BreastScreen Australia after completion of a negative 
screening episode and before their next screen, with a date of diagnosis 
<365 days after the date of attendance of their previous screening episode 
ii. The number of women aged 50–74 years with an invasive breast cancer 
diagnosed by BreastScreen Australia at early rescreen <365 days after the 
date of attendance of their previous negative screening episode and who 
present with a breast lump and/or clear or blood-stained nipple discharge in 
the breast in which the breast cancer was diagnosed. 
iii. The number of women aged 50–74 years with an invasive breast cancer 
diagnosed by BreastScreen Australia at early review ≥183 days and <365 
days after the date of attendance of their previous screening episode. 
A.1, A.2, A.5, B.9.1, B.10, C.2, C.5, D.1, D.11.1, D.11.2, D.11.3, E.12, F.1.1, F.1.2, 
F.4 
Denominator The number of women-years at risk in the specified period for women aged  
50–74 years. 
This is all women aged 50–74 years who attended the Service and/or SCU for 
screening during the index year who have not had a previous history of breast 
cancer.  
A.1, A.2, B.2, B.7.1, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 10,000 
Specifications Numerator—interval invasive breast cancers 
• Invasive cancers diagnosed outside BreastScreen Australia in screened 
women with a previous negative screening episode and a date of diagnosis 
<365 days after the date of attendance of their previous screening episode. 
• Invasive cancer detected through BreastScreen Australia at early rescreen 
<365 days after the date of attendance of a previous negative screening 
episode where the woman presents with a breast lump and/or clear or blood 
stained nipple discharge in the breast in which the cancer was diagnosed.  
• Invasive cancers detected through BreastScreen Australia at early review 
≥183 days and <365 days after the date of attendance of their previous 
screening episode. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present.  
Exclusions: 
• Invasive breast cancer detected through BreastScreen Australia at early 
review <183 days from date of attendance of their previous screening episode. 
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Denominator—women-years at risk 
• All women screened aged 50–74 years who who attended the Service and/or 
SCU for screening during the index year who have not reported a personal 
history of invasive cancer or DCIS. 
• Women who are recommended for annual rescreening are only at risk of 
interval cancer up to and including 364 days after the date of attendance of 
their previous negative screening episode. 
• Women who are recommended for routine rescreening are only at risk of 
interval cancer up to and including 729 days after the date of attendance of 
their previous negative screening episode. 
To calculate women years at risk 
• Select on reference period 
• Use A.1 and B.9.1 to ensure correct linking of data elements. 
• Count is of individual women, not lesions. 
• Age calculated on date of attendance of last screening episode in the 
reference period. 
• Exclude women with a previous history of breast cancer. 
 
Other 
Calculate the denominator first. The numerator is a subset of the denominator, i.e. 
A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 are used 
to ensure correct linking of data elements when selecting additional data elements 
for the numerator. Note that all the data elements specified in the denominator are 
not restated in the numerator. 
Algorithm 2.3.1 (a) (i) 
[A.1 & B.9.1 & ((C.5=1 or 2) or 
 (if C.5=3 or 4 or 5 & D.11.1=1 or 2)) or  
(if D.11.1=4 or 5 & E.12=1 or 2) &  
((F.1.1=1 & (F.1.2—C.2<365 days) & (F.4=1.1 to 1.10))] 
 
 
 
 
x 10,000 
  
2.3.1 (a) (ii) 
[A.1 & B.9.1 & (((C.5=1 or 2) or ((C.5=4 or 5 & D.11.1=1 or 2) or  
(if D.11.1=4 or 5 & E.12=1 or 2) &  
(next B.9.1 and C.2<365 days)) &  
where ((B.10=1 or 2 or 3 for A.5) &  
(F.4=1.1 to 1.10 for same A.5))) at A.2  
& (F.1.2—C.2 <365 days)] 
 
 
 
 
 
 
 
 
 
x 10,000 
 2.3.1 (a) (iii) 
[A.1 & B.9.1 & (((D.1=2 & D.11.1=4 or 5) &  
(F.4=1.1 to 1.10)) or if ((D.11.1=3) &  
((F.1.2 between D.11.3 & (D.11.3 + D.11.2) where 
 (D.11.3—C.2 + D.11.2≥183 days)))at A.2] 
 
 
 
 
 
 
x 10,000 
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 [A.1 & B.9.1 & ((C.2 between start & end date) &  
(C.2—B2≥50 & ≤74) &  
(B.7.1=2) & (C.5, D.11.1 or E.12=1 or 2)) at A.2] 
 
Notes • Early rescreen is defined as a rescreen with a date of attendance <730 days 
after the date of attendance of a woman’s previous screening episode for 
women on two-yearly screens, or a rescreen with a date of attendance <365 
days after the date of attendance of a woman’s previous screening episode for 
women on annual screens. 
• Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
• There is variability across jurisdictions as to whether symptomatic women are 
screened. 
• Coding should be checked to ensure that the date for F.1.1 Reason for 
histopathology have been coded correctly to identify each situation as listed 
under the numerator and in the specifications where an interval cancer has 
been diagnosed. 
• For small services, data could be collected over consecutive 12-month periods 
to increase the number of women screened before calculating the interval 
cancer detection rate, for a more meaningful result. 
• NAS Measure 2.3.1 counts interval invasive breast cancers diagnosed in the 
first calendar year following a negative screening episode. NAS Measure 2.3.2 
counts interval invasive breast cancers diagnosed in the second calendar year 
following a negative screening episode. 
Former NAS 2.4.2 (a) 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.3—The Service and/or SCU minimises the number of interval 
invasive breast cancers. 
NAS Measure 2.3.1 (b) 
<7.5 per 10,000 women aged 50–69 years who attend for screening are 
diagnosed with an interval invasive breast cancer in the first calendar year 
following a negative screening episode. 
Data Dictionary Measure 
The number of women aged 50–69 years who are diagnosed with an interval invasive breast cancer 
between 0 and 364 days following a negative screening episode per 10,000 women screened.  
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.5 Lesion number 
B.2 Date of birth 
B.7.1 Previous history of breast cancer 
B.9.1 Round number—State/Territory program 
B.10 Symptom status 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.1 Reason for assessment 
D.11.1 Recommendation—assessment 
D.11.2 Recommendation—number of months 
D.11.3 Date recommendation made 
E.12 Recommendation—definitive 
F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis 
F.4 Histopathology of malignant lesion 
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More information on interval cancers 
Interval cancers are invasive breast cancers that are diagnosed in the interval 
between the completion of a negative screening episode and the commencement 
of the next screening episode. For most women, the next screening episode will 
occur around 24 months after her previous negative screening episode, as the 
recommended screening interval for most women in BreastScreen Australia is 24 
months. The exception to this is women on annual screens, for whom the next 
screening episode will occur around 12 months after her previous negative 
screening episode. 
An interval cancer may be:  
• an aggressive breast cancer that emerges and grows very rapidly in the 
period between screening episodes  
• a breast cancer that, due to the characteristics of the cancer or the breast 
tissue, is not visible on screening mammography and therefore not able to be 
detected 
• a breast cancer that can be retrospectively detected on the previous screening 
mammogram.  
The first two types of interval cancer described above are true interval cancers, 
and therefore do not represent any failure in detection; the third represents a 
failure of the screening process. Through the BreastScreen accreditation process, 
state and territory BreastScreen programs are required to audit interval cancers. 
On investigation, more than 80% are found to be true interval cancers. 
Interval cancers may be detected outside BreastScreen Australia or through 
BreastScreen Australia, depending on the policies for screening symptomatic 
women that exist in each State and Territory. 
Interval cancers diagnosed outside BreastScreen Australia 
The majority of interval cancers are detected outside BreastScreen Australia. In 
this scenario, following the completion of a negative screening episode, if a 
woman develops signs or symptoms of breast cancer, she will typically visit her 
General Practitioner and from there be assessed privately in a diagnostic clinic. If 
it is found that she has developed breast cancer, details of this diagnosis will be 
provided to the cancer register in that state or territory. BreastScreen registers link 
to the cancer register in their state or territory on an annual basis, which allows 
them to discover any invasive breast cancers that were diagnosed in screened 
women outside BreastScreen Australia. If this cancer was diagnosed within 729 
days of the date of attendance of her previous negative screen (or within 364 days 
of the date of attendance of her previous negative screen for women on annual 
screens), this will be categorised as an interval cancer. 
Interval cancers diagnosed within BreastScreen Australia— early rescreen 
More rarely, if a woman develops signs or symptoms of breast cancer following 
the completion of a negative screening episode, rather attending a private 
diagnostic clinic, she may return to BreastScreen Australia early to have her 
breast symptoms assessed through the Program.  
This is called an ‘early rescreen’ if her date of attendance for this screen is <730 
days after the date of attendance of her previous screen (or <365 days after the 
date of attendance of her previous screen for women on annual screens). 
If a woman attends BreastScreen Australia <730 days after the date of attendance 
of her previous negative screen AND presents with a breast lump and/or clear or 
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blood-stained nipple discharge AND has an invasive breast cancer detected in 
that same breast, this cancer will be categorised as an interval cancer. 
Invasive breast cancers that are found in women who attend BreastScreen 
Australia <730 days after the date of attendance of her previous negative screen 
but do not adhere to the above conditions are categorised as screen-detected 
cancers, not interval cancers (that is, there needs to be a breast lump or clear or 
blood-stained nipple discharge in the breast in which the cancer was detected, not 
just a cancer detected in a woman at early rescreen). Women with no breast 
symptoms are likely to be attending an early rescreen because it is more 
convenient for her to attend at that time, or for reasons related to available 
resources (for instance that may be when a mobile clinic is available). 
Note that policies for screening symptomatic women differ across States and 
Territories; some will redirect women with symptoms down a diagnostic pathway 
outside BreastScreen Australia, whereas others will accept a woman for an early 
rescreen through BreastScreen Australia. The specifications above are to ensure 
that these cancers are captured and counted as interval cancers regardless of 
whether their detection is in a private diagnostic clinic or through BreastScreen 
Australia. 
Interval cancers diagnosed within BreastScreen Australia— early review 
Also rarely, women who attend BreastScreen Australia for early review may have 
an invasive breast cancer detected. Early review is the recall of a woman for 
further assessment within 364 days of the screening date and following an 
equivocal assessment visit (where a decision cannot be made). Early review 
within 182 days of the screening date is considered to be part of the screening 
episode and invasive breast cancers found as a result of the review are 
considered to be screen-detected. Early review carried out at 183 days or more 
from the date of screening (but less than 365 days), occurs after the screening 
episode is complete and invasive breast cancers found are considered to be 
interval cancers.  
Interval cancers, regardless of where they are detected, are separated into those 
that are diagnosed in the first calendar year (0–364 days) following a negative 
screening episode, and those that are diagnosed in the second calendar year 
(365–729 days) following a negative screening episode.  
This measure counts interval cancers that are diagnosed in the first calendar year 
following a negative screening episode. 
Numerator Sum all cases i to iii to derive the numerator. 
i. The number of women aged 50–69 years with an invasive breast cancer 
diagnosed outside BreastScreen Australia after completion of a negative 
screening episode and before their next screen, with a date of diagnosis 
<365 days after the date of attendance of their previous screening episode. 
ii. The number of women aged 50–69 years with an invasive breast cancer 
diagnosed by BreastScreen Australia at early rescreen <365 days after the 
date of attendance of their previous negative screening episode and who 
present with a breast lump and/or clear or blood-stained nipple discharge in 
the breast in which the breast cancer was diagnosed. 
iii. The number of women aged 50–69 years with an invasive breast cancer 
diagnosed by BreastScreen Australia at early review ≥183 days and <365 
days after the date of attendance of their previous screening episode. 
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A.1, A.2, A.5, B.9.1, B.10, C.2, C.5, D.1, D.11.1, D.11.2, D.11.3, E.12, F.1.1, F.1.2, 
F.4 
Denominator The number of women-years at risk in the specified period for women aged  
50–69 years. 
This is all women aged 50–69 years who attended the Service and/or SCU for 
screening during the index year who have not had a previous history of breast 
cancer.  
A.1, A.2, B.2, B.7.1, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 10,000 
Specifications Numerator—interval invasive breast cancers 
• Invasive cancers diagnosed outside BreastScreen Australia in screened 
women with a previous negative screening episode and a date of diagnosis 
<365 days after the date of attendance of their previous screening episode. 
• Invasive cancer detected through BreastScreen Australia at early rescreen 
<365 days after the date of attendance of a previous negative screening 
episode where the woman presents with a breast lump and/or clear or blood 
stained nipple discharge in the breast in which the cancer was diagnosed.  
• Invasive cancers detected through BreastScreen Australia at early review 
≥183 days and <365 days after the date of attendance of their previous 
screening episode. 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present.  
Exclusions: 
• Invasive breast cancer detected through BreastScreen Australia at early 
review <183 days from date of attendance of their previous screening episode. 
Denominator—women-years at risk 
• All women screened aged 50–69 years who who attended the Service and/or 
SCU for screening during the index year who have not reported a personal 
history of invasive cancer or DCIS. 
• Women who are recommended for annual rescreening are only at risk of 
interval cancer up to and including 364 days after the date of attendance of 
their previous negative screening episode. 
• Women who are recommended for routine rescreening are only at risk of 
interval cancer up to and including 729 days after the date of attendance of 
their previous negative screening episode. 
To calculate women years at risk 
• Select on reference period 
• Use A.1 and B.9.1 to ensure correct linking of data elements. 
• Count is of individual women, not lesions. 
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• Age calculated on date of attendance of last screening episode in the 
reference period. 
• Exclude women with a previous history of breast cancer. 
 
Other 
Calculate the denominator first. The numerator is a subset of the denominator, i.e. 
A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 are used 
to ensure correct linking of data elements when selecting additional data elements 
for the numerator. Note that all the data elements specified in the denominator are 
not restated in the numerator. 
Algorithm 2.3.1 (b) (i) 
[A.1 & B.9.1 & ((C.5=1 or 2) or 
 (if C.5=3 or 4 or 5 & D.11.1=1 or 2)) or  
(if D.11.1=4 or 5 & E.12=1 or 2) &  
((F.1.1=1 & (F.1.2—C.2<365 days) & (F.4=1.1 to 1.10))] 
 
 
 
 
x 10,000 
  
2.3.1 (b) (ii) 
[A.1 & B.9.1 & (((C.5=1 or 2) or ((C.5=4 or 5 & D.11.1=1 or 2) or  
(if D.11.1=4 or 5 & E.12=1 or 2) &  
(next B.9.1 and C.2<365 days)) &  
where ((B.10=1 or 2 or 3 for A.5) &  
(F.4=1.1 to 1.10 for same A.5))) at A.2  
& (F.1.2—C.2 <365 days)] 
 
 
 
 
 
 
 
 
 
x 10,000 
 2.3.1 (b) (iii) 
[A.1 & B.9.1 & (((D.1=2 & D.11.1=4 or 5) &  
(F.4=1.1 to 1.10)) or if ((D.11.1=3) &  
((F.1.2 between D.11.3 & (D.11.3 + D.11.2) where 
 (D.11.3—C.2 + D.11.2≥183 days)))at A.2] 
 
 
 
 
 
 
x 10,000 
   
 [A.1 & B.9.1 & ((C.2 between start & end date) &  
(C.2—B2≥50 & ≤69) &  
(B.7.1=2) & (C.5, D.11.1 or E.12=1 or 2)) at A.2] 
 
Notes • Early rescreen is defined as a rescreen with a date of attendance <730 days 
after the date of attendance of a woman’s previous screening episode for 
women on two-yearly screens, or a rescreen with a date of attendance <364 
days after the date of attendance of a woman’s previous screening episode for 
women on annual screens. 
• Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
• There is variability across jurisdictions as to whether symptomatic women are 
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screened. 
• Coding should be checked to ensure that the date for F.1.1 Reason for 
histopathology have been coded correctly to identify each situation as listed 
under the numerator and in the specifications where an interval cancer has 
been diagnosed. 
• For small services, data could be collected over consecutive 12-month periods 
to increase the number of women screened before calculating the interval 
cancer detection rate, for a more meaningful result. 
• NAS Measure 2.3.1 counts interval invasive breast cancers diagnosed in the 
first calendar year following a negative screening episode. NAS Measure 2.3.2 
counts interval invasive breast cancers diagnosed in the second calendar year 
following a negative screening episode. 
Former NAS 2.4.2 (a) 
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2. Cancer Detection Standard  
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.3—The Service and/or SCU minimises the number of interval 
invasive breast cancers. 
NAS Measure 2.3.2 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for screening who are diagnosed with an interval 
invasive breast cancer in the second calendar year following a negative 
screening episode. 
Data Dictionary Measure 
The number of women aged 50–74 years who are diagnosed with an interval invasive breast cancer 
between 365 and 729 days following a negative screening episode per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.5 Lesion number 
B.2 Date of birth 
B.7.1 Previous history of breast cancer 
B.9.1 Round number—State/Territory program 
B.10 Symptom status 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis 
F.4 Histopathology of malignant lesion 
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More information on interval cancers 
Interval cancers are invasive breast cancers that are diagnosed in the interval 
between the completion of a negative screening episode and the commencement 
of the next screening episode. For most women, the next screening episode will 
occur around 24 months after her previous negative screening episode, as the 
recommended screening interval for most women in BreastScreen Australia is 24 
months. The exception to this is women on annual screens, for whom the next 
screening episode will occur around 12 months after her previous negative 
screening episode. 
An interval cancer may be:  
• an aggressive breast cancer that emerges and grows very rapidly in the 
period between screening episodes  
• a breast cancer that, due to the characteristics of the cancer or the breast 
tissue, is not visible on screening mammography and therefore not able to be 
detected 
• a breast cancer that can be retrospectively detected on the previous screening 
mammogram.  
The first two types of interval cancer described above are true interval cancers, 
and therefore do not represent any failure in detection; the third represents a 
failure of the screening process. Through the BreastScreen accreditation process, 
state and territory BreastScreen programs are required to audit interval cancers. 
On investigation, more than 80% are found to be true interval cancers. 
Interval cancers may be detected outside BreastScreen Australia or through 
BreastScreen Australia, depending on the policies for screening symptomatic 
women that exist in each State and Territory. 
Interval cancers diagnosed outside BreastScreen Australia 
The majority of interval cancers are detected outside BreastScreen Australia. In 
this scenario, following the completion of a negative screening episode, if a 
woman develops signs or symptoms of breast cancer, she will typically visit her 
General Practitioner and from there be assessed privately in a diagnostic clinic. If 
it is found that she has developed breast cancer, details of this diagnosis will be 
provided to the cancer register in that state or territory. BreastScreen registers link 
to the cancer register in their state or territory on an annual basis, which allows 
them to discover any invasive breast cancers that were diagnosed in screened 
women outside BreastScreen Australia. If this cancer was diagnosed within 729 
days of the date of attendance of her previous negative screen (or within 364 days 
of the date of attendance of her previous negative screen for women on annual 
screens), this will be categorised as an interval cancer. 
Interval cancers diagnosed within BreastScreen Australia— early rescreen 
More rarely, if a woman develops signs or symptoms of breast cancer following 
the completion of a negative screening episode, rather attending a private 
diagnostic clinic, she may return to BreastScreen Australia early to have her 
breast symptoms assessed through the Program.  
This is called an ‘early rescreen’ if her date of attendance for this screen is <730 
days after the date of attendance of her previous screen (or <365 days after the 
date of attendance of her previous screen for women on annual screens). 
If a woman attends BreastScreen Australia <730 days after the date of attendance 
of her previous negative screen AND presents with a breast lump and/or clear or 
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blood-stained nipple discharge AND has an invasive breast cancer detected in 
that same breast, this cancer will be categorised as an interval cancer. 
Invasive breast cancers that are found in women who attend BreastScreen 
Australia <730 days after the date of attendance of her previous negative screen 
but do not adhere to the above conditions are categorised as screen-detected 
cancers, not interval cancers (that is, there needs to be a breast lump or clear or 
blood-stained nipple discharge in the breast in which the cancer was detected, not 
just a cancer detected in a woman at early rescreen). Women with no breast 
symptoms are likely to be attending an early rescreen because it is more 
convenient for her to attend at that time, or for reasons related to available 
resources (for instance that may be when a mobile clinic is available). 
Note that policies for screening symptomatic women differ across States and 
Territories; some will redirect women with symptoms down a diagnostic pathway 
outside BreastScreen Australia, whereas others will accept a woman for an early 
rescreen through BreastScreen Australia. The specifications above are to ensure 
that these cancers are captured and counted as interval cancers regardless of 
whether their detection is in a private diagnostic clinic or through BreastScreen 
Australia. 
Interval cancers diagnosed within BreastScreen Australia— early review 
Also rarely, women who attend BreastScreen Australia for early review may have 
an invasive breast cancer detected. Early review is the recall of a woman for 
further assessment within 364 days of the screening date and following an 
equivocal assessment visit (where a decision cannot be made). Early review 
within 182 days of the screening date is considered to be part of the screening 
episode and invasive breast cancers found as a result of the review are 
considered to be screen-detected. Early review carried out at 183 days or more 
from the date of screening (but less than 365 days), occurs after the screening 
episode is complete and invasive breast cancers found are considered to be 
interval cancers.  
Interval cancers, regardless of where they are detected, are separated into those 
that are diagnosed in the first calendar year (0–364 days) following a negative 
screening episode, and those that are diagnosed in the second calendar year 
(365–729 days) following a negative screening episode.  
This measure counts interval cancers that are diagnosed in the first calendar year 
following a negative screening episode. 
Numerator Sum cases i and ii to derive the numerator. 
i. The number of women aged 50–74 years with an invasive breast cancer 
diagnosed outside BreastScreen Australia after completion of a negative 
screening episode and before their next screen, with a date of diagnosis 
≥365 days and <730 days after the date of attendance of their previous 
screening episode. 
ii. The number of women aged 50–74 years with an invasive breast cancer 
diagnosed by BreastScreen Australia at early rescreen ≥365 days and <730 
days after the date of attendance of their previous negative screening 
episode and who present with a breast lump and/or clear or blood-stained 
nipple discharge in the breast in which the breast cancer was diagnosed. 
A.1, A.2, A.5, B.9.1, B.10, C.2, C.5, D.11.1, E.12, F.1.1, F.1.2, F.4 
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Denominator The number of women-years at risk in the specified period for women aged  
50–74 years. 
This is all women aged 50–74 years who attended the Service and/or SCU for 
screening during the index year who have not had a previous history of breast 
cancer.  
A.1, A.2, B.2, B.7.1, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 10,000 
Specifications Numerator—interval invasive breast cancers 
• Invasive cancers diagnosed outside BreastScreen Australia in screened 
women with a previous negative screening episode and a date of diagnosis 
≥365 days and <730 days after the date of attendance of their previous 
screening episode. 
• Invasive cancer detected through BreastScreen Australia at early rescreen 
≥365 days and <730 days after the date of attendance of a previous negative 
screening episode where the woman presents with a breast lump and/or clear 
or blood stained nipple discharge in the breast in which the cancer was 
diagnosed.  
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present.  
Denominator—women-years at risk 
• All women screened aged 50–74 years who who attended the Service and/or 
SCU for screening during the index year who have not reported a personal 
history of invasive cancer or DCIS. 
• Women who are recommended for annual rescreening are only at risk of 
interval cancer up to and including 364 days after the date of attendance of 
their previous negative screening episode. 
• Women who are recommended for routine rescreening are only at risk of 
interval cancer up to and including 729 days after the date of attendance of 
their previous negative screening episode. 
To calculate women years at risk 
• Select on reference period 
• Use A.1 and B.9.1 to ensure correct linking of data elements. 
• Count is of individual women, not lesions. 
• Age calculated on date of attendance of last screening episode in the 
reference period. 
• Exclude women with a previous history of breast cancer. 
 
Other 
Calculate the denominator first. The numerator is a subset of the denominator, i.e. 
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A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 are used 
to ensure correct linking of data elements when selecting additional data elements 
for the numerator. Note that all the data elements specified in the denominator are 
not restated in the numerator. 
Algorithm 2.3.2 (a) (i) 
[A.1 & B.9.1 & ((C.5=1 or 2) or  
(if C.5=3 or 4 or 5 & D.11.1=1 or 2)) or  
( D.11.1=4 or 5 & E.12=1 or 2)) &  
((F.1.1=1 & (F.1.2—C.2≥365 days & <730 days) &  
(F.4=1.1 to 1.10))] 
 
 
 
 
 
 
 
x 10,000 
 2.3.2 (a) (ii) 
[A.1 & B.9.1 & (((C.5=1) or (C.5=4 or 5 & D.11.1=1) or  
(D.11.1=4 or 5 & E.12=1)) & 
 (next B.9.1 and C.2≥365 days & <730 days) &  
where ((B.10=1 or 2 or 3 for A.5) & 
 (F.4=1.1 to 1.10 for same A.5) &  
(F.1.2—C.2≥365 days & <730 days ))) at A.2] 
 
 
 
 
 
 
x 10,000 
 [A.1 & B.9.1 & ((C.2 between start & end date) & 
 (C.2—B2≥50 & ≤74) &  
 (B.7.1=2) & ((C.5=1) or (if C.5=3 or 4 or 5 then D.11.1=1) or  
(if D.11.1=4 or 5 then E.12=1))) at A.2] 
 
 
Notes • Early rescreen is defined as a rescreen with a date of attendance <730 days 
after the date of attendance of a woman’s previous screening episode for 
women on two-yearly screens, or a rescreen with a date of attendance <364 
days after the date of attendance of a woman’s previous screening episode for 
women on annual screens. 
• Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
• There is variability across jurisdictions as to whether symptomatic women are 
screened. 
• Coding should be checked to ensure that the date for F.1.1 Reason for 
histopathology have been coded correctly to identify each situation as listed 
under the numerator and in the specifications where an interval cancer has 
been diagnosed. 
• For small services, data could be collected over consecutive 12-month periods 
to increase the number of women screened before calculating the interval 
cancer detection rate, for a more meaningful result. 
• NAS Measure 2.3.1 counts interval invasive breast cancers diagnosed in the 
first calendar year following a negative screening episode. NAS Measure 2.3.2 
counts interval invasive breast cancers diagnosed in the second calendar year 
following a negative screening episode. 
Former NAS 2.4.2 (b) 
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2. Cancer Detection Standard  
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.3—The Service and/or SCU minimises the number of interval 
invasive breast cancers. 
NAS Measure 2.3.2 (b) 
≤15 per 10,000 women aged 50–69 years who attend for screening are 
diagnosed with an interval invasive breast cancer in the second calendar year 
following a negative screening episode. 
Data Dictionary Measure 
The number of women aged 50–69 years who are diagnosed with an interval invasive breast cancer 
between 365 and 729 days following a negative screening episode per 10,000 women screened. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.5 Lesion number 
B.2 Date of birth 
B.7.1 Previous history of breast cancer 
B.9.1 Round number—State/Territory program 
B.10 Symptom status 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.11.1 Recommendation—assessment 
E.12 Recommendation—definitive 
F.1.1 Reason for histopathology 
F.1.2 Date of diagnosis 
F.4 Histopathology of malignant lesion 
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More information on interval cancers 
Interval cancers are invasive breast cancers that are diagnosed in the interval 
between the completion of a negative screening episode and the commencement 
of the next screening episode. For most women, the next screening episode will 
occur around 24 months after her previous negative screening episode, as the 
recommended screening interval for most women in BreastScreen Australia is 24 
months. The exception to this is women on annual screens, for whom the next 
screening episode will occur around 12 months after her previous negative 
screening episode. 
An interval cancer may be:  
• an aggressive breast cancer that emerges and grows very rapidly in the 
period between screening episodes  
• a breast cancer that, due to the characteristics of the cancer or the breast 
tissue, is not visible on screening mammography and therefore not able to be 
detected 
• a breast cancer that can be retrospectively detected on the previous screening 
mammogram.  
The first two types of interval cancer described above are true interval cancers, 
and therefore do not represent any failure in detection; the third represents a 
failure of the screening process. Through the BreastScreen accreditation process, 
state and territory BreastScreen programs are required to audit interval cancers. 
On investigation, more than 80% are found to be true interval cancers. 
Interval cancers may be detected outside BreastScreen Australia or through 
BreastScreen Australia, depending on the policies for screening symptomatic 
women that exist in each State and Territory. 
Interval cancers diagnosed outside BreastScreen Australia 
The majority of interval cancers are detected outside BreastScreen Australia. In 
this scenario, following the completion of a negative screening episode, if a 
woman develops signs or symptoms of breast cancer, she will typically visit her 
General Practitioner and from there be assessed privately in a diagnostic clinic. If 
it is found that she has developed breast cancer, details of this diagnosis will be 
provided to the cancer register in that state or territory. BreastScreen registers link 
to the cancer register in their state or territory on an annual basis, which allows 
them to discover any invasive breast cancers that were diagnosed in screened 
women outside BreastScreen Australia. If this cancer was diagnosed within 729 
days of the date of attendance of her previous negative screen (or within 364 days 
of the date of attendance of her previous negative screen for women on annual 
screens), this will be categorised as an interval cancer. 
Interval cancers diagnosed within BreastScreen Australia— early rescreen 
More rarely, if a woman develops signs or symptoms of breast cancer following 
the completion of a negative screening episode, rather attending a private 
diagnostic clinic, she may return to BreastScreen Australia early to have her 
breast symptoms assessed through the Program.  
This is called an ‘early rescreen’ if her date of attendance for this screen is <730 
days after the date of attendance of her previous screen (or <365 days after the 
date of attendance of her previous screen for women on annual screens). 
If a woman attends BreastScreen Australia <730 days after the date of attendance 
of her previous negative screen AND presents with a breast lump and/or clear or 
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blood-stained nipple discharge AND has an invasive breast cancer detected in 
that same breast, this cancer will be categorised as an interval cancer. 
Invasive breast cancers that are found in women who attend BreastScreen 
Australia <730 days after the date of attendance of her previous negative screen 
but do not adhere to the above conditions are categorised as screen-detected 
cancers, not interval cancers (that is, there needs to be a breast lump or clear or 
blood-stained nipple discharge in the breast in which the cancer was detected, not 
just a cancer detected in a woman at early rescreen). Women with no breast 
symptoms are likely to be attending an early rescreen because it is more 
convenient for her to attend at that time, or for reasons related to available 
resources (for instance that may be when a mobile clinic is available). 
Note that policies for screening symptomatic women differ across States and 
Territories; some will redirect women with symptoms down a diagnostic pathway 
outside BreastScreen Australia, whereas others will accept a woman for an early 
rescreen through BreastScreen Australia. The specifications above are to ensure 
that these cancers are captured and counted as interval cancers regardless of 
whether their detection is in a private diagnostic clinic or through BreastScreen 
Australia. 
Interval cancers diagnosed within BreastScreen Australia— early review 
Also rarely, women who attend BreastScreen Australia for early review may have 
an invasive breast cancer detected. Early review is the recall of a woman for 
further assessment within 364 days of the screening date and following an 
equivocal assessment visit (where a decision cannot be made). Early review 
within 182 days of the screening date is considered to be part of the screening 
episode and invasive breast cancers found as a result of the review are 
considered to be screen-detected. Early review carried out at 183 days or more 
from the date of screening (but less than 365 days), occurs after the screening 
episode is complete and invasive breast cancers found are considered to be 
interval cancers.  
Interval cancers, regardless of where they are detected, are separated into those 
that are diagnosed in the first calendar year (0–364 days) following a negative 
screening episode, and those that are diagnosed in the second calendar year 
(365–729 days) following a negative screening episode.  
This measure counts interval cancers that are diagnosed in the first calendar year 
following a negative screening episode. 
Numerator Sum cases i and ii to derive the numerator. 
iii. The number of women aged 50–69 years with an invasive breast cancer 
diagnosed outside BreastScreen Australia after completion of a negative 
screening episode and before their next screen, with a date of diagnosis 
≥365 days and <730 days after the date of attendance of their previous 
screening episode. 
iv. The number of women aged 50–69 years with an invasive breast cancer 
diagnosed by BreastScreen Australia at early rescreen ≥365 days and <730 
days after the date of attendance of their previous negative screening 
episode and who present with a breast lump and/or clear or blood-stained 
nipple discharge in the breast in which the breast cancer was diagnosed. 
A.1, A.2, A.5, B.9.1, B.10, C.2, C.5, D.11.1, E.12, F.1.1, F.1.2, F.4 
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Denominator The number of women-years at risk in the specified period for women aged  
50–74 years. 
This is all women aged 50–69 years who attended the Service and/or SCU for 
screening during the index year who have not had a previous history of breast 
cancer.  
A.1, A.2, B.2, B.7.1, B.9.1, C.2, C.5, D.11.1, E.12 
Formula Numerator / Denominator x 10,000 
Specifications Numerator—interval invasive breast cancers 
• Invasive cancers diagnosed outside BreastScreen Australia in screened 
women with a previous negative screening episode and a date of diagnosis 
≥365 days and <730 days after the date of attendance of their previous 
screening episode. 
• Invasive cancer detected through BreastScreen Australia at early rescreen 
≥365 days and <730 days after the date of attendance of a previous negative 
screening episode where the woman presents with a breast lump and/or clear 
or blood stained nipple discharge in the breast in which the cancer was 
diagnosed.  
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• If there is micro-invasion in the presence of DCIS, the lesion with micro-
invasion is the dominant lesion over DCIS. 
• Paget’s disease is only included if an invasive component is present.  
Denominator—women-years at risk 
• All women screened aged 50–69 years who who attended the Service and/or 
SCU for screening during the index year who have not reported a personal 
history of invasive cancer or DCIS. 
• Women who are recommended for annual rescreening are only at risk of 
interval cancer up to and including 364 days after the date of attendance of 
their previous negative screening episode. 
• Women who are recommended for routine rescreening are only at risk of 
interval cancer up to and including 729 days after the date of attendance of 
their previous negative screening episode. 
To calculate women years at risk 
• Select on reference period 
• Use A.1 and B.9.1 to ensure correct linking of data elements. 
• Count is of individual women, not lesions. 
• Age calculated on date of attendance of last screening episode in the 
reference period. 
• Exclude women with a previous history of breast cancer. 
 
Other 
Calculate the denominator first. The numerator is a subset of the denominator, i.e. 
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A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 are used 
to ensure correct linking of data elements when selecting additional data elements 
for the numerator. Note that all the data elements specified in the denominator are 
not restated in the numerator. 
Algorithm 2.3.2 (b) (i) 
[A.1 & B.9.1 & ((C.5=1 or 2) or  
(if C.5=3 or 4 or 5 & D.11.1=1 or 2)) or  
( D.11.1=4 or 5 & E.12=1 or 2)) &  
((F.1.1=1 & (F.1.2—C.2≥365 days & <730 days) &  
(F.4=1.1 to 1.10))] 
 
 
 
 
 
 
 
x 10,000 
 2.3.2 (b) (ii) 
[A.1 & B.9.1 & (((C.5=1) or (C.5=4 or 5 & D.11.1=1) or  
(D.11.1=4 or 5 & E.12=1)) & 
 (next B.9.1 and C.2≥365 days & <730 days) &  
where ((B.10=1 or 2 or 3 for A.5) & 
 (F.4=1.1 to 1.10 for same A.5) &  
(F.1.2—C.2≥365 days & <730 days ))) at A.2] 
 
 
 
 
 
 
x 10,000 
 [A.1 & B.9.1 & ((C.2 between start & end date) & 
 (C.2—B2≥50 & ≤69) &  
 (B.7.1=2) & ((C.5=1) or (if C.5=3 or 4 or 5 then D.11.1=1) or  
(if D.11.1=4 or 5 then E.12=1))) at A.2] 
 
 
Notes • Early rescreen is defined as a rescreen with a date of attendance <730 days 
after the date of attendance of a woman’s previous screening episode for 
women on two-yearly screens, or a rescreen with a date of attendance <364 
days after the date of attendance of a woman’s previous screening episode for 
women on annual screens. 
• Indicator is expressed per 10,000 women screened. 
• The calculation of this measure will produce one result. 
• There is variability across jurisdictions as to whether symptomatic women are 
screened. 
• Coding should be checked to ensure that the date for F.1.1 Reason for 
histopathology have been coded correctly to identify each situation as listed 
under the numerator and in the specifications where an interval cancer has 
been diagnosed. 
• For small services, data could be collected over consecutive 12-month periods 
to increase the number of women screened before calculating the interval 
cancer detection rate, for a more meaningful result. 
• NAS Measure 2.3.1 counts interval invasive breast cancers diagnosed in the 
first calendar year following a negative screening episode. NAS Measure 2.3.2 
counts interval invasive breast cancers diagnosed in the second calendar year 
following a negative screening episode. 
Former NAS 2.4.2 (b) 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.4—The Service and/or SCU ensures high quality screen reading. 
NAS Measure 2.4.1 
All screen readers read at least 2,000 mammographic screening cases within 
the Program per year. 
Data Dictionary Measure 
The number of mammographic screening cases read by readers per year. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.6 Service provider identifier 
Numerator The number of cases read by each reader. 
A.1, A.6 
Denominator Not applicable 
Formula Number of cases read by each reader. 
Specifications • Select on reference period. 
• Count is of number of cases read. 
• Cases of both symptomatic and asymptomatic women to be counted. 
• To identify all images read, select from all relevant services, as a reader may 
read for more than one service. 
Algorithm For each A.6 (ΣA.1) 
Notes • Indicator is expressed as the number of cases read per reader. 
• The result of this calculation should be presented as two components: 
 number of images read by each reader –
 the number of readers who meet the measure. –
Former NAS 2.12.3 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.5—The Service and/or SCU ensures high quality imaging. 
NAS Measure 2.5.1 
The Service and/or SCU monitors and reports the percentage of women who 
have up to 4 images per screen, including technical repeats. 
Data Dictionary Measure 
The percentage of women in any 12-month period who have up to 4 images per screen, including 
technical repeats. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.3.1 Total number of images used 
Numerator The number of screening episodes among women where the woman have up to 4 
images per screen. 
A.1, C.3.1 
Denominator Number of screening episodes among women. 
A.1, ,B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count all screening episodes for each woman in the reference period. 
• Technical repeats to be included with total number of images. 
• The calculation gives the per cent of women who had up to 4 images per 
screen. 
• Where this element is unmet, the Service and/or SCU will provide additional 
information on the dosage used. 
Algorithm 
For each A.1 (C.3.1>0 and <4) 
[A.1 & B.9.1 & (C.2 between start date & end date)] 
 
x 100 
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Notes • Indicator is expressed as a proportion of screening episode. 
• The calculation of this measure will produce one result. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.5—The Service and/or SCU ensures high quality imaging. 
NAS Measure 2.5.2  
The overall repeat rate for the Service and/or SCU is ≤2% of all screening 
images. 
Data Dictionary Measure 
The percentage of the total number of screening images used in any 12-month period which are for 
repeat images. However, the Service and/or SCU will demonstrate that this is also calculated on a 
monthly basis. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.2 Screening unit identifier 
C.2 Date of first attendance for this episode 
C.3.1 Total number of images used 
C.3.3 Number of technical repeats 
Numerator The total number of images repeated due to technically unsatisfactory images at 
the screening visit. 
A.2, C.2, C.3.3 
Denominator The total number of images taken to screen a woman at her screening visit(s). 
A.2, C.2, C.3.1 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of images, not screening visits or women. 
• Only images taken or repeated at screening to be counted (not assessment 
images). 
• Repeat images taken at the initial visit and at any technical repeat visit are to 
be counted. 
• Technical repeats include those initiated by the radiographer and those 
requested by the reader(s). 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
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Algorithm 
[((C.2 between start date & end date) & (Σ C.3.3)) at A.2] 
[((C.2 between start date & end date) & (Σ C.3.1)) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of images. 
• The calculation of this measure will produce one result. 
Former NAS 2.10.3 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.1 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for annual screening. 
Data Dictionary Measure 
The percentage of women aged 50–74 years who attend for annual screening. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.8 Annual screening flag 
Numerator Number of women aged 50–74 years recommended for annual rescreening who 
attend for screening in the reference period. 
A.1, B.9.1, C.8 
Denominator Number of women aged 50–74 years who attend for screening. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is women. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
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• Where a woman has two screening episodes in the reference period, select 
the last screen. 
Algorithm 
[A.1 & B.9.1 & (C.8=1)] 
[A.1 & B.9.1 & ((last C.2 between start date & end date) & 
 (last C.2—B.2≥50 & ≤74)) at A.2] 
 
x 100 
Notes • This indicator is expressed per 100 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 1.5.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.1 (b) 
≤10% of women aged 50–69 years attend for annual screening. 
Data Dictionary Measure 
The percentage of women aged 50–69 years who attend for annual screening. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.8 Annual screening flag 
Numerator Number of women aged 50–69 years recommended for annual rescreening who 
attend for screening in the reference period. 
A.1, B.9.1, C.8 
Denominator Number of women aged 50–69 years who attend for screening. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Where a woman has two screening episodes in the reference period, select 
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the last screen. 
Algorithm 
[A.1 & B.9.1 & (C.8=1)] 
[A.1 & B.9.1 & ((last C.2 between start date & end date) & 
 (last C.2—B.2≥50 & ≤69)) at A.2] 
 
x 100 
Notes • This indicator is expressed per 100 women screened. 
• The calculation of this measure will produce one result. 
Former NAS 1.5.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.2 
The Service and/or SCU monitors and reports the proportion of women who 
attend for annual screening, aged 40–49 years and 75 years and over. 
Data Dictionary Measure 
The percentage of women who attend for annual screening, aged 40–49 years and 75 years and 
over. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.8 Annual screening flag 
Numerator i. Number of women aged 40–49 years recommended for annual 
rescreening who attend for screening. 
ii. Number of women aged 75 years recommended for annual rescreening 
who attend for screening. 
A.1, B.9.1, C.8 
Denominator i. Number of women aged 40–49 years who attend for screening. 
ii. Number of women aged 75 years and over who attend for screening. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Reference period based on date of first attendance for screening. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
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i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in the numerator 
and the denominator. 
• Where a woman has two screening episodes in the reference period, select 
the last screen. 
Algorithm 2.6.2 (i) 
[A.1& B.9.1 & C.8=1] 
[A.1 & B.9.1 & ((last C.2 between start date & end date) & 
 (last C.2—B.2≥40 & ≤49)) at A.2] 
 
 
x 100 
 2.6.2 (ii) 
[A.1& B.9.1 & C.8=1] 
[A.1 & B.9.1 & ((last C.2 between start date & end date) & 
 (last C.2—B.2≥75)) at A.2] 
 
 
x 100 
Notes • Indicator is expressed per 100 women screened. 
• The calculation of this measure will produce two results. 
Former NAS 1.5.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.3 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their first screening episode and are recalled for 
assessment. 
Data Dictionary Measure 
The percentage of women aged 50-74 who attend for their first screening episode and are recalled 
for assessment. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
Numerator Number of women aged 50–74 years who attend for their first screening episode 
and who are recalled for assessment because of (separately): 
i. mammographic recall only (C.5=3 and 5), and 
ii. recall for other reasons (non-mammographic) (C.5=4) and/or 
iii. combined recall (C.5=3 and 4 and 5) 
A.1, B.9.1, C.5 
Denominator Number of women aged 50–74 years who attend for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on the date of the first attendance for screening. 
• Count is of women as a woman can only have one first screening episode. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
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• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
Algorithm 2.6.3 (a) (i) 
[A.1 & B.9.1=1 & (C.5=3 or 5)] 
[A.1 & B.9.1=1 &(C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
 
x 100 
 2.6.3 (a) (ii) 
[A.1 & B.9.1=1 & (C.5=4)] 
[A.1 & B.9.1=1 &(C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
 
x 100 
 2.6.3 (a) (iii) 
[A.1 & B.9.1=1 & (C.5=3 or 4 or 5)] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women screened. 
• The calculation of this measure will produce three results for recall to 
assessment (mammographic recall, recall for other reasons and combined 
recall). 
Former NAS 2.6.1 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.3 (b) 
<10% of women aged 50–69 years who attend for their first screening episode 
are recalled for assessment. 
Data Dictionary Measure 
The percentage of women aged 50-69 who attend for their first screening episode are recalled for 
assessment. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
Numerator Number of women aged 50–69 years who attend for their first screening episode 
and who are recalled for assessment because of (separately): 
i. mammographic recall only (C.5=3 and 5), and 
ii. recall for other reasons (non-mammographic) (C.5=4) and/or 
iii. combined recall (C.5=3 and 4 and 5) 
A.1, B.9.1, C.5 
Denominator Number of women aged 50–69 years who attend for their first screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on the date of the first attendance for screening. 
• Count is of women as a woman can only have one first screening episode. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
 334 BreastScreen Australia data dictionary: version 1.1 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
Algorithm 2.6.3 (b) (i) 
[A.1 & B.9.1=1 & (C.5=3 or 5)] 
[A.1 & B.9.1=1 &(C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69) at A.2] 
 
 
x 100 
 2.6.3 (b) (ii) 
[A.1 & B.9.1=1 & (C.5=4)] 
[A.1 & B.9.1=1 &(C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69) at A.2] 
 
 
x 100 
 2.6.3 (b) (iii) 
[A.1 & B.9.1=1 & (C.5=3 or 4 or 5)] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women screened. 
• The calculation of this measure will produce three results for recall to 
assessment (mammographic recall, recall for other reasons and combined 
recall). 
Former NAS 2.6.1 
  
 BreastScreen Australia data dictionary: version 1.1 335 
2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.4 (a) 
The Service and/or SCU monitors and reports the proportion of women aged 
50–74 years who attend for their second or subsequent screening episode and 
are recalled for assessment. 
Data Dictionary Measure 
The percentage of women aged 50–74 years who attend for their second or subsequent screening 
episode and are recalled for assessment. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
Numerator Number of women aged 50–74 years who attend for their second or subsequent 
screening episodes who are recalled for assessment because of (separately): 
i. mammographic recall only (C.5=3 and 5), and 
ii. recall for other reasons (non-mammographic) (C.5=4) and/or 
iii. combined recall (C.5=3 and 4 and 5) 
A.1, B.9.1, C.5 
Denominator Number of women aged 50–74 years who attend for their second or subsequent 
screening episodes. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on the date of first attendance for screening. 
• Count is of women who are recalled for assessment. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
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i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• While a rare event, if a woman was recalled at separate screening episodes 
during the reporting period, both recalls should be counted in the numerator 
and both screening episodes should be counted in the denominator. 
Algorithm 2.6.4 (a) (i) 
[A.1 & B.9.1>1 & (C.5=3 or 5)] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
 
x 100 
 2.6.4 (a) (ii) 
[A.1 & B.9.1>1 & (C.5=4)] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
 
x 100 
 2.6.4 (a) (iii) 
[A.1 & B.9.1>1 & (C.5=3 or 4 or 5)] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤74) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women who are recalled for 
assessment. 
• The calculation of this measure will produce three results for recall to 
assessment (mammographic recall, recall for other reasons and combined 
recall). 
Former NAS 2.6.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.4 (b) 
<5% of women aged 50–69 years who attend for their second or subsequent 
screening episode are recalled for assessment. 
Data Dictionary Measure 
The percentage of women aged 50–69 who attend for their second or subsequent screening episode 
and are recalled for assessment. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
Numerator Number of women aged 50–69 years who attend for their second or subsequent 
screening episode who are recalled for assessment because of (separately): 
i. mammographic recall only (C.5=3 and 5), and 
ii. recall for other reasons (non-mammographic) (C.5=4) and/or 
iii. combined recall (C.5=3 and 4 and 5). 
A.1, B.9.1, C.5 
Denominator Number of women aged 50–69 years who attend for their second or subsequent 
screening episode. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on the date of first attendance for screening. 
• Count is of women who are recalled for assessment. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
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are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• While a rare event, if a woman was recalled at separate screening episodes 
during the reporting period, both recalls should be counted in the numerator 
and both screening episodes should be counted in the denominator. 
Algorithm 2.6.4 (b) (i) 
[A.1 & B.9.1>1 & (C.5=3 or 5)] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69) at A.2] 
 
 
x 100 
 2.6.4 (b) (ii) 
[A.1 & B.9.1>1 & (C.5=4)] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) & 
 (C.2—B.2≥50 & ≤69) at A.2] 
 
 
x 100 
 2.6.4 (b) (iii) 
[A.1 & B.9.1>1 & (C.5=3 or 4 or 5)] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤69) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women who are recalled for 
assessment. 
• The calculation of this measure will produce three results for recall to 
assessment (mammographic recall, recall for other reasons and combined 
recall). 
Former NAS 2.6.2 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.5 
The Service and/or SCU monitors and reports the positive predictive value of a 
recall to assessment for detecting invasive breast cancer or DCIS in women 
aged 50–74 years who attend for their first screening episode. 
Data Dictionary Measure 
The percentage of women aged 50–74 years recalled for assessment at their first screening episode 
who receive a definitive diagnosis of invasive breast cancer or DCIS. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesions 
Numerator Number of women aged 50–74 years who attend for their first screening episode 
who are recalled for assessment and are diagnosed with invasive breast cancer or 
DCIS. 
A.1, B.9.1, F.1.1, F.4 
Denominator Number of women aged 50–74 years who attend for their first screening episode 
who are recalled for assessment. 
A.1, A.2, B.2, B.9.1, C.2, C.5 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women as a woman can only have one first screening episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
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data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Invasive breast cancer specifications 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review >6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
DCIS specifications 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’). 
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1=1 & ((F.1.1=2) & (F.4=1.1 to 1.10 or 2.1 to 2.4))] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤74) & (C.5=3) at A.2] 
 
x 100 
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Notes • Indicator is expressed as a proportion of women recalled to assessment. 
• The calculation of this measure will produce one result for the positive 
predictive value of a screen for detecting invasive breast cancer or DCIS. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.6 
The Service and/or SCU monitors and reports the positive predictive value of a 
recall to assessment for detecting invasive breast cancer or DCIS in women 
aged 50–74 years who attend for their second or subsequent screening 
episode. 
Data Dictionary Measure 
The percentage of women aged 50–74 years recalled for assessment at their second or subsequent 
screening episode who receive a definitive diagnosis of invasive breast cancer or DCIS. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesions 
Numerator Number of women aged 50–74 years who attend for a subsequent screening 
episode who are recalled to assessment and who are diagnosed with invasive 
breast cancer or DCIS. 
A.1, B.9.1, F.1.1, F.4 
Denominator Number of women aged 50–74 years who attend for a second or subsequent 
screening episode and are recalled to assessment. 
A.1, A.2, B.2, B.9.1, C.2, C.5 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
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are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Age calculated as at the date of first attendance for the screening episode 
selected. 
• While a rare event, if breast cancer were detected for a woman at separate 
screening episodes during the reporting period, both cases of breast cancer 
should be included in the numerator. 
• If a woman was recommended for assessment at two separate screening 
episodes within the time period then these should both be included in the 
denominator. 
• A screen-detected breast cancer is one that is histologically confirmed as a 
breast cancer before completion of an episode of screening at BreastScreen 
Australia. 
• Includes all women screened by the Service and/or SCU even if they are 
assessed elsewhere. 
• If the woman did not undergo surgery, it may be possible to identify whether 
the breast cancer is invasive from the core biopsy histopathology. 
Cancer detection specifications 
Inclusions: 
• Tumours should be recorded and sized as invasive cancers if they include any 
invasive component. 
• Micro-invasive tumours to be included. 
• Paget’s disease is only included if an invasive component is present. 
• Invasive breast cancer detected at early review <6 months from the initial 
screening date. 
Exclusions: 
• Cancer detected at early review >6 months from the initial screening date. 
• Invasive cancer diagnosed at early rescreen where the woman presents with 
a breast lump and/or clear or blood stained nipple discharge in the breast in 
which the cancer was diagnosed. 
• Women who present at assessment with interval signs and symptoms. 
DCIS specifications 
Inclusions: 
• Include DCIS tumours only (no invasive component). 
• Equivocal invasive tumours are to be included as DCIS. 
• Intracystic or noninvasive papillary carcinoma is to be included (categorised 
as ‘Other DCIS’). 
• Paget’s disease in the absence of DCIS should be included as DCIS 
(categorised as ‘Other DCIS’) unless there is an invasive component  
(Paget’s disease in the presence of DCIS should be categorised as DCIS). 
Exclusions: 
• DCIS with microinvasion (classified as an invasive breast malignancy). 
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• Lobular carcinoma in situ (LCIS) including pleomorphic LCIS. 
Algorithm 
[A.1 & B.9.1>1 & ((F.1.1=2) & (F.4=1.1 to 1.10 or 2.1 to 2.4))] 
[A.1 & B.9.1>1 & (C.2 between start date & end date) &  
(C.2—B.2≥50 & ≤74) & (C.5=3) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of women recalled to assessment. 
• The calculation of this measure will produce one result for the positive 
predictive value of a screen for detecting invasive breast cancer or DCIS. 
Former NAS New 
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2. Cancer Detection Standard 
Breast cancer detection is maximised in the target population and harm is 
minimised. 
Criterion 2.6—Investigations and recall for assessment of non-malignant 
lesions is minimised. 
NAS Measure 2.6.7 
<0.2% of women who attend for screening are recommended for early review 
for further assessment. 
Data Dictionary Measure 
The percentage of women who attend for screening who are recommended for early review for 
further assessment. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
D.11.1 Recommendation—assessment 
D.11.2 Recommendation—number of months 
D.11.3 Date recommendation made 
D.11.4 Assessment visit—date 
E.12 Recommendation—definitive 
Numerator Number of women who attend for screening who are recommended for early 
review. 
A.1, A.3, B.9.1, C.2, D.11.1, D.11.2, D.11.3, D.11.4, E.12 
Denominator Number of women who attend for screening. 
A.1, A.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Reference period is based on the date of the first attendance for screening. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
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data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3—Assessment unit identifier in this instance includes all women screened 
and assessed by the Service and/or SCU. Women screened elsewhere and 
assessed by the Service and/or SCU are excluded. Assessments performed 
outside the Service and/or SCU are to be excluded. 
• If a woman has more than one screening and assessment episode during the 
period, both episodes are included. 
• Women who are recommended for early review after an excision should be 
included in the numerator. 
Algorithm 
[A.1 & B.9.1 & (D.11.1=3 where (D.11.2 + D11.3—C.2≤365 days))  
&/or (E.12=3 & D.11.4—C.2≤365 days) at A.3] 
[A.1 & B.9.1 & (C.2 between start date & end date) at A.2] 
 
 
x 100 
Notes • Indicator is expressed per 100 women screened. 
• Early review is the recall of a woman for further assessment within 12 months 
of the screening date and following an equivocal assessment visit (where a 
decision cannot be made). Early review within six months of the screening 
date is considered to be part of the screening episode and invasive breast 
cancers found as a result of the review are considered to be screen-detected. 
Early review carried out at six months or more from the date of screening, 
occurs after the screening episode is complete and invasive breast cancers 
found are considered to be interval cancers. 
• The calculation of this measure will provide one result. 
• All women on early review are to be included in the calculation. 
Former NAS 2.22.1 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe, and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.1  
<5% of all percutaneous needle biopsies of malignant breast lesions are 
classified as benign or inadequate/insufficient. 
Data Dictionary Measure 
The number of percutaneous needle biopsies with a benign or inadequate result and malignant result 
on final histology as a percentage of all lesions sampled through percutaneous needle biopsy and 
returning a malignant result on final histology plus all cases called malignant on percutaneous needle 
biopsy and never confirmed by final histology but were clinically presumed to be malignant. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.8.3 Percutaneous needle biopsy result 
D.10 Final result of assessment visit 
D.11.4 Assessment visit—date 
E.1 Local excision performed 
F.4 Histopathology of malignant lesions 
G.4 Surgical treatment 
Numerator Number of percutaneous needle biopsies with a benign or inadequate 
percutaneous needle biopsy result and malignant result on final histology. 
A.1, B.9.1, D.8.3, F.4 
Denominator Number of percutaneous needle biopsies returning a malignant result on final 
histology plus all cases called malignant on percutaneous needle biopsy and 
never confirmed by final histology but were clinically presumed to be malignant. 
A.1, A.3, B.9.1, D.8.3, D.10, D.11.4, E.1, F.4, G.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of fine needle aspiration and core biopsy procedures performed. 
• Where multiple fine needle aspiration or core biopsy procedures that yielded 
an inadequate result were performed include all procedures. 
• The reference period is based on the first date of attendance for assessment. 
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• Note that all the data elements specified in the denominator are not restated 
in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• All lesions where core biopsy is performed need to be followed through to final 
result. 
• Measuring the false negative rate of non-breast lesions such as lymph nodes 
is complex. Therefore, biopsies of lymph nodes should not be included in this 
NAS Measure as the monitoring of these is best completed as part of a 
separate study. 
• In some cases, the histology result from the core biopsy will be the final result. 
• A.3 includes all women assessed by the Service and/or SCU even if screened 
elsewhere. Procedures performed outside the Service and/or SCU are to be 
excluded. 
• E.1 is used to indicate whether histological confirmation is available. 
• For lesions called malignant on biopsy and never confirmed on final histology 
but clinically presumed to be malignant, and where there are no core or local 
excision results, the final diagnosis is made on the malignant cytology. 
• Interval cancers are not included. 
Algorithm 
[A.1 & B.9.1 & (D.8.3=1 or 2) & (F.4=1.1 to 1.10 or 2.1 to 2.4)] 
[A.1 & B.9.1 & (D.11.4 & (D.8.3=not null) &  
(E.1=1 & F.4=1.1 to 1.10 or 2.1 to 2.4) +  
(D.8.3=5 & D.10) where E.1=2 & (G.4=not null)) at A.3] 
 
x 100 
Notes • Indicator is expressed as a proportion of procedures. 
• The calculation of this measure will produce one result. 
• Previously, NAS relating to FNA cytology and core biopsy were separated and 
given different targets according to the modality used. This measure combines 
previous NAS 2.18.1, 2.18.2 and 2.19.5. The intent of this measure is to adopt 
an outcomes based approach, requiring minimum performance targets and 
leaving it to each Service and/or SCU to determine which approach would be 
implemented in their setting to achieve the desired goals. 
• This may include non-representative core biopsies implying the lesion has 
been missed during the procedure, which is not a judgement on the accuracy 
of interpretation, but on the technical aspects of core biopsy performance. 
• Inadequate percutaneous needle biopsies are defined as samples of 
insufficient yield for adequate diagnosis of the lesion. In cases of core 
biopsies for micro calcifications this includes samples without calcium. 
• Fine needle aspiration biopsies tend to have higher inadequate outcomes—
this will influence the result returned for this measure for Services performing 
a high proportion of FNA procedures. 
Former NAS New 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.2  
0% of benign lesions assessed by percutaneous needle biopsy have a false 
positive cancer diagnosis, when the definitive needle biopsy result is achieved 
after performance of the final needle biopsy at an assessment episode(s). A 
false positive FNA which is followed by a true negative core biopsy, prior to 
recommendation for surgery or treatment, is not considered to be a false 
positive ‘percutaneous needle biopsy’ for the purpose of this standard. 
 
Where NAS Measure 3.1.2 is not met, a root cause analysis on 100% of false 
positive cancer diagnoses is conducted by the Service and/or SCU 
Data Dictionary Measure 
The number of lesions assessed by percutaneous needle biopsy with a malignant result on biopsy 
and a non-malignant result on final histology as a percentage of all lesions biopsied returning a non-
malignant result on final histology. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.8.3 Percutaneous needle biopsy result 
D.11.4 Assessment visit—date 
E.1 Local excision performed 
F.3 Histopathology of non-malignant lesions 
F.4 Histopathology of malignant lesions 
Numerator Number of percutaneous needle biopsies with a malignant percutaneous needle 
biopsy result and non-malignant result on final histology. 
A.1, B.9.1, D.8.3, F.3, F.4 
Denominator Number of all biopsies with a non-malignant result on final histology. 
A.1, A.3, B.9.1, D.8.3, D.11.4, E.1, F.3, F.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of fine needle aspiration and core biopsy procedures performed. 
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• Where multiple fine needle aspiration or core biopsy procedures are 
performed, count each procedure. 
• The reference period is based on the first date of attendance for assessment. 
• In the numerator the percutaneous needle biopsy returns a malignant result 
but was shown to be benign on final histology. 
• A false positive FNA which is followed by a true negative core biopsy, prior to 
recommendation for surgery or treatment, is not considered to be a false 
positive ‘percutaneous needle biopsy’ for the purpose of this measure. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• All lesions where percutaneous needle biopsy is performed need to be 
followed through to final result. 
• In some cases, the histology result from the core biopsy will be the final result. 
• A.3 includes all women assessed by the Service and/or SCU even if screened 
elsewhere. Procedures performed outside the Service and/or SCU are to be 
excluded. 
• E.1 is used to indicate whether histological confirmation is available. 
Algorithm 
[A.1 & B.9.1 & ((D.8.3=5) & (F.3=not null & F.4=null))]  
[A.1 & B.9.1 & (D.11.4 & (D.8.3=not null) &  
(E.1=1 & F.3=not null & F.4 = null)) at A.3] 
 
x 100 
Notes • If a lesion at assessment had multiple discordant biopsies (i.e. one malignant, 
one benign), then it should only be considered a false positive for the 
calculation of this measure if the malignant assessment biopsy was 
considered definitive. i.e. if there were a malignant FNA (false positive test) 
followed by a benign core (true negative test) then the false positive would not 
be counted in this measure, as no harm reached the client. 
• Indicator is expressed as a proportion of procedures. 
• The calculation of this measure will produce one result. 
• Previously, NAS relating to FNA cytology and core biopsy were separated and 
given different targets according to the modality used. This measure is based 
on the previous NAS 2.19.6 (b), which was only calculated for FNA cytology. 
The intent of this measure is to adopt an outcomes based approach, requiring 
minimum performance targets and leaving it to each Service and/or SCU to 
determine which approach would be implemented in their setting to achieve 
the desired goals. 
• On occasions, the entire lesion is removed at core biopsy, leaving only non-
malignant tissue in the surgical specimen. If the case is reviewed and 
malignancy is confirmed in the core biopsy, this should not be classified as a 
false positive. 
• The threshold for false positive cancer diagnoses has been set at zero to 
ensure client safety, transparency and accountability and the need for such 
events to be reported and investigated whenever they occur. More information 
is provided in the NAS commentary. 
Former NAS New 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.3 
The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. 
Data Dictionary Measure 
The number of percutaneous needle biopsies with a malignant biopsy result and returning a 
malignant result on final histology plus all cases called malignant on biopsy and never confirmed by 
final histology but were clinically presumed to be malignant, as a percentage of all percutaneous 
needle biopsies returning a final malignant histology result plus all procedures where the lesion was 
called malignant on biopsy and never confirmed by final histology but were clinically presumed to be 
malignant. 
Reference 
period 
The most recent 12-month period (either calendar or financial years) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.8.3 Percutaneous needle biopsy result 
D.10 Final result of assessment visit 
D.11.4 Assessment visit—date 
E.1 Local excision performed 
F.4 Histopathology of malignant lesions 
G.4 Surgical treatment 
Numerator Number of percutaneous needle biopsies with a malignant result and confirmed as 
malignant on final histology plus all cases called malignant on percutaneous 
needle biopsy and never confirmed by final histology but were clinically presumed 
to be malignant. 
A.1, B.9.1, D.8.3, D.10, E.1, F.4, G.4 
Denominator Number of percutaneous needle biopsies returning a malignant result on final 
histology plus all cases called malignant on percutaneous needle biopsy and 
never confirmed by final histology but were clinically presumed to be malignant. 
A.1, A.3, B.9.1, D.8.3, D.10, D.11.4, E.1, F.4, G.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
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• Count is of fine needle aspiration and core biopsy procedures performed. 
• The reference period is based on first attendance date for assessment. 
• Where a woman has multiple fine needle aspiration cytology and core biopsy 
procedures each procedure is to be counted. 
• Note that all the data elements specified in the denominator are not restated 
in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• All lesions where percutaneous needle biopsy is performed need to be 
followed through to final result. 
• In some cases, the histology result from the core biopsy will be the final result. 
• A.3 includes all women assessed by the Service and/or SCU even if screened 
elsewhere. Procedures performed outside the Service and/or SCU are to be 
excluded. 
• E.1 is used to indicate whether histological confirmation is available. 
• For lesions called malignant on biopsy and never confirmed on final histology 
but are clinically presumed to be malignant, and where there are no core or 
local excision results, the final diagnosis is made on the malignant cytology. 
Algorithm 
[A.1 & B.9.1 & ((D.8.3=5) & (E.1=1 & F.4=1.1 to 1.10 or 2.1 to 2.4)) +  
((D.8.3=5 & D.10=5) where (E.1=2 & G.4=not null))]  
[A.1 & B.9.1 where (D.11.4 & D.8.3=not null &  
(E.1=1 & F.4 =1.1 to 1.10 or 2.1 to 2.4)) +  
((D.8.3=5 & D.10=5) where (E.1=2 & (G.4=not null))) at A.3] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of percutaneous needle biopsy 
procedures. 
• The calculation of this measure will produce one result. 
• Previously, NAS relating to FNA cytology and core biopsy were separated and 
given different targets according to the modality used This element combines 
previous NAS 2.19.8 and 2.19.10. The intent of this measure is to adopt an 
outcomes based approach, requiring minimum performance targets and 
leaving it to each service to determine which approach would be implemented 
in their setting to achieve the desired goals. 
• On occasions, the entire lesion is removed at core biopsy, leaving only non-
malignant tissue in the surgical specimen. If the case is reviewed and 
malignancy is confirmed in the core biopsy, this should not be classified as a 
false positive. 
Former NAS New 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.4 
≤0.35% of women who attend for their first screening episode are found not to 
have invasive breast cancer or DCIS after diagnostic open biopsy. 
Data Dictionary Measure 
The percentage of the total number of women who attend for their first screening episode who are 
found not to have invasive breast cancer or DCIS after diagnostic open biopsy. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for screening 
D.11.1 Recommendation—assessment 
E.1 Local excision performed 
F.3 Histopathology of non-malignant lesions 
F.4 Histopathology of malignant lesions 
F.7 Dominant lesion identifier number 
Numerator Number of women assessed following their first screening episode who were 
found not to have invasive cancer or DCIS after diagnostic open biopsy which was 
recommended by the Service and/or SCU. 
A.1, A.3, B.9.1, D.11.1, E.1, F.3, F.4, F.7 
Denominator Number of women who attended for their first screening episode. 
A.1, A.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of individual women, not screening episodes as a woman can only 
have one first screening episode. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• As this is a measure of the effectiveness of assessment, the numerator is a 
subset of the denominator (i.e. women screened during the reporting period) 
but includes only those women assessed by the Service and/or SCU. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Where a core biopsy removes a cancer and the subsequent excision is 
negative this is not a true false positive. 
• A.3 includes all women screened and assessed by the Service and/or SCU. 
Women screened elsewhere and assessed by the Service and/or SCU are 
excluded. Assessments performed outside the Service and/or SCU are to be 
excluded. 
• Women who are found to have a malignant lesion that is not invasive breast 
cancer or DCIS are not included in the numerator. 
Algorithm 
[A.1 & B.9.1=1 & ((D.11.1=5 at A.3) &  
(E.1=1 & F.7 where (F.3=not null and F.4=null))] 
[A.1 & B.9.1=1 & (C.2 between start date & end date) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.8.1 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.5 
≤0.16% of women who attend for their second or subsequent screening 
episode are found not to have invasive breast cancer or DCIS after diagnostic 
open biopsy. 
Data Dictionary Measure 
The percentage of the total number of women who attend for their second or subsequent screening 
episode who are found not to have invasive cancer or DCIS after diagnostic open biopsy. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for screening 
D.11.1 Recommendation—assessment 
E.1 Local excision performed 
F.3 Histopathology of non-malignant lesion 
F.4 Histopathology of malignant lesions 
F.7 Dominant lesion identifier number 
Numerator Number of women who attended for their second or subsequent screening 
episode were found not to have invasive cancer or DCIS after excision which was 
recommended by the Service and/or SCU. 
A.1, A3, B.9.1, D.11.1, E.1, F.3, F.4, F.7 
Denominator Number of women attending for a second or subsequent screening episode. 
A.1, A.2, B.9.1, C.2. 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
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the denominator are not restated in the numerator. 
• As this is a measure of the effectiveness of assessment, the numerator is a 
subset of the denominator (i.e. women screened during the reporting period) 
but includes only those women assessed by the Service and/or SCU. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Where a core biopsy removes a cancer and the subsequent excision is 
negative this is not a true false positive. 
• A.3 includes all women screened and assessed by the Service and/or SCU. 
Women screened elsewhere and assessed by the Service and/or SCU are 
excluded. Assessments performed outside the Service and/or SCU are to be 
excluded. 
• Women who are found to have a malignant lesion that is not invasive breast 
cancer or DCIS are not included in the numerator. 
• While a rare event, if a woman had an unnecessary diagnostic open biopsy in 
separate screening episodes during the reporting period, both cases should 
be included in the numerator and both screening episodes should be included 
in the denominator. 
Algorithm 
[A.1 & B.9.1≥2 & ((D.11.1=5 at A.3) &  
(E.1=1 & F.7 where (F.3=not null and F.4=null))] 
[A.1 & B.9.1≥2 & (C.2 between start date & end date) at A.2] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women screened. 
• The calculation of this measure will produce one result. 
Former NAS 2.8.2 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.6 
All women with impalpable lesions undergoing excision have specimen 
imaging recorded. 
Data Dictionary Measure 
The percentage of women with impalpable lesions at assessment undergoing excision who had 
specimen imaging recorded. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
A.5 Lesion number 
B.9.1 Round number—State/Territory program 
D.11.4 Assessment visit—date 
E.1 Local excision performed 
E.5 Palpability of lesion 
E.7 Specimen x-ray 
Numerator Number of women undergoing excision with specimen imaging recorded. 
A.1, A.5, B.9.1, E.7 
Denominator Number of women with impalpable lesions at assessment who undergo excision. 
A.1, A.3, A.5, B.9.1, D.11.4, E.1, E.5 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on assessment date. 
• Count is of women. 
• Includes diagnostic open biopsy and treatment excisions. If a woman has a 
mastectomy, then specimen imaging may not be performed. 
• Imaging may include x-ray or ultrasound. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
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• The reference period is established by selecting D.2.2—Date of first 
attendance for assessment (between start date and end date). 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3 includes women assessed by the Service and/or SCU even if screened 
elsewhere. 
• This measure relates to women assessed by the Service and/or SCU as the 
Service and/or SCU may be able to influence the performance of this 
procedure. 
• If E.5 Palpability of lesion at assessment is not available, impalpable lesions 
can be identified through E.4.1—Marking method if the lesion has been 
localised. However, in some instances, palpable lesions are also localised, 
and impalpable lesions will not require marking. 
• If a woman has a mastectomy, then specimen imaging may not be performed. 
• Where a woman has multiple lesions undergoing excision a woman is only 
counted in the numerator if specimen imaging was recorded for all the lesions. 
The woman would only be counted once in the denominator.  
• The measure relates to specimen imaging being ‘recorded’, rather than 
specimen imaging being ‘performed’ to ensure that the image is retained 
rather than just taken. Pathology received is sufficient to indicate that imaging 
was recorded. 
Algorithm 
[A.1 & B.9.1 & A.5 where E.7=1] 
[A.1 & B.9.1 & D.11.4 & (E.1=1 & A.5 where (E.5=2)) at A.3] 
 
x 100 
Notes • Indicator is expressed as a proportion of women with impalpable lesions at 
assessment who undergo excision. 
• In some instances palpable lesions may also be localised which means that 
some palpable lesions may be counted in this element. 
• The calculation of this measure will produce one result. 
• Specimen imaging is to be undertaken and recorded for a lump that is 
impalpable pre-operatively. 
• Specimen imaging is to be undertaken and recorded for any intra-operative 
localised procedure for impalpable lesions. 
• Specimen imaging is to be undertaken and recorded if a lump becomes 
palpable during an operation. 
Former NAS 2.21.2 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.7 
≥95% of all lesions are correctly identified at first excision. 
Data Dictionary Measure 
The percentage of all lesions which are correctly identified at first excision through correlation of final 
pathology with specimen radiography findings and with screening assessment results. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
A.5 Lesion number 
B.9.1 Round number—State/Territory program 
D.11.4 Assessment visit—date 
E.1 Local excision performed 
E.2 Date local excision performed 
E.8.1 Lesion removal 
Numerator Number of lesions correctly identified at first excision. 
A.1, A.5, B.9.1, E.2, E.8.1 
Denominator Number of lesions undergoing excision. 
A.1, A.3, A.5, B.9.1, D.11.4, E.1 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on assessment date. 
• Count is of lesions. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator.  A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in the numerator 
and the denominator. 
• A.3 includes women assessed by the Service and/or SCU even if screened 
elsewhere. 
 360 BreastScreen Australia data dictionary: version 1.1 
• This measure relates to women assessed by the Service and/or SCU as the 
Service and/or SCU may be able to influence the performance of this 
procedure. 
Algorithm 
[A.1 & B.9.1 & (each A.5 where E.8.1=1) at first E.2] 
[A.1 & B.9.1 & D.11.4 & (E.1=1 & each A.5 ) at A.3] 
 
x 100 
Notes • Indicator is expressed as a proportion of all lesions undergoing excision. 
• The calculation of this measure will provide one result. 
• Note: NAS Measure 3.1.7 relates to all lesions whereas former NAS 2.21.3 
related to impalpable lesions. 
Former NAS 2.21.3 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.8 (a) 
≥85% of invasive breast cancers or DCIS are diagnosed without the need for 
excision. 
Data Dictionary Measure 
The total number of invasive breast cancers or DCIS diagnosed without the need for excision 
expressed as a percentage of total breast cancers or DCIS diagnosed. 
Reference period The most recent 12-month period (either calendar or financial year) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.11.1 Recommendation—assessment  
D.11.4 Assessment visit—date 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identification number 
Numerator Number of women assessed by the Service and/or SCU who had an invasive 
cancer or DCIS diagnosed preoperatively. 
A.1, B.9.1, D.11.1 
Denominator Number of women assessed by the Service and/or SCU who had an invasive 
cancer or DCIS diagnosed. 
A.1, A.3, B.9.1, D.11.4, F.1.1, F.4, F.7 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women with a cancer detected. 
• Calculate the denominator first. The numerator is a subset of the 
denominator, i.e. A.1 in the numerator is the same A.1 in the denominator. 
A.1 and B.9.1 are used to ensure correct linking of data elements when 
selecting additional data elements for the numerator. Note that all the data 
elements specified in the denominator are not restated in the numerator. 
• The reference period is based on assessment date. 
• Where this target is not achieved, the Service and/or SCU provides the 
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proportion of invasive breast cancers and DCIS diagnosed pre-
operatively. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3 includes all women assessed by the Service and/or SCU even if 
screened elsewhere. Procedures performed outside the Service and/or 
SCU are to be excluded. 
• As this is a measure of the effectiveness of assessment and includes all 
women assessed by the Service and/or SCU, select the reporting period 
on the date of first attendance for assessment. 
• There may be rare occasions when a woman has more than one 
assessment episode which results in a cancer being detected. In this 
instance, both episodes are counted. 
Algorithm 
[A.1 & B.9.1 & (D.11.1=4)] 
[A.1 & B.9.1 & D.11.4 & ((F.1.1=2 &  
(F.7 = (F.4=1.1 to 1.10 or 2.1 to 2.4))) at A.3] 
 
x 100 
Notes • Indicator is expressed as a proportion of women diagnosed with breast 
cancer. 
• The calculation of this measure will produce one result. 
Former NAS 2.7.1 
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3. Assessment Standard 
Assessment and diagnosis of breast cancer is appropriate, safe and effective. 
Criterion 3.1—The Service and/or SCU maximises the efficacy of assessment. 
NAS Measure 3.1.8 (b) 
Where part (a) is not met, the Service and/or SCU provides the proportion of 
breast cancers that are diagnosed as invasive and DCIS without the need for 
excision. 
Data Dictionary Measure 
The proportion of breast cancers that are diagnosed preoperatively that are invasive breast cancer 
and DCIS. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements 
 
A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.11.1 Recommendation—assessment  
D.11.4 Assessment visit—date 
F.1.1 Reason for histopathology 
F.4 Histopathology of malignant lesion 
F.7 Dominant lesion identification number 
Numerator i. Invasive breast cancer 
Number of women assessed by the Service and/or SCU who had an 
invasive breast cancer that was diagnosed preoperatively. 
ii. DCIS 
Number of women assessed by the Service and/or SCU who had a DCIS 
that was diagnosed preoperatively. 
A.1, B.9.1, F.4 
Denominator Number of women assessed by the Service and/or SCU who had an invasive 
cancer or DCIS that was diagnosed preoperatively. 
A.1, A.3, B.9.1, D.11.1, D.11.4, F.1.1, F.4, F.7 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women with an invasive cancer or DCIS detected. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
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i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• The reference period is based on assessment date. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3 includes all women assessed by the Service and/or SCU even if screened 
elsewhere. Procedures performed outside the Service and/or SCU are to be 
excluded. 
• As this is a measure of the effectiveness of assessment and includes all 
women assessed by the Service and/or SCU, select the reporting period on 
the date of first attendance for assessment. 
• In the rare event that a woman meets the criteria in separate screening 
episodes, include both screening episodes. 
Algorithm NAS Measure 3.2.9 (b) (i) Of the cancers and DCIS diagnosed  
pre-operatively, what proportion were invasive breast cancer? 
[A.1 & B.9.1 & F.4=1.1 to 1.10] 
[A.1 & B.9.1 & D.11.4 & (D.11.1=4) & 
(F.1.1=2 & (F.7 = (F.4=1.1 to 1.10 or 2.1 to 2.4))) at A.3] 
NAS Measure 3.2.9 (b) (ii) Of the cancers and DCIS diagnosed  
pre-operatively, what proportion were DCIS? 
[A.1 & B.9.1 & F.4=2.1 to 2.4] 
[A.1 & B.9.1 & D.11.4 & (D.11.1=4) & 
(F.1.1=2 & (F.7 = (F.4=1.1 to 1.10 or 2.1 to 2.4))) at A.3] 
 
 
 
x 100 
 
 
 
 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women diagnosed with breast 
cancer. 
• The calculation of this measure will produce two results (one for invasive 
breast cancers and one for DCIS). 
Former NAS New 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.1—The Service and/or SCU ensures that women progress through 
the screening pathway in a timely manner. 
NAS Measure 4.1.1 (a) 
≥90% of women aged 50–74 years attend for a screening appointment within 28 
calendar days of their booking date (fixed sites only). 
Data Dictionary Measure 
The percentage of women who attend for a screening appointment within 28 calendar days of their 
booking date. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.1 Booking date 
C.2 Date of first attendance for this episode 
Numerator Number of women aged 50–74 years who attend for a screening appointment 
within 28 calendar days of their booking date at fixed sites only. 
A.1, B.9.1, C.1, C.2 
Denominator Number of women aged 50–74 years who attend for a screening appointment at 
fixed sites only. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
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• This measure relates to fixed screening sites only. 
• Where a woman has more than one screening episode in the reference period 
count all screening episodes. 
Algorithm 
[A.1 & B.9.1 & ((C.2—C.1) ≤28 days)]  
[A.1 & B.9.1 & ((C.2 between start date & end date) & 
 ((C.2—B.2≥50 & ≤74) at A.2=’fixed site’)] 
 
x 100 
Notes • NAS Measures 4.1.1 (a) and (b) are the only measures within ‘Criteria 4.1– 
The Service and/or SCU ensures that women progress through the screening 
pathway in a timely manner’ that is restricted to women aged 50–74 years. 
The rationale for this is that the requirement that women attend for a 
screening appointment within 28 calendar days of their booking date should 
only apply to women in the target group (50-74); however once women attend 
their screen, they should all have timely acces to screening results, 
assessment visits and assessment results etc., regardless of age. 
• Indicator is expressed as a proportion of women attending a screening 
appointment. 
• Calculation of this measure will produce one result. 
• Where clients book an appointment and subsequently choose to change their 
appointment, and it is not feasible to calculate the difference between the 
appointment date and the date when they changed their appointment (this 
difference is the true waiting time), then, if possible, remove such clients from 
the calculation. 
• This NAS Measure should be calculated on first attempt for screening to avoid 
measuring the time from booking to second attempt at screening. 
• An alternative method of calculating this NAS Measure is to export all 
screening appointments with the number of days from booking to appointment 
from lowest to highest then note the time taken to achieve 90% from booking 
date to screening date. 
• Where NAS Measure 4.1.1 (a) is unmet, calculate NAS Measure 4.1.1 (b). 
Former NAS 3.7.1 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.1—The Service and/or SCU ensures that women progress through 
the screening pathway in a timely manner. 
NAS Measure 4.1.1 (b) 
Where part (a) is not met, the Service and/or SCU records and reports the time 
taken to achieve 90% from booking to screening (fixed sites only). 
Data Dictionary Measure 
The number of days taken between booking and attending for 90% of women. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.2 Date of birth 
B.9.1 Round number—State/Territory program 
C.1 Booking date 
C.2 Date of first attendance for this episode 
Numerator Number of days from booking to screening, at fixed sites only, required to achieve 
90% of women aged 50–74 years attending for screening episodes.  
A.1, B.9.1, C.1, C.2 
Denominator Number of women aged 50–74 years who attend for a screening appointment at 
fixed sites only. 
A.1, A.2, B.2, B.9.1, C.2 
Formula Minimum number of days from booking date to screening date where 
Numerator / Denominator x 100 = 90% is achieved 
Specifications • Select on reference period. 
• Count is of women screened, determined for each consecutive interval (in 
days) from booking to screening. The cumulative count of women for each 
interval as a percentage of total women screened is determined until 90% of 
total women screened is reached. At 90%, the interval (in days) represents 
the waiting time from booking to screening before 90% of women attending for 
screening is achieved. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
 368 BreastScreen Australia data dictionary: version 1.1 
• This measure relates to fixed screening sites only. 
• This algorithm calculates the total number of days for each screening episode 
between a woman’s booking date and screening date. 
• Where a woman has more than one screening episode in the reference period 
count all screening episodes. 
Algorithm 
∑ number of women screened (A.1 & B.9.1)  
for each interval (in days) between C.2 and C.1 
[A.1 & B.9.1 & ((C.2 between start date & end date) &  
((C.2—B.2≥50 & ≤74) at A.2=’fixed site’)] 
Calculate n (number of days) where algorithm = 90% 
 
 
x 100 
Notes • NAS Measures 4.1.1 (a) and (b) are the only measures within ‘Criteria 4.1– 
The Service and/or SCU ensures that women progress through the screening 
pathway in a timely manner’ that is restricted to women aged 50–74 years. 
The rationale for this is that the requirement that women attend for a 
screening appointment within 28 calendar days of their booking date should 
only apply to women in the target group (50–74); however once women attend 
their screen, they should all have timely acces to screening results, 
assessment visits and assessment results etc., regardless of age. 
• Indicator is expressed as a proportion of screening episodes. 
• Calculation of this measure will produce one result. 
Former NAS New 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.1—The Service and/or SCU ensures that women progress through 
the screening pathway in a timely manner. 
NAS Measure 4.1.2 
≥90% of women have a documented notification of the results of screening 
within 14 calendar days of the date of screening. 
Data Dictionary Measure 
The percentage of women who have documented notification of the results of screening within 14 
calendar days of the date of screening. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.6 Date woman notified of screening results 
Numerator Number of screening episodes where women have a documented notification of 
their results within 14 calendar days of the screening visit. 
A.1, B.9.1, C.2, C.6 
Denominator Number of screening episodes. 
A.1, A.2, B.9.1, C.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of screening episodes, not women. If a woman has more than one 
screening episode during the period, then all screening episodes are included. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• This measure relates to all women screened including those recalled to 
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assessment. 
• Documented notification refers to contact with the woman, for example by a 
phone call in which the woman is directly spoken with, by letter or via email. 
• Date of screen is date of last screening attendance. 
• The date of notification is the date the result letter is sent or the woman is 
contacted verbally. 
Algorithm 
[A.1 & B.9.1 & ((C.6—C.2)≤14 days)] 
[A.1 & B.9.1 & (C.2 between start date & end date) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of screening episodes. 
• The calculation of this measure will produce one result. 
Former NAS 3.8.1 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.1 (a) 
≥90% of women requiring assessment attend an assessment visit within 28 
calendar days of their screening visit. 
Data Dictionary Measure 
The percentage of women requiring assessment who attend for an assessment visit within 28 
calendar days of their screening visit. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.2.2 Date of first attendance for assessment. 
Numerator Number of women requiring assessment who attend an assessment visit within 28 
calendar days of their screening visit. 
A.1, B.9.1, C.2, D.2.2 
Denominator Number of women requiring assessment as a result of their screening visit. 
A.1, A.2, B.9.1, C.2, C.5 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of screening episodes in the reference period.  
• There may be cases where a woman has two screening episodes in which 
she attended assessment in the one reference period. Where this is the case 
both screening episodes should be counted. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
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• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Exclude women who are screened by the Service and/or SCU but are 
assessed outside the Service and/or SCU. 
Algorithm 
[A.1 & B.9.1 & ((D.2.2—C.2) ≤28 days)] 
[A.1 & B.9.1 & ((C.2 between start date & end date) &  
(C.5=3 or 4 or 5)) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of screening episodes among women 
attending assessment. 
• Calculation of this measure will produce one result. 
• Where NAS Measure 4.2.1 (a) is unmet, NAS Measure 4.2.1 (b) or NAS 
Measure 4.2.1 (c) are calculated. 
Former NAS 3.7.2 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.1 (b) 
Where part (a) is not met, the Service and/or SCU records and reports the 
number of days the Service and/or SCU takes to achieve 90%. 
Data Dictionary Measure 
The number of days the Service and/or SCU takes to achieve 90%. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.2.2 Date of first attendance for assessment. 
Numerator Number of days taken for 90% of women requiring assessment to attend for 
assessment. 
A.1, B.9.1, C.2, D.2.2 
Denominator Number of women requiring assessment as a result of their screening visit. 
A.1, A.2, B.9.1, C.2, C.5 
Formula Minimum number of days from screening date to assessment date where 
Numerator / Denominator x 100 = 90% is achieved 
Specifications • Select on reference period. 
• Count is of screening episodes among women assessed, determined for each 
consecutive interval (in days) from screening date to assessment date. The 
cumulative count of women for each interval as a percentage of total women 
requiring assessment is determined until 90% of total women screened is 
reached. At the 90% mark, the interval (in days) represents the waiting time 
from screening to assessment before 90% of women attending for 
assessment is achieved. 
• An alternative method of calculating this sub element is to export all screening 
appointments along with the number of days from booking to appointment 
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from lowest to highest then note the time taken to achieve 90% from booking 
date to screening date. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Exclude women who are screened by the Service and/or SCU but are 
assessed outside the Service and/or SCU. 
Algorithm 
[ ∑ number of women assessed (A.1 & B.9.1) for each interval  
(in days) between C.2 and D.2.2] 
[A.1 & B.9.1 &((C.2 between start date & end date) &  
(C.5=3 or 4 or 5)) at A.2] 
Calculate n (number of days) where algorithm = 90% 
 
 
x 100 
Notes • Indicator is expressed as a proportion of screening episodes among women 
requiring assessment. 
• Calculation of this measure will produce one result. 
Former NAS New 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.1 (c) 
Where part (a) is not met, the Service and/or SCU records and reports the 
percentage of women who were offered assessment within 28 calendar days of 
their screening visit. 
Data Dictionary Measure 
The percentage of women who were offered assessment within 28 calendar days of their screening 
visit. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
C.5 Recommendation—screening 
D.2.3 Date of first offered assessment appointment 
Numerator Number of women requiring assessment who are offered assessment within 28 
calendar days of their screening visit. 
A.1, B.9.1, C.2, D.2.3 
Denominator Number of women requiring assessment as a result of their screening visit. 
A.1, A.2, B.9.1, C.2, C.5 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is women. 
• While a rare event if a woman has two separate screening episodes during 
the reference period include both. 
• Both symptomatic and asymptomatic women to be counted in the numerator 
and the denominator. 
• Exclude women who are screened by the Service and/or SCU but are 
assessed outside the Service and/or SCU. 
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Algorithm 
[A.1 & B.9.1 & ((D2.3—C.2) ≤28 days)] 
[A.1 & B.9.1 & ((C.2 between start date & end date) &  
(C.5=3 or 4 or 5)) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of women requiring assessment. 
• Calculation of this measure will produce one result. 
• Currently not all state and territory BreastScreen registers contain the data 
fields required to calculate this measure. 
Former NAS New 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.2 
≥95% of women not requiring percutaneous needle biopsy at assessment 
receive a definitive recommendation at their first assessment visit. 
Data Dictionary Measure 
The percentage of women attending assessment who do not require percutaneous needle biopsy 
who receive a definitive outcome at their first assessment visit. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
A.5 Lesion number 
B.9.1 Round number—State/Territory program 
D.2.1 Attendance for assessment 
D.2.2 Date of first attendance for assessment 
D.8.1 Percutaneous needle biopsy performed 
D.11.1 Recommendation—assessment 
D.11.3 Date recommendation made 
Numerator Number of women who attended for assessment and did not require percutaneous 
needle biopsy who received a definitive outcome at their first assessment visit. 
A.1, B.9.1, D.2.2, D.11.1, D.11.3 
Denominator Number of women who attended for assessment and did not require percutaneous 
needle biopsy. 
A.1, A.3, A.5, B.9.1, D.2.1, D.2.2, D.8.1 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on date of first visit to assessment 
• Count is of women assessed who did not require a percutaneous needle 
biopsy (women who chose not to have a percutaneous biopsy are not 
included in this count as this has no bearing on whether a biopsy was 
clinically required or not). 
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• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3 includes women assessed by the Service and/or SCU even if screened 
elsewhere. 
• Mobile assessments or ‘step down’ assessments should be included. 
• Definitive outcome is identified from the last assessment recommendation, i.e. 
D.11.1 Recommendation—Assessment. An assessment outcome of early 
review is not considered to be a definitive outcome and therefore is not 
counted in the numerator. 
Algorithm 
[A.1 & B.9.1 & ((D.11.1=1 or 2 or 4 or 5) & (D.2.2=D.11.3))] 
[A.1 & B.9.1 & (D.2.2 between start date & end date) &  
(D.2.1=1 & (each A.5 where D.8.1=5)) at A.3] 
 
x 100 
Notes • Indicator is expressed as a proportion of women assessed not requiring 
percutaneous needle biopsy. 
• It is assumed that a woman is told of her outcome at her first assessment visit 
where no percutaneous needle biopsy is required. 
• The calculation of this measure will produce one result. 
Former NAS 2.20.3 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.3 
≥95% of women require no more than two procedural assessment visits to 
receive a definitive recommendation from assessment. 
Data Dictionary Measure 
The percentage of women attending assessment who receive a definitive recommendation from 
assessment in no more than two visits. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.1 Reason for assessment 
D.2.2 Date of first attendance for assessment 
D.11.1 Recommendation—assessment  
D.11.4 Assessment visit—date 
Numerator Number of women who attend for assessment and receive a definitive 
recommendation in no more than two procedural assessment visits during the 
same episode. 
A.1, B.9.1, D.2.2, D.11.1, D.11.4, 
Denominator Number of women who attend for assessment. 
A.1, A.3, B.9.1, D.1, D.2.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on assessment date. 
• Count is of women assessed. 
• The intent of this element is that a woman should require no more than two 
procedural visits and one results visit. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
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data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• Use D.11.4 to count number of dates of each assessment visit for each 
episode, or use visit number if States/Territories have a field specified. 
• A.3 includes all women assessed by the Service and/or SCU even if screened 
elsewhere. 
• An assessment visit should include a step down visit. 
• Definitive outcome is identified from the last assessment recommendation, i.e. 
D.11.1 Recommendation—Assessment. Note that an assessment 
recommendation of early review is not a definitive outcome of assessment 
and therefore should not be included in the numerator. 
• Women attending for early review should be excluded from the denominator 
as the initial assessment visit for that early review may not be captured during 
the reference period. 
Algorithm 
[A.1 & B.9.1 & D.2.2 &  
((Count of D.11.4 ≤2) & last D.11.1=1 or 2 or 4 or 5)] 
[A.1 & B.9.1 & (first D.2.2 between start date &  
end date and D.1<>2) at first A.3] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women assessed. 
• The calculation of this measure will produce one result. 
Former NAS 2.20.1 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.4 
≥85% of women are verbally given the results of percutaneous needle biopsy 
within seven calendar days of the assessment procedure. 
Data Dictionary Measure 
The percentage of women who have percutaneous needle biopsy at assessment who are verbally 
given the results within seven calendar days. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.8.3 Percutaneous needle biopsy result 
D.11.4 Assessment visit—date 
D.13.2 Date woman notified verbally of biopsy result 
Numerator Number of percutaneous needle biopsies performed where the woman is verbally 
given the results within seven calendar days of the assessment procedure. 
A.1, B.9.1, D.8.3, D.11.4, D.13.2 
Denominator Number of percutaneous needle biopsies performed. 
A.1, A.3, B.9.1, D.8.3, D.11.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period based on date of first attendance for assessment. 
• Count is of all percutaneous needle biopsy procedures. 
• Where a woman has multiple procedures, count each procedure. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
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• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3 includes women assessed by the Service and/or SCU even if screened 
elsewhere. Procedures performed outside the Service and/or SCU are to be 
excluded. 
Algorithm 
[A.1 & B.9.1 & for each D.8.3=not null  
(D.13.2—D.11.4≤ 7calendar days)]  
[A.1 & B.9.1 & each (D.8.3=not null) & D.11.4 at A.3] 
 
 
x 100 
Notes Indicator is expressed as a proportion of all percutaneous needle biopsy 
procedures. 
The calculation of this measure will produce one result. 
If a woman has separate procedures on different days, both event intervals should 
be assessed. Where there are multiple procedures on different days, it is ideal to 
be able to define the interval between each procedure and the date the woman 
was notified verbally of her results; however this may not be possible for all 
services since in some cases only one date for results is able to be recorded. 
Some services may find it difficult to record the date the results were 
communicated to the women for each procedure. 
A new data dictionary Data element D.13.2 Date woman notified verbally of biopsy 
results was created for use in calculating this NAS Measure. 
Former NAS 3.8.3 (a) / 3.8.3 (b) 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.5 
≥95% of women complete all assessment within 15 calendar days. 
Data Dictionary Measure 
The percentage of women attending assessment who receive a definitive outcome of assessment 
within 15 calendar days. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.1 Reason for assessment 
D.2.2 Date of first attendance at assessment 
D.11.1 Recommendation—assessment 
D.13.1  Date woman notified in writing of assessment results 
D.13.2  Date woman notified verbally of biopsy results 
Numerator Number of women who attend for assessment and receive a definitive outcome of 
the assessment either verbally or in writing within 15 calendar days. 
A.1, B.9.1, D.2.2, D.11.1, D.13.1, D13.2 
Denominator Number of women who attend for assessment. 
A1, A.3, B.9.1, D.1, D.2.2 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women assessed. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Reference period is based on assessment date associated with that round. 
• Both symptomatic and asymptomatic women to be counted both in the 
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numerator and denominator. 
• A.3 includes all women assessed by the Service and/or SCU even if screened 
elsewhere. 
• Women who had mobile assessments or ‘step down’ assessments should not 
be included. 
• Definitive outcome is identified from the last assessment recommendation, i.e. 
D.11.1 Recommendation—Assessment. Note that an assessment 
recommendation of early review is not a definitive outcome of assessment 
and therefore should not be included in the numerator. 
Algorithm 
[A.1 & B.9.1 & ((D.11.1=1 or 2 or 4 or 5) & 
 (D.11.1 or D.13.1 or D.13.2—D.2.2≤15 days))] 
[A.1 & B.9.1 & (first D.2.2 between start date & end date) & 
(D.1<>2) at first A.3] 
 
 
x 100 
Notes • Indicator is expressed as a proportion of women assessed. 
• The calculation of this measure will produce one result. 
Former NAS 2.20.2 
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4. Timeliness Standard 
Screening and assessment services are provided to women in a timely and 
efficient manner. 
Criterion 4.2—The Service and/or SCU ensures that women progress through 
the assessment pathway in a timely manner. 
NAS Measure 4.2.6 
All women are notified of the results of their assessment in writing within 14 
calendar days of the date of completion of assessment. 
Data Dictionary Measure 
The percentage of women assessed who have a letter sent notifying them of the results of 
assessment within 14 calendar days of the date of completion of assessment. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.3 Assessment unit identifier 
B.9.1 Round number—State/Territory program 
D.2.1 Attendance for assessment 
D.11.3 Date recommendation made 
D.11.4 Assessment visit—date 
D.13.1 Date woman notified in writing of assessment results 
Numerator Number of women assessed who have a letter sent notifying them of their results 
within 14 calendar days of the assessment visit. 
A.1, B.9.1, D.11.3, D.13.1 
Denominator Number of women who attend for assessment. 
A.1, A.3, B.9.1, D.2.1, D.11.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Reference period is based on assessment date. 
• Count is of women assessed. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• The reference period is established by selecting D.2.2—Date of first 
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attendance for assessment (between start date and end date). 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• A.3 includes women assessed by the Service and/or SCU even if screened 
elsewhere. Procedures performed outside the Service and/or SCU are to be 
excluded. 
Algorithm 
[A.1 & B.9.1 & (D.13.1—D.11.3≤14 days)] 
[A.1 & B.9.1 & (D.11.4 & D.2.1=1) at A.3] 
 
x 100 
Notes • Indicator is expressed as a proportion of women assessed. 
• The calculation of this measure will provide one result. 
Former NAS 3.8.6 
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5. Data Management and Information Systems Standard 
Data and information management systems and processes ensure the safe and 
effective use of data for strategic, clinical management and service 
improvement purposes. 
Criterion 5.1—The Service and/or SCU ensures the collection of treatment 
information about women with breast cancer. 
NAS Measure 5.1.1 
≥95% of data dictionary compliant surgical histopathology information is 
received by the Service and/or SCU. 
Data Dictionary Measure 
The percentage of surgical histopathology information received by the Service and/or SCU. 
Reference period The most recent 12-month period (either calendar or financial year) for which 
data are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
E.1 Local excision performed 
E.9 Local excision result 
E.12 Recommendation—definitive 
F.1.1 Reason for histopathology 
F.1.3 Cancer diagnosed in BreastScreen Australia 
F.4 Histopathology of malignant lesion 
G.4 Surgical treatment 
Numerator Number of women diagnosed with breast cancer who have undergone 
surgery for whom the Service and/or SCU has received surgical 
histopathology information. 
A.1, B.9.1, G.4 
Denominator Number of women diagnosed with breast cancer by the Service and/or SCU 
who have undergone surgery. 
A.1, A.2, B.9.1, C.2, E.1, E.9, E.12, F.1.1, F.1.3, F.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the 
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denominator, i.e. A.1 in the numerator is the same A.1 in the 
denominator. A.1 and B.9.1 are used to ensure correct linking of data 
elements when selecting additional data elements for the numerator. 
Note that all the data elements specified in the denominator are not 
restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• This measure relates to women screened by the Service and/or SCU 
who had a malignancy diagnosed regardless of whether they were 
assessed by the Service and/or SCU. 
• Information with respect to interval cancers is to be requested if the 
interval cancer was detected by the Service and/or SCU, i.e. early 
rescreen of a symptomatic woman or at early review at six months or 
more after the screening episode is complete. 
• Information supplied should comply with the data dictionary for this NAS 
Measure to be met. 
• This NAS Measure relates to excisions only. 
Algorithm 
[A.1 & B.9.1 & (G.4 not null)] 
[A.1 & B.9.1 & ((C.2 between start date & end date) & 
((F.1.1=2 or (F.1.1=1 & F.1.3=1)) & (F.4=1.1 to 1.10 or 2.1 to 2.4))  
if (E.12=4 & E.1=1 & E.9=1)) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of women diagnosed with breast 
cancer and who have had surgery. 
• The calculation of this measure will provide one result. 
Former NAS 2.24.3 
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5. Data Management and Information Systems Standard 
Data and information management systems and processes ensure the safe and 
effective use of data for strategic, clinical management and service 
improvement purposes. 
Criterion 5.1—The Service and/SCU ensure the collection of treatment 
information about women with breast cancer. 
NAS Measure 5.1.2 
≥95% of data dictionary compliant primary treatment information is received by 
the Service and/or SCU. 
Data Dictionary Measure 
The percentage of primary treatment information received by the Service and/or SCU. 
Reference 
period 
The most recent 12-month period (either calendar or financial year) for which data 
are available. 
Data collection BreastScreen Australia data dictionary 
Data source State and territory BreastScreen registers 
Data elements A.1 Client identifier number 
A.2 Screening unit identifier 
B.9.1 Round number—State/Territory program 
C.2 Date of first attendance for this episode 
D.11.1 Recommendation—assessment 
F.1.1 Reason for histopathology 
F.1.3 Cancer diagnosed in BreastScreen Australia 
F.4 Histopathology of malignant lesion 
G.4 Surgical treatment 
G.5.1 Radiotherapy 
G.5.2 Chemotherapy 
Numerator Number of women diagnosed with breast cancer by the Service and/or SCU who 
have undergone primary treatment for whom the Service and/or SCU received 
primary treatment information. 
A.1, B.9.1, G.4, G.5.1, G.5.2 
Denominator Number of women diagnosed with breast cancer by the Service and/or SCU who 
have undergone primary treatment. 
A.1, A.2, B.9.1, C.2, D.11.1, F.1.1, F.1.3, F.4 
Formula Numerator / Denominator x 100 
Specifications • Select on reference period. 
• Count is of women. 
• Calculate the denominator first. The numerator is a subset of the denominator, 
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i.e. A.1 in the numerator is the same A.1 in the denominator. A.1 and B.9.1 
are used to ensure correct linking of data elements when selecting additional 
data elements for the numerator. Note that all the data elements specified in 
the denominator are not restated in the numerator. 
• Both symptomatic and asymptomatic women to be counted in both the 
numerator and the denominator. 
• This measure relates to women screened by the Service and/or SCU who had 
breast cancer diagnosed regardless of whether they were assessed by the 
Service and/or SCU. 
• Information with respect to interval cancers is to be requested if the interval 
cancer was detected by the Service and/or SCU, i.e. early rescreen of a 
symptomatic woman or at early review at six months or more after the 
screening episode is complete. 
• Information supplied should comply with the data dictionary for this NAS 
Measure to be met. 
Algorithm 
[A.1 & B.9.1 & ((G.4 not null) or (G.5.1 not null) or (G.5.2  not null))]  
[A.1 & B.9.1 & (C.2 between start date & end date) &  
(D.11.1=4 or D.11.1=5 and ((F.1.1=2 or (F1.1=1 & F.1.3=1) &  
(F.4=1.1 to 1.10 or 2.1 to 2.4))) at A.2] 
 
x 100 
Notes • Indicator is expressed as a proportion of women diagnosed with breast 
cancer. 
• The calculation of this measure will provide one result. 
Former NAS 2.24.4 
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5.2 Reporting matrix and performance measures for 
NAS Measures relating to percutaneous needle 
biopsy (Assessment Standard 3)  
Reporting matrix 
Percutaneous 
needle biopsy → 
Final histology ↓ 
Malignant Suspicious Atypical Benign Inadequate Total 
Total malignant Box 1 Box 2 Box 3 Box 4 Box 5 Box 6 
Invasive Box 7 Box 8 Box 9 Box 10 Box 11 Box 12 
Non-invasive Box 13 Box 14 Box 15 Box 16 Box 17 Box 18 
Total benign Box 19 Box 20 Box 21 Box 22 Box 23 Box 24 
No histology Box 25 Box 26 Box 27 Box 28 Box 29 Box 30 
Total  Box 31 Box 32 Box 33 Box 34 Box 35 Box 36 
Each box (numbered 1–36) of the tables above is used to calculate the number of cases of 
percutaneous needle biopsies, that is all fine needle aspirations and core biopsies performed cross 
referenced with the worst histology diagnosis. Note that all procedures should be included. 
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Calculation of Performance Measures 
Performance NAS Measure 3.1.1  
<5% of all percutaneous needle biopsies of malignant breast 
lesions are classified as benign or inadequate/insufficient. = 
4+5 
x 100% 
6+25 
Performance NAS Measure 3.1.2   
0% of benign lesions assessed by percutaneous needle biopsy 
have a false positive cancer diagnosis, when the definitive needle 
biopsy result is achieved after performance of the final needle 
biopsy at an assessment episode(s). A false positive FNA which is 
followed by a true negative core biopsy, prior to recommendation 
for surgery or treatment, is not considered to be a false positive 
‘percutaneous needle biopsy’ for the purpose of this standard. 
= 
 
19 
x 100% 24 
Performance NAS Measure 3.1.3   
The absolute sensitivity of a diagnosis of breast cancer based on 
percutaneous needle biopsy is >90%. = 
1+25 
x 100% 
6+25 
 BreastScreen Australia data dictionary: version 1.1 393 
Appendix 1: Metadata and data standards 
Detailed description of the format for data element 
definitions 
All data element definitions included in this data dictionary are based on ISO/IEC Standard 
11179 Specification and Standardization of Data Elements—the international standard for 
defining data elements issued by the International Organization for Standardization and the 
International Electrotechnical Commission. The meanings of the various parts of the format 
are provided below. 
«NAME» 
 
 Status Effective Date Reg. Auth. ID No. 
    
    
NCSI Model Location Data Class Version 
   
Identifying and definitional attributes 
Data element type:  
Definition:  
Context:  
Relational and representational attributes 
Datatype:  Representational form:  
Field size:  Min. Max. Representational layout:  
Data domain:  
Guide for use:  
Collection methods:  
Related data elements:  
Related NAS Measures:  
Administrative attributes 
Source document:  
Source organisation:  
Comments:  
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Identifying and definitional attributes 
Name: A single or multi-word designation assigned to a data element. This 
appears in the heading for each unique data definition in the 
Dictionary. 
Status: The operational status (CURRENT, SUPERSEDES) of the data 
element. 
Data element type: A data element may be either: 
(a) a DATA CONCEPT—a concept which can be represented in 
the form of a data element, described independently of any 
particular representation, for example ‘Informal carer’, which 
does not have any particular representation of its own, except 
through data elements such as ‘Carer availability’ and 
‘Relationship of carer to care recipient’. 
(b) a DATA ELEMENT—a unit of data for which the definition, 
identification, representation and permissible values are 
specified by means of a set of attributes. For example, a 
person’s ‘Date of birth’ is a unit of data for which the definition, 
identification, representation and permissible values are 
specified. 
(c) a DERIVED DATA ELEMENT—a data element for which values 
are derived by calculation using the values of other data 
elements.  
(d) a COMPOSITE DATA ELEMENT—a data element where 
values represent a grouping of the values of other data 
elements in a specified order. 
Definition: A statement that expresses the essential nature of a data element 
and its differentiation from all other data elements. 
Context: A designation or description of the application environment or 
discipline in which a name is applied or from which it originates. For 
the Dictionary this attribute may also include the justification for 
collecting the data elements and uses of the information. 
Relational and representational attributes 
Data type: The type of symbol, character or other designation used to 
represent a data element. Examples include integer, numeric, 
alphanumeric, and alphabetic. For example, the data type for 
‘Marital status’ is a numeric drawn from a domain or codeset in 
which numeric characters such as 1 = Never married, and 4 = 
Separated are used to denote a data domain value (see Data 
domain below). 
Representational form: Name or description of the form of representation for the data 
element, such as ‘CODE’, ‘Quantitative value’, and ‘DATE’. For 
example, the representational form for ‘Country of birth’ is ‘CODE’ 
because the form of representation is individual numbers that each 
represent a different country. 
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Field size (minimum and 
maximum): 
The minimum and maximum number, respectively, of storage units 
(of the corresponding datatype) to represent the data element 
value. For example, a data element value expressed in dollars may 
require a minimum field size of one character (1) up to a maximum 
field size of nine characters (999999999). Field size does not 
generally include characters used to mark logical separations of 
values such as commas, hyphens or slashes. 
Representational layout: The layout of characters in data element values expressed by a 
character string representation. Examples include ‘DDMMYYYY’ for 
calendar date, ‘N’ for a 1-digit numeric field, and ‘$$$,$$$,$$$’ for 
data elements about expenditure. 
Data domain: The set of representations of permissible instances of the data 
element, according to the representation form, layout, data type 
and maximum size specified in the corresponding attributes. The 
set can be specified by name (such as valid date), by reference to 
a source (such as the ABS Classification of Languages), or by 
enumeration of the representation of the instances (for example, for 
‘Labour force status’ values are 1 = Employed, 2 = Unemployed, 
and so on). 
Guide for use (optional): Additional comments or advice on the interpretation or application 
of the attribute ‘data domain’. This attribute has no direct 
counterpart in the ISO/IEC Standard 11179 but has been included 
to assist in clarification of issues relating to the classification of data 
elements. 
Collection methods 
(optional): 
Comments and advice concerning the actual capture of data for the 
particular data element, including guidelines on the design of 
questions for use in collecting information, and treatment of ‘not 
stated’ or non-response. This attribute is not specified in the 
ISO/IEC Standard 11179 but has been added to cover important 
issues about the actual collection of data. 
Related data elements 
(optional): 
Shows relationships between the data element (or data concept) 
and other data elements/concepts in the Dictionary, including the 
type of relationship, for example ‘supersedes data element X.X’. 
Related NAS Measures 
(optional): 
Shows relationships between the data element (or data concept) 
and other NAS Measures in the Dictionary. 
Administrative attributes 
Source document (optional): The document from which definitional or representational attributes 
originate. 
Source organisation: The organisation responsible for the source document and/or the 
development of the data definition. This attribute is not specified in 
ISO/IEC Standard 11179 but has been added for completeness. 
The Source organisation is not necessarily the organisation 
responsible for the ongoing development/maintenance of the data 
element definition. 
Comments (optional): Any additional explanatory remarks on the data element. 
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Appendix 2: Classifications 
Australian Standard Geographical Classification 
(ASGC) and Australian Statistical Geography 
Standard (ASGS) 
In 2011 the ABS replaced the Australian Standard Geographical Classification (ASGC) (ABS 
2006) with the new Australian Statistical Geography Standard (ASGS) (ABS 2011). The ASGS 
comprises a hierarchy of geographic regions and is the future geographical standard on 
which the ABS will release statistical data. Statistical Areas Levels 1–4 (SA1, SA2, SA3 and 
SA4) are components of the new ASGS while Statistical Local Areas (SLA) belonged to the 
old ASGC structure. 
ASGS structures will be updated every Census year. In comparison, SLA boundaries were 
updated annually. 
To assign a single geographic identifier based on the ASGS using Australian address 
components: 
• SA1 classification requires street address, suburb/locality, postcode and state 
• SA2 or SA3 classification requires suburb/locality, postcode and state 
• SA4 can be generated from postcode only. 
SA2 level data are used in developing ABS products including Remoteness Area (RA) 
definitions, and Socioeconomic Indexes for Areas (SEIFA). 
This classification allocates one in five remoteness categories to areas depending on their 
distance from different-sized urban centres, where the population size of the urban centre is 
considered to govern the range and type of services available.  
Socio-Economic Indexes for Areas (SEIFA) 
Socio-Economic Indexes for Areas (SEIFA) is a product developed by the ABS that ranks 
areas in Australia according to relative socioeconomic advantage and disadvantage. The 
indexes are based on information from the five-yearly Census. 
For the purposes of SEIFA, the ABS continues to broadly define relative socioeconomic 
advantage and disadvantage in terms of people’s access to material and social resources, and 
their ability to participate in society. 
SEIFA 2011 is based on Census 2011 data, and consists of four indexes, each focusing on a 
different aspect of socioeconomic advantage and disadvantage, and being a summary of a 
different subset of Census variables. 
Differences between SEIFA 2011 and previous years 
SEIFA 2011 consists of the same 4 indexes as used in 2006 and 2001. 
SEIFA 2011 uses the ASGS, which is a change from past versions, which used the Australian 
Standard Geographical Classification. The main implication for SEIFA from this change is 
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that the new base unit of analysis is the Statistical Area Level 2 (SA2), rather than the Census 
Collection District (CD) used in the past.  
Index scores for larger geographic areas have been produced by taking population-weighted 
averages of constituent SA2 scores. 
The methods used for SEIFA 2011 are generally the same as previously, although the 
exclusion rules have been updated to ensure a reliable index score is obtained for as many 
areas as possible. 
Of particular note to users of past versions of SEIFA, one of the Indexes, the Index of Relative 
Socio-economic Disadvantage (IRSD, see below), no longer contains the variable relating to 
the proportion of people identifying as Indigenous in an area. 
Index of Relative Socio-Economic Disadvantage 
The Index of Relative Socio-economic Disadvantage (IRSD) is one of four Socio-Economic 
Indexes for Areas (SEIFAs) developed by the Australian Bureau of Statistics (ABS 2013). This 
index is based on factors such as average household income, education levels and 
unemployment rates. Rather than being a person-based measure, the IRSD is an area-based 
measure of socioeconomic status in which small areas of Australia are classified on a 
continuum from disadvantaged to affluent. This information is used as a proxy for the 
socioeconomic status of people living in those areas and may not be correct for each 
individual person in any particular area.  
Standard Australian Classification of Countries  
The Standard Australian Classification of Countries is the Australian statistical standard for 
statistics classified by language (ABS 2014). It was designed for use in the collection, 
aggregation and dissemination of data relating to languages spoken in Australia and used to 
classify the language variables ‘First language spoken’, ‘Languages spoken at home’, ‘Main 
language spoken’ and ‘Main language other than English spoken at home’. The classification 
was developed through extensive research, stakeholder consultation and data analysis.  
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Glossary 
Aboriginal or Torres Strait Islander: A person of Aboriginal and/or Torres Strait Islander 
descent who identifies as an Aboriginal and/or Torres Strait Islander. 
Absolute sensitivity: Is the measure of success in the diagnosis of cancer by percutaneous 
needle biopsy.  
Architectural distortion: Abnormal configuration of the ductal and ligamentous structures 
of breast parenchyma compared with the remainder of the breast tissue markings. Includes 
speculation, focal retraction, distortion of the parenchymal edge, or disorganisation of 
markings. 
Aspiration: Putting a hypodermic needle into the tissue or area of concern and drawing back 
on the syringe to obtain fluid or cells. 
Assessment centre/clinic: The centre where women are recalled for diagnostic work-up due 
to an abnormality detected as a result of the screening visit, signs/symptoms reported at the 
screening visit, or for other reasons, either within or outside BreastScreen Australia.   
Assessment episode: An assessment episode includes all attendances for assessment during 
a particular screening episode. An assessment episode is complete when there is one of three 
outcomes: return for routine rescreening, referral for definitive treatment or recommendation 
for early review. 
Assessment visit: Any visit by a woman to an assessment clinic for the purpose of all follow-
up investigative procedures arising from a woman’s attendance for screening up to and 
including cytological or histological diagnosis.  This includes attending the assessment clinic 
for the purpose of receiving results.   
Axillary dissection: Surgical excision of the axillary contents (fat and lymph nodes) en bloc 
with mastectomy or as an independent procedure. The extent of the axillary dissection is 
further defined in the following way: 
• Level 1—excision of the axillary contents up to the inferior border of the pectoralis minor 
muscle. 
• Level 2—excision of the axillary contents up to the superior border of the pectoralis 
minor muscle. 
• Level 3—excision of the axillary contents up to the apex of the axilla. 
Axillary lymph node dissection: Surgical removal of lymph nodes found in the armpit 
region. See axillary dissection. 
Axillary lymph nodes: Lymph nodes found in the armpit area. 
Benchmarking: A continuous process of measuring quality or performance against the 
highest standards.  
Benign: Not malignant, not cancer. 
Benign diagnostic open biopsy: An open biopsy recommended by the Service for diagnostic 
purposes and where the histopathology was not of invasive cancer or DCIS; examples 
include atypical hyperplasia, radial scar or LCIS. 
Bilateral: Involving both sides, such as both breasts. 
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Biopsy: Removal of a sample of tissue or cells from the body to assist in diagnosis of a 
disease. 
Breast conserving surgery: Surgery where the cancer is removed, together with a margin of 
normal breast tissue. The whole breast is not removed. 
Calcification: The deposition of calcium salts in body tissues. In the breast, calcification can 
be seen in normal and abnormal ducts and in association with some carcinomas, both 
invasive and in situ. 
Cancer: A malignant growth. See also carcinoma. 
Cancer death: A death where the underlying cause is indicated as cancer. 
Carcinoma: A malignant tumour arising from epithelial cells, which are cells lining the 
external or internal surfaces of the body. Carcinomas spread to nearby tissues. They may also 
spread to distant sites such as lung, liver, lymph nodes and bone. Also see metastasis. 
Carcinoma in situ (CIS): A non-invasive lesion in which neoplastic cells are confined by the 
basement membrane. Carcinoma in situ has an increased risk of becoming an invasive 
carcinoma if untreated. See also ductal carcinoma in situ and lobular carcinoma in situ. 
Carcinoma NOS: Carcinoma not otherwise specified. Frequently used as a synonym for 
invasive ductal carcinoma or Carcinoma of No Special Type. 
Catchment area: Catchment area is a geographic region based on service size in relation to 
the population, accessibility and location of other services.  
Clinical examination of breast: The physical examination of the breast and axilla by a health 
professional. 
Combined recall to assessment: Recall to assessment for a mammographic abnormality as 
well as non-mammographic abnormality. 
Complete local excision: The complete removal of a tumour with a surrounding margin of 
normal breast tissue. Also known as CLE and breast conserving surgery. 
Consensus reading: Where the screen readers consider the mammogram together to reach 
agreement over discordant reads. 
Core biopsy: The sampling of breast tissue with a cutting needle, 14 gauge or larger, to 
obtain a tiny cylinder of tissue for histological examination. This technique may involve a 
mechanical device to drive the cutting needle. 
Cyst: Fluid-filled sac. 
Cytological diagnosis: A diagnosis based on looking at cells.  
Cytology: Assessment of cellular detail and abnormalities in a preparation of cells obtained 
by fine needle aspiration (FNA), or by other methods such as imprint or duct discharge 
cytology (NHMRC 1995). 
Definitive outcome at assessment: An assessment recommendation of: 1. Routine rescreen 
at 2 years; 2. Routine rescreen at 1 year; 3. Definitive treatment for cancer. 
Definitive result: Whether the lesion is malignant or non-malignant.  No definitive result 
applies where the sample obtained does not permit definitive diagnosis and where further 
biopsy will not be performed. The decision not to perform further biopsy may be either the 
woman’s or the surgeon’s. 
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DCIS (Ductal carcinoma in situ): A form of carcinoma in situ with no invasive component, 
diagnosed by its characteristic histopathologic features. Frequently associated with 
mammographic abnormalities, including calcification. There is an increased risk of 
progression to invasive carcinoma at the same site as the DCIS if not adequately treated. 
Diagnostic mammography: Mammography which is performed when a woman has signs or 
symptoms of disease. 
Discrete mass with or without calcification: A mass is a space-occupying lesion seen in two 
projections, and is described by density and edge characteristics. Density may be high, low 
or variable compared to normal breast tissue. The outline (edge) may be smooth, lobulated, 
irregular, speculated, stellate, or obscured by superimposed parenchyma. Features 
suspicious for malignancy include increased density and an irregular, speculated or stellate 
border, or portion of border. 
Double reading: Where the screening films are independently read by two readers. 
Ductal carcinoma in situ: See DCIS. 
Early review: The recall of a woman for further assessment within 12 months of the 
screening date and following an equivocal assessment visit (where a decision cannot be 
made). Early review within 6 months of the screening date is considered part of the 
screening episode and cancers found as a result of the review are considered to be screen-
detected; but cancers found at early review carried out at 6 months or more from the date of 
screening are considered to be interval cancers. 
Eligible women: Any woman aged 40 years or over. 
Excision: Surgical removal by cutting, as of a tumour or a portion of a structure or organ. 
Fine needle aspiration biopsy: The sampling of cells from breast tissue for examination by a 
pathologist. Also known as FNA, FNAB or FNB. 
First screen: Women who are attending for their first screening episode within the National 
Program, including the pilot phase and regardless of the Service. Also known as the initial 
screen. 
FNA: The sampling of cells from breast tissue for examination by a pathologist. Also known 
as fine needle aspiration biopsy, FNAB or FNB. 
FNAB: The sampling of cells from breast tissue for examination by a pathologist. Also 
known as FNA, fine needle aspiration biopsy or FNB. 
Frozen section: Freezing of a tissue biopsy to facilitate cutting a thin tissue section which is 
stained and examined microscopically. Usually used to obtain a tissue diagnosis at or during 
an operation.   
Grade: The degree of similarity of the cancer cells to normal cells:  
• A grade 1 carcinoma is well differentiated and is associated with a good prognosis.  
• A grade 2 carcinoma is moderately differentiated and is associated with an intermediate 
prognosis.  
• A grade 3 carcinoma is poorly differentiated and is associated with a poor prognosis.  
Tumour grade is assigned by an assessment of microscopic features of the tumour by a 
histopathologist.  
Histology: An examination of the body tissue by a pathologist using a microscope. 
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Histopathology: Microscopic study of diseased tissue, usually performed by a 
histopathologist.  
Impalpable: Not able to be felt on a clinical examination. 
Inadequate percutaneous needle biopsy result: Inadequate percutaneous needle biopsies 
are defined as samples of insufficient yield for adequate diagnosis of the screen-detected 
lesion. In cases of core biopsies for micro-calcifications this includes samples without 
calcium. 
Indigenous: A person of Aboriginal and/or Torres Strait Islander descent who identifies as 
an Aboriginal and/or Torres Strait Islander. 
Initial screen: Women who are attending for their first screening episode within the 
National Program, including the pilot phase and regardless of the Service.  Also known as a 
first screen. 
Interval cancers: Interval cancers are invasive breast cancers that are diagnosed in the 
interval between the completion of a negative screening episode and the commencement of 
the next screening episode. For most women, the next screening episode will occur around 
24 months after her previous negative screening episode, as the recommended screening 
interval for most women in BreastScreen Australia is 24 months. The exception to this is 
women on annual screens, for whom the next screening episode will occur around 12 
months after her previous negative screening episode. 
An interval cancer may be:  
• an aggressive breast cancer that emerges and grows very rapidly in the period between 
screening episodes  
• a breast cancer that, due to the characteristics of the cancer or the breast tissue, is not 
visible on screening mammography and therefore not able to be detected 
• a breast cancer that can be retrospectively detected on the previous screening 
mammogram.  
The first two types of interval cancer described above are true interval cancers, and therefore 
do not represent any failure in detection; the third represents a failure of the screening 
process. Through the BreastScreen accreditation process, state and territory BreastScreen 
programs are required to audit interval cancers. On investigation, more than 80% are found 
to be true interval cancers. 
Interval cancers may be detected outside BreastScreen Australia or through BreastScreen 
Australia, depending on the policies for screening symptomatic women that exist in each 
State and Territory. 
Invasive: The tendency of a malignant process or growth to spread into healthy tissue 
(Thomas 1997). Invasion occurs when cancer cells push between and break through other 
surrounding cells and structures (AIHW 2000a).  An invasive cancer is greater than 15 mm 
(as compared to a small invasive cancer which is less than or equal to 15 mm). Tumours 
demonstrating micro-invasion should be reduced and sized as invasive cancers and not as 
DCIS. Invasive cancer excludes DCIS.   
Jurisdiction: The territory over which authority is exercised. In this data dictionary the term 
is used to refer to an Australian state or territory. 
LCIS (Lobular carcinoma in situ): A typical epithelial process characterised by an increased 
risk of progression to invasive carcinoma. It is difficult to detect by mammography.  
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Lobular carcinoma in situ: See LCIS. 
Localisation: Method used to locate/mark an impalpable lesion for surgical removal with 
wire marker or carbon. 
Local excision: An excision limited to the immediate area of the lesion in question. 
Lumpectomy: Surgical removal of a lump from the breast. Also see complete local excision. 
Lymph node: A lymphoid organ comprising specialised white cells or lymphocytes and 
related cells. They have a filtering function and are the site of development of  
antibody-producing (B) lymphocytes and plasma cells, and cytotoxic and memory (T) 
lymphocytes. Lymph nodes are found along lymphatic channels, particularly the axillae, 
neck and inguinal regions. Axillary lymph nodes are a common site for metastatic breast 
carcinoma. 
Main language other than English spoken at home: The language reported by a person as 
the main language other than English spoken by a person in his/her home (or most recent 
private residential setting occupied by the person) on a regular basis, to communicate with 
other residents of the home or setting and regular visitors (see also Data Element B.4). 
Malignant: A tumour having the capacity to invade and destroy tissue locally, and 
metastasise via the bloodstream or lymph to distant sites and cause death. 
Mammogram: A soft tissue x-ray of the breast which may be used to evaluate a lump or 
which may be used as a screening test in women with no signs or symptoms of breast cancer. 
Mammography: The process of taking a mammogram. 
Mammographic recall: A recall due to a suspicious (screening) mammogram. 
Metastasis: The spread of a cancer from the primary site to somewhere else via the 
bloodstream or lymphatic system. 
METeOR: METeOR is Australia’s repository for national metadata standards for health, 
housing and community services statistics and information <http://meteor.aihw.gov.au>. 
Morbidity: A measure of illness when referring to ill health in an individual or ill health in a 
population group. In the broadest sense, morbidity is any departure, subjective or objective, 
from a state of physiological or psychological wellbeing. 
Multidisciplinary approach to assessment: Where the radiologist and the surgeon, or other 
designated examining clinician, are in attendance together at assessment to correlate and 
evaluate the clinical and imaging findings and to decide on further investigations or 
management. 
Multiple masses: More than one lesion which conforms to the definition of a suspicious 
mass. 
Non-mammographic recall: Recall to assessment for reasons other than a mammographic 
abnormality, for example, signs or symptoms. 
Non-specific density: Asymmetry of breast tissue seen in either one or two planes not 
accurately described by other categories.  Additional imaging may reveal normal breast 
parenchymal appearances, or an underlying mass, or definite architectural distortion.  
Includes new densities with poorly defined characteristics. 
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Open biopsy: A surgical procedure performed under local or general anaesthetic in which a 
sample of breast tissue for histological examination is obtained in a conventional surgical 
procedure, using an open incision. 
Pathologist: Doctor who specialises in examining tissue and diagnosing disease. 
Pathology: Scientific study of the alterations produced by disease. 
Percutaneous needle biopsy: Fine needle aspiration or core biopsy. 
Preoperative diagnosis of cancer: A malignant result on FNA or core biopsy (includes DCIS 
and invasive cancer) which is consistent with suspicious or malignant imaging findings. 
Primary breast tumour: Tumour arising in the breast, and derived from breast tissue. 
Primary treatment: All treatment modalities initiated within 6 months of diagnosis. This 
does not include treatment for recurrence or metastases. 
Radical mastectomy: Total mastectomy with removal of all lymph nodes from the armpit 
and removal of muscles of the chest. This operation is obsolete and should be performed 
rarely. Also known as Halsted mastectomy. 
Radiographic: Pertaining to an x-ray. 
Radiotherapy: The use of radiation, usually x-rays or gamma rays, to kill tumour cells. 
Sensitivity: The proportion of people with a disease who are correctly diagnosed (test 
positive based on diagnostic criteria). The higher the sensitivity of a test or diagnostic 
criteria, the lower the rate of ‘false negatives’—people who have a disease but are not 
identified through the test. 
Screen-detected abnormalities: Abnormalities which are observed on a screening test. 
Screen-detected cancer: A screen-detected breast cancer is any invasive breast cancer or 
DCIS diagnosed during the screening episode. 
Screening: The presumptive identification of unrecognised disease or defect by the 
application of tests, examinations or other procedures which can be applied rapidly. 
Screening tests sort out apparently well persons who probably have a disease from those 
who probably do not. 
Screening and Assessment Service: An integrated service consisting of an assessment 
centre/service and its associated screening units. 
Screening episode: A screening episode includes all attendances for screening and 
assessment within 6 months relating to a particular round of screening. It commences at the 
date of attendance for screening. It is completed when: 
• a recommendation is made to return the woman to routine rescreening  
• a recommendation is made for early review at 6 months or more from the screening date 
• a diagnosis of cancer is made 
• the woman fails to attend for technical recall or assessment within 6 months 
• the woman dies. 
Screening mammography: Mammography which is performed when a woman does not 
have signs or symptoms of disease. 
Second or subsequent screen: Women who are attending for any screening episode in 
BreastScreen Australia other than their first screen. 
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Screening unit: A screening unit is usually one site, fixed or mobile. 
Size of tumour: The greatest dimension of the tumour in millimetres. This is ideally 
determined from the fresh specimen or, if appropriate, from histopathology slides. 
Small invasive cancer: An invasive cancer less than or equal to 15 mm. 
Symptom: A lump or nipple discharge (clear or bloody). 
Staff: Staff refers to any person employed by the service, which includes full-time, part-time 
and casual staff. 
Stellate lesion: Speculations of variable length radiating from a central point or mass.  When 
a central mass is present, it may be small or large, and of low, mixed or high density 
compared to surrounding breast parenchyma. 
Step-down clinic: A step-down assessment includes diagnostic further views and does not 
include clinical assessment, ultrasound or biopsy. A step-down clinic is a mobile clinic and 
not in the assessment centre setting. The aim of a step-down is convenience, as the woman 
does not need to travel into a city centre. 
Stereotaxis: A radiological technique to accurately localise a lesion in the breast. Used to 
permit precise insertion of a needle in order to obtain material for cytology (fine needle) or 
histology (core biopsy) or as an aid to surgical excision of an impalpable lesion. 
Surgical unit: A BreastScreen Australia identifier for the surgical unit attended by the 
woman for local excision of a lesion, unique within the state or territory. 
Target group: Women aged between 50 and 74 years. 
Technical repeat: The taking of further films initiated by the radiographer or radiologist due 
to technically unsatisfactory films at the screening visit. 
Total mastectomy: Surgery to remove the entire breast, including the nipple and areola. 
Tumour: An abnormal growth of tissue. Tumours may be benign or malignant. If malignant 
they may be primary or secondary (metastatic).  
Two standard views: The cranio-caudal and medio-lateral oblique views in mammography. 
Ultrasound: Production of a visual image of a part of the body by recording the echoes of 
sound waves directed into the body. 
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Version 1.1
Breastscreen Australia aims to reduce illness and death 
resulting from breast cancer through organised screening 
to detect cases of unsuspected breast cancer in women, 
thus enabling early intervention. 
The BreastScreen Australia data dictionary is intended 
to be the authoritative source of data definitions used 
by Breastscreen Australia to meet the need for national 
consistency in data collected for program monitoring and 
evaluation, and for accreditation of Breastscreen Australia 
services.
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